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GENERAL INTRODUCTION
“Pain is a major healthcare problem worldwide. Although acute pain may reasonably be considered a 
symptom of disease or injury, chronic and recurrent pain is a specific healthcare problem, a disease in its 
own right” (IASP 2001).
Pain is a biopsychosocial phenomenon defined as “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such damage” [1]. Pain is 
regarded as a subjective experience and thus implies consciousness, as described in 1968 by 
McCaffery: “Pain is whatever the experiencing person says it is, existing whenever he says it does” [2]. 
Moreover, the patient has to be considered as the expert of his/her own pain, which makes it difficult 
to document pain objectively, but it also makes pain a highly individual disease which requires a 
personalized approach and treatment. 
Nociception is defined by the IASP as “the neural process of encoding noxious stimuli” [3], whereby 
information about a harmful stimulus is passed on via the activation of nociceptors to the brain. 
However, nociception alone is not enough to rate a stimulus as pain. To experience a nociceptive 
stimulus as ‘pain’, a person is influenced by personal memory, emotions, pathology and cognitive 
factors [4].
Section1 of the introduction discusses the classification of patients’ pain based on the type and 
duration of the pain. Section 2 describes the neuroanatomy and physiology of pain, neuropathic pain 
in particular, and provides additional information about pain processing. The epidemiology, burden, 
costs and consequences of (neuropathic) pain are described in Section 3. Section 4 introduces 
the assessment of neuropathic pain in daily clinical practice. In Section 5, the requirements for a 
screening tool for the assessment of (neuropathic) pain are specified. The research questions to be 
answered in this thesis are then introduced in the final section of the Introduction.
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CLASSIFICATION OF PAIN
Pain has multiple causes, and people’s response to pain is various and individually fixed, depending 
on, for example, the circumstances. This section discusses how patients’ pain can be classified based 
on the type and/or duration of pain.
Classification based on type of pain
Nociceptive pain: the IASP define nociceptive pain as “pain that arises from actual or threatened 
damage to non-neural tissue and is due to the activation of nociceptors” [5]. This type of pain mostly 
results from a clear, identifiable mechanical, thermal or chemical damage to various parts of the 
body (somatic: such as skin, bones, muscles; or visceral: abdominal or thoracic internal organs). 
The pain is felt at the site of the injury or by stimulation of local nociceptors without injury, and is 
relatively easy to treat [1]. In recent years, pain has also been described as inflammatory pain and 
visceral pain, both with a more causal than mechanistic orientation. Inflammatory pain is defined as 
‘a result of activation and sensitization of the nociceptive pain pathway by a variety of mediators released 
at a site of tissue inflammation’ [6]. Inflammatory pain can be found in patients with, amongst others, 
rheumatoid arthritis, pancreatitis, or a herpes zoster infection. Visceral pain arises from the internal 
organs; it often has a diffuse localization due to major perceptive fields, overlap of innervations and 
‘cross-talking’ of innervating nerves. The pain refers to other areas of the body and is associated with 
motor- and autonomic reflexes [7]. An example of visceral pain is deep pain from the bladder which 
is referred to the perianal region [8]. 
Neuropathic pain: in 1994, neuropathic pain was defined as “Pain initiated or caused by a primary 
lesion or dysfunction in the nervous system” [1]. However in 2008, neuropathic pain was redefined as 
“Pain arising as a direct consequence of a lesion or disease affecting the somatosensory system” [9, 10]. 
According to the IASP taxonomy, neuropathic pain is not a diagnosis but a ‘clinical description which 
requires a demonstrable lesion or a disease that satisfies established neurological diagnostic criteria’ [9]. 
It is divided into central and peripheral neuropathic pain. Central neuropathic pain is caused by a 
lesion or disease of the central somatosensory nervous system, for example in patients with a spinal 
cord injury or multiple sclerosis. In peripheral neuropathic pain, the lesion or disease is localized in 
the peripheral somatosensory nervous system, for example in patients with diabetic neuropathy, or 
as a side effect after treatment for cancer with chemotherapy [9]. 
Nociplastic pain: in November 2017 (after our study was completed), the International Association 
for the Study of Pain (IASP) acknowledged nociplastic pain as the third mechanistic descriptor for 
chronic pain states in addition to nociceptive and neuropathic pain, because in 2008, the term 
‘dysfunction’ was removed from the definition of neuropathic pain [11-14]. It is now defined as “Pain 
that arises from altered nociception despite no clear evidence of actual or threatened tissue damage 
causing the activation of peripheral nociceptors or evidence for disease or lesion of the somatosensory 
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system causing pain” [11]. Patients in this group are in pain but neither from an obvious activation of 
their nociceptors nor from neuropathy. Nociplastic pain is suggested to be an altered nociceptive 
function based on clinical, physical and psychological observations and it can occur in combination 
with nociceptive pain and/ or neuropathic pain. The advantage of this third descriptor is that it 
gives more recognition to pain as experienced by the patient, and it is intended to improve the 
diagnosis and treatment of patients with (chronic) pain by creating an extra subdivision. As 
debate is a fundamental part of an academic environment, there is an ongoing discussion about 
the use of the term nociplastic pain and its meaning[11-19]. The question then arises, ‘What does 
‘altered nociception’ mean?” Does this refer to a change in the nociceptors or is there a change in 
the signal processing of the nociceptive input, or perhaps both? Nociceptor activity or activity in 
the pathways/cortical networks is not necessarily pain [12]. Describing a persistent pain condition 
without a clear medical explanation and without objective criteria for assessment and diagnosis 
will lead to a continuation of the debate about this new mechanistic descriptor until research 
provides more insights into this phenomenon [12]. Pain conditions fitting this description are, 
amongst others, fibromyalgia, CRPS and irritable bowel syndrome [11]. One of the extensively 
described phenomena which fits the term nociplastic pain is ‘central sensitization’ [20]. Central 
sensitization is defined as “an amplification of neural signaling within the central nervous system that 
elicits hypersensitivity” [21, 22]. Moreover, the IASP defines central sensitization as “an increased 
response and reduced threshold of nociceptive neurons in the central nervous system to their normal 
or subthreshold afferent input” [23]. Correctly determining and recognizing central sensitization is 
important when diagnosing the patient, classifying the patient’s pain, and in treatment [20, 24-27]. 
However, as Kosek et al [16] suggested, the underlying mechanism of nociplastic pain may also be 
the central sensitization of nociception or nociceptive pathways. Research in the field of nociplastic 
pain should target identifying the suggested altered nociceptive function in patients with (chronic) 
pain and, consequently, developing treatment opportunities. 
Mixed pain: pain can be classified as an independent condition, but also as part of a ‘mixed pain 
condition’ [28, 29] in which, for example, nociceptive pain and neuropathic pain are present in one 
patient. Because of the coexistence of pain classifications in daily clinical practice, it is better to 
speak of an absent or present neuropathic pain component in patients’ pain (NePC) with respect to 
mixed pain conditions.
Pain of unknown origin: pain can also be classified as ‘pain from an unidentified source’; this used to 
be termed ‘idiopathic pain’. It is now defined as “pain of unknown cause and origin” [11]. 
Classification based on duration of pain
Besides the differentiation in type of pain, patients can be classified based on the duration of their 
pain. Acute pain is defined as “pain of recent onset and probable limited duration. It usually has an 
identifiable temporal and causal relationship to injury or disease” [30]. Acute pain may induce chronic 
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pain states [31, 32]; for example after undergoing surgery, it is known that acute pain is followed by 
chronic pain in 10-50% of patients[33] . The definition of chronic pain is “pain that extends beyond 
the expected period of healing” [1]. Chronic pain is recognized as pain that persists or recurs after 
normal healing time, and that lacks the acute warning function of physiological nociception [34, 
35]. Chronic pain can be present without an identifiable temporal or causal relationship with the 
injury or disease according to currently available diagnostic methods. In daily clinical practice, pain 
is regarded as ‘chronic’ if it lasts for more than (or recurs within) 3-6 months [1].
NEUROANATOMY AND PHYSIOLOGY OF PAIN AND NEUROPATHIC PAIN IN 
PARTICULAR
In this section, I provide an overview of the physiological mechanisms of pain and the important 
pain pathways between receptors and the brain. 
In normal conditions, pain is a protective natural response to a disease or injury after a body is 
threatened. The protective function of the nociceptive sensory system is divided into a somatosensory 
and a homeostatic part. The somatosensory part localizes the disease or injury and causes painful 
stimuli, followed by corresponding fast motor reflexes. The homeostatic function results in 
hyperalgesia and autonomic adaptation during the healing phase in pathological conditions [36, 
37]. Pain is the result of a complex interaction between signaling systems, modulation that may 
originate from higher centers, and the unique perception of the individual [8] (figure 1). In addition 
to the experience of pain, an increase in heart rate and blood pressure, sweating and changes in 
respiratory behavior can occur after activation of the nociceptors due to sympathetic activation.
The pain signaling pathway
Primary afferents: Nociceptors are receptors (free nerve endings) found in a range of tissues activated 
by specific painful stimuli such as the free nerve endings of cutaneous nociceptors localized in the 
epidermal layer of the skin. Other nociceptors, such as the high-threshold mechanoreceptors, 
respond to mechanical deformation (pressure, stretch, etc.). Another example, polymodal receptors, 
respond to a variety of tissue damaging inputs (mechanical, temperature and chemical stimuli). 
Inflammatory mediators such as hydrogen ions (protons), 5-hydoxytryptamine (5-HT), cytokines, 
bradykinin, histamine, prostaglandins, and leucotrienes, activate and sensitize the free nerve 
endings of different types of nerve fibers [8]. Aβ fibers generate touch, pressure, proprioception and 
vibration signals; Aδ may produce acute, well localized sharp pain, and C fibers result in warmth, 
delayed, and more diffuse pain, and a long-lasting burning sensation. Type III & IV fibers are sensitive 
to deep (muscular) pressure (table 1) [38, 39]. These primary afferent nerve fibers have cell bodies in 
the dorsal root ganglia or in the trigeminal ganglion, and terminate in the dorsal horn of the spinal 
cord [8]. 
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Figure 1: The pain signaling pathway. Illustration: Rogier Trompert Medical Art
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Table 1: Sensory modalities, receptors and suggested testing modalities. Adapted from Walk et al [38]. 
Sensory Modality Principal receptors Axon type Postulated mechanism 
of allodynia/ 
hyperalgesia
Testing 
instruments
Dynamic mechanical Meissner’s
Pacinian
Hair follicle
Aβ, some C
Aβ
Aβ
Central sensitization Brush
Cotton wisp
Cotton swab
Cutaneous punctuate 
(blunt)
Merkel
Ruffini
Aβ
Aβ
Some C
Central sensitization Von Frey hair
Cutaneous punctuate 
(sharp)
Free nerve endings Aδ Central sensitization
Peripheral sensitization
Pin (wooden 
cocktail stick)
Deep pressure Intramuscular afferents Type III, IV Unknown Pressure 
algometer
Vibration Pacinian Aβ Unknown Tuning fork 
(128Hz)
Innocuous warm Free nerve endings C Peripheral sensitization Heated surface
Innocuous cool Free nerve endings Aδ Unknown Metallic surface 
at room 
temperature
Noxious heat Free nerve endings C
Aδ
Peripheral sensitization Heated surface
Noxious cold Free nerve endings C
Some Aδ
Reduced inhibition
Central sensitization
Peripheral sensitization
Cooled surface
Metallic surface in 
ice water
Second order neurons: primary nociceptive afferents synaps onto second order neurons in the spinal 
dorsal horn in the various Rexed laminae. Moreover, inhibitory interneurons add to the complex 
structure of the dorsal horn. Information from the nociceptors is integrated and modulated and 
passed on to the supraspinal centers. Furthermore, descending tracts from higher centers exert 
their inhibitory effect on the neurons in the dorsal horn [8].
Ascending tracts: the second order neurons cross over to the contralateral side of the myelum and 
ascend to higher structures via the spinothalamic tract and the spinoreticular tract. The spinothalamic 
tract (also known as the anterolateral system) is divided in a lateral (‘neospinothalamic’) tract and 
an anterior (‘paleospinothalamic’) tract. The lateral tract transmits pain and temperature, whereas 
the anterior spinothalamic tract transmits crude touch and firm pressure. Sensations of tactile 
processing and proprioception are conveyed via the dorsal column-medial lemniscus pathway. The 
lateral tract is involved in the sensory-discriminative aspect of pain; the anterior tract is involved in 
the autonomic and affective part of pain. The spinoreticular tract is phylogenetically more ancient 
than the spinothalamic tract and is involved in the perception of diffuse, emotionally disturbing pain 
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[8, 40]. It also plays an important role in autonomous functions like breathing, heart and circulation, 
and the regulation of posture and muscle tone.
The brain: a very important area for pain processing is the thalamus; from there the sensory 
information is distributed to the cerebral cortex [41]. Via the spinothalamic tracts, the axons 
terminate in the thalamic nuclei and connect further to the primary and secondary somatosensory 
cortex, the insula, the anterior cingulated cortex, and the prefrontal cortex [42]. These areas are 
known for the perception of pain and their interaction with, for example, areas associated with 
motor function [8]. The cortico-limbic structures integrate the sensation of pain and the pain effect.
Descending tracts: the descending tracts play an important role in pain modulation. Descending 
pain inhibition is, among others, controlled via neurotransmitters (Noradrenaline and 5-HT). Via the 
peri-aquaductal grey and the nucleus raphe magnus, the brainstem is involved in reducing pain 
transmission in the dorsal horn of the spinal cord where incoming stimuli are toned or blocked [8].
Neuropathic pain 
Neuropathic pain is a direct result of damage to the nervous system [9]. It can develop after an injury 
to or a disease affecting the peripheral nerve (peripheral neuropathic pain), or parts of the central 
nervous system (central neuropathic pain). It is often accompanied by maladaptive changes in the 
nervous system (changes in the injured neurons and along the ascending and descending modulatory 
pathways) [43, 44]. Peripheral neuropathic pain can be a result of surgery, as well as, amongst others, 
from herpes zoster, radiculopathy, diabetes mellitus, chemotherapy, or a peripheral nerve injury [45]. 
Central neuropathic pain can be a result of stroke (‘central post-stroke pain’) or, for example, be caused 
by a neurodegenerative disease like morbus Parkinson [46]. However, not all patients with a lesion or 
disease in the peripheral or central somatosensory system develop neuropathic pain [39]. 
The sensory abnormalities which the patient experiences are crucial to the clinical diagnosis of 
neuropathic pain, and to distinguish this type of pain from nociceptive and nociplastic pain [47]. Nerve 
damage can result in structural changes in the nerve itself but also to functional changes in the nervous 
system. These changes may cause a variety of continuous or intermittent symptoms [48]. Patients 
with neuropathic pain may experience symptoms like burning, painful cold, electric shocks, shooting, 
stabbing, tingling, pins and needles, numbness and/or itch [47]. Moreover, the pain can be evoked by a 
stimulus or it can be spontaneous, i.e. pain not evoked by a stimulus [8, 39], and may present as allodynia, 
hyperalgesia, hyperpathia, hyperesthesia and/or dysesthesia. It can also result in an decreased response 
to a stimulus, which can be described as analgesia, hypoalgesia and hypoesthesia (Table 2). Provocation 
of pain can occur via dynamic (e.g. stroking with a brush), and or static (e.g. touching with a finger) stimuli. 
The symptoms and signs may be similar for both central and peripheral neuropathic pain therefore it is 
not always easy to judge where the injury or disease affects the nervous system[8]. 
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Table 2:  Clinical manifestation of neuropathic pain. Adapted from Merskey and Bogduk, Classification 
of Chronic Pain [1, 120].
Term                                                      Description
Allodynia Pain due to a stimulus that does not normally provoke pain
Hyperalgesia An increased response to a stimulus that is normally painful
Hyperesthesia Increased sensitivity to stimulation
Hyperpathia A painful syndrome characterized by an abnormally painful reaction to a 
stimulus, especially a repetitive stimulus, as well as an increased threshold
Paresthesia An abnormal sensation, whether spontaneous or evoked
Dysesthesia An unpleasant abnormal sensation whether spontaneous or evoked
Analgesia Absence of pain in response to stimulation that would normally be painful
Hypoalgesia Diminished pain in response to a normally painful stimulus
Hypoesthesia Decreased sensitivity to stimulation
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Table 3:  Changes in the nervous system due to or caused by neuropathic pain and consequences for 
the patient. Adapted from Colloca et al [39].
Changes in Description Consequences
Pain signaling In patients with neuropathic pain, the changes in the 
(electrical) properties of the sensory nerves might 
result in an imbalance between the central excitatory 
and inhibitory signaling. This leads to an impairment of 
the inhibitory interneurons and the descending control 
systems.
In the spinal cord, at the level of the dorsal horn 
neurons, there is a change in the transmission of 
sensory signals and disinhibition or facilitation 
mechanisms.
An increase in excitation and facilitation and a decrease 
in inhibition is existing in the peripheral nervous 
system, the spinal cord and the brain.
Change to a state of
hyperexcitability
Ongoing changes in the 
sensory pathway might 
contribute to the fact that  
neuropathic pain becomes 
chronic neuropathic pain
Ion channels Neuropathy causes changes in the ion channels in the 
affected nerves which influences the sensory signaling 
at the spinal level and in the brain.
 
Experiences by the patient 
of ongoing pain; numbness 
and/or evoked pains
Second order 
nociceptive neurons 
An increased excitability of spinal neurons leads to 
an enhanced response to several sensory modalities. 
It allows low-threshold mechanosensitive (Aβ & Aδ) 
afferent nerve fibers to activate the second order 
nociceptive neurons. These are transmitting sensory 
information to the brain, and increases the receptive 
fields of the neurons in a way that a given stimulus is 
excitating more secondary order nociceptive neurons 
[20, 121].
Hyperexcitability can be caused by a loss of 
γ-aminobutyric acid (GABA)- releasing inhibitory 
interneurons. These inhibitory neurons can switch 
to utilize excitatory actions in the spinal cord [122]. 
Moreover, functional changes in non-neuronal 
cells in the spinal cord (by example microglia and 
astrocytes) might play a role in the development of 
hypersensitivity [123].
Generates central 
sensitization
The changes in second 
order neurons might 
explain the existence of  
allodynia 
Development of 
hypersensitivity
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Table 3 continued
Inhibitory 
modulation 
Inhibitory interneurons and the descending 
modulatory control systems are less functional in 
patients with neuropathic pain. Moreover, the brain 
(the limbic regions) receives transformed and abnormal 
sensory input via altered projections to the thalamus, 
cortex and parallel pathways.
The cingulate cortex and amygdala are involved in 
persistent pain  and are associated with neuropathic 
pain comorbidities [124].
Noradrenergic inhibition (via α2-adrenergic receptors) 
in the spinal cord is reduced in patients with 
neuropathic pain. Consequently, enhanced serotonin 
signaling (via 5-HT2 and 5-HT3 serotonin receptors) 
becomes more leading.
High pain ratings, anxiety, 
depression and / or 
sleeping problems are 
transmitted as painful 
messages which dominates 
the limbic functioning
The brainstem excitatory 
pathways are more 
important in the 
maintenance of pain than in 
pain induction.
CPM is impaired or lost in 
patients with neuropathic 
pain.
Pain modulation 
mechanisms
A patient with neuropathic pain might experience 
mild or even debilitating pain. The difference might be 
influenced by the modulation of the pain signal in the 
central nervous system.
The perception of pain by the patient can be 
disinhibited due to a decreased descending 
endogenous inhibition (known as a less-efficient 
conditioned pain modulation (CPM) and / or facilitated 
through sensitization of the ascending pain pathways 
(known as an enhanced temporal summation). 
Temporal summation may be increased in patients with 
as well as without neuropathic pain but in patients 
with neuropathic pain it is present with a more obvious 
increase [125].
CPM is less efficient in 
patients with pain than in 
healthy controls [126]. 
Influencing patients’  pain 
modulation mechanisms 
might be promising for a 
personalized approach to 
treat patients with pain 
[127-129].
Based on animal and human research, it is clear that a lesion of the afferent pathways is necessary to 
develop neuropathic pain, but various mechanisms may lead to its development. Importantly, these 
mechanisms are not disease specific [47]. This indicates the complexity of neuropathic pain and 
draws attention to the importance of identifying the underlying pain mechanism in an individual 
patient to tailor the treatment regimen [47]. Colloca et al. [39] summarized several changes and 
alterations resulting from a lesion or disease in the somatosensory system related to neuropathic 
pain (table 3). These changes can occur in pain signaling with respect to electrical properties, ion 
channels, second order nociceptive neurons, the inhibitory modulations, and other pain modulation 
mechanisms, and have consequences for the pain experienced by the patient. Whether these 
changes in the pain modulation mechanisms are therapeutic targets should be the subject of future 
research [56-58].
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EPIDEMIOLOGY, BURDEN, COSTS AND CONSEQUENCES OF CHRONIC 
PAIN, AND OF NEUROPATHIC PAIN IN PARTICULAR
Pain is a major clinical, social and economic problem. It has challenged generations of, amongst 
others, (para-)medical professionals, psychologists and researchers. However, for many patients, 
pain remains a threat to the quality of their daily lives. 
Chronic pain
Epidemiology of chronic pain: based on surveys, chronic pain prevalence estimates range between 
10%-30% [49]. In Europe, the prevalence of chronic pain is estimated, on average, to be 19%; in the 
Netherlands it is 18% [50]: patients in this survey suffered from pain for more than 6 months and 
had a pain intensity of ≥5 on a Numeric Rating Scale (NRS) ranging from 1 (no pain) to 10 (worst 
pain imaginable) at their last pain episode. Besides pain, 21% of the patients were diagnosed with 
depression because of the pain, and 61% had a reduced capacity for regular work. In the previous 
six months, they had visited a physician between 2-9 times. The majority of these patients were seen 
in primary care, only 2% of all patients were treated by a pain specialist. One-third of the patients 
received no treatment, overall 40% reported inadequate management of their pain. Management 
of patients’ pain consisted of prescription medications, non-prescription medications, and/or non-
pharmacological treatments such as physical therapy and cognitive behavioral therapy (CBT). The 
article also described the socio-demographic factors associated with chronic pain: female gender; 
older age; higher weight, lower socio-economic status; geographical and cultural background; 
history of alcoholism, employment status/ occupational factors, higher level of catastrophizing, and 
a history of abuse or interpersonal violence [51-54]. 
Burden of chronic pain: The most recent estimations of the global burden of disease are likely to 
underestimate the contribution of chronic pain [55-57]. The physical and emotional burden is high, 
which results in a lower quality and quantity of life, lower functional status (chronic pain impedes 
activities in daily life, less capability to work and less working efficiency) and lower mental health 
[49, 58]. There is a clear correlation between chronic pain and quality of life (QoL). Using the Short 
Form-36 General health Questionnaire (SF-36), the physical health composite score is about ten 
points lower in patients with chronic pain than in people with no pain [49]. An effective therapy for 
patients with chronic pain (a reduction of pain intensity of at least 50%) leads to improvements in 
fatigue, sleep, depression, QoL and work [49, 59].
Costs of chronic pain: the direct and indirect costs resulting from chronic pain are high. Direct costs 
are those which can be directly assigned to a disease, such as nursing days, outpatient consultations, 
operations, and medication, as well as travel expenses and treatment costs incurred by the patient. 
Indirect costs are those that cannot be attributed directly to a disease. These are, for example, costs 
incurred during extra years of life, or so-called production losses due to sickness absence. Moreover, 
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the costs and effects of informal care are also increasingly reflected in these indirect costs. In the 
USA, [60] chronic pain impacts 100 million adults and the annual costs are estimated at $560 to $635 
billion; this is much higher than the economic costs of the six most expensive major diagnoses in 
the USA: cardiovascular diseases ($309 billion); neoplasms ($243 billion); injury and poisoning ($205 
billion); endocrine, nutritional and metabolic diseases ($127 billion), digestive system diseases 
($112 billion), and respiratory system diseases ($112 billion). The total costs due to chronic pain in 
the Netherlands are estimated at over €20 billion, annually [61].
Neuropathic pain
Epidemiology of neuropathic pain: the incidence of neuropathic pain in the Dutch general population 
[62] is 8.2 cases per 1000 person-years. Neuropathic pain is 63% more common in women than in 
men and has the highest prevalence in those aged between 70 and 79 [62]. In a systematic review 
by Van Hecke et al., [63] the population prevalence of pain with neuropathic characteristics was 
estimated to be between 6.9% and 10%. Moore et al stated that 7% of the patients with chronic 
pain suffered from pain due to an NePC [49]. Recently, the prevalence of probable neuropathic pain 
in the USA was estimated to be 10% [64]. In patients with cancer, the prevalence of pain with a 
neuropathic mechanism was estimated to be 18.7% -21.4% [65]. Due to aging, higher prevalence 
of diabetes mellitus, surgery, and the increasing incidence of cancer (with and without treatment 
with surgery and/or chemotherapy), peripheral neuropathic pain will probably be more common in 
the future because these diseases and their treatments can affect the sensory nervous system [39].
Burden of neuropathic pain: neuropathic pain is associated with a poor general health status; this is 
comparable to other severe chronic disease. All three dimensions, the physical, psychological, and 
social dimension are affected [66]. Patients with neuropathic pain have a lower health-related quality 
of life compared to the general population [67]. A survey using the SF-36 reported that Health-
related QoL was as severely affected in patients with neuropathic pain as in patients affected with 
a coronary artery disease, clinical depression, recent myocardial infarct or inadequately controlled 
diabetes mellitus [68]. The physical component score of the SF-12 can be qualified as severe 
impairment: 94% of the included patients with neuropathic pain combined with breakthrough pain 
scored below the population mean score [69]. As suggested by Attal et al. [70] the specific signs and 
symptoms of neuropathic pain and the painful and/or unpleasant nature of these symptoms also 
have an impact on Health-related QoL.
Costs of neuropathic pain: neuropathic pain results in a substantial use of health resources, in 
particular by patients who have been referred to specialized pain clinics for pain control via 
primary care or other specialists [71]. The additional health care costs incurred in patients whose 
pain is mainly treated in pain clinics are compensated by lower costs of other pain management 
components, resulting in comparable average monthly total costs [71]. In a recent European study, 
Liedgens et al. concluded that there is an economic and socioeconomic burden due to neuropathic 
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pain as a result of healthcare and societal costs to the wider economy. The estimated total annual 
costs per patient with neuropathic pain range from € 9,305 (Italy) to €14,446 (Germany) [72]. 
THE ASSESSMENT OF NEUROPATHIC PAIN IN DAILY CLINICAL PRACTICE 
Neuropathic pain is considered to be ‘a difficult clinical entity’ because of the lack of a diagnostic 
gold standard and the inadequate treatment response [73]. Examination, in particular physical 
examination of the patient, is important to link a patient’s pain to a lesion or disease of the 
somatosensory nervous system. The goal of the assessment is to distinguish the neuropathic pain 
component from musculoskeletal pain and other types of pain, and to distinguish a neuropathic 
pain component from pain due to changes in the nociceptive system following, for example, 
inflammatory pain. 
History taking and physical assessment: A key diagnostic item in history taking is the area of abnormal 
sensation described by the patient. Patients’ pain is maximum within this area of sensory deficit. 
In addition to this ‘region of pain’, the patient describes pain with a burning, stabbing, lancinating, 
shooting sensation, together with, for example, tingling, crawling or electrical sensations. Moreover, 
in history taking, attention should be paid to the time course and the pain intensity [74]. Clinical 
examination by a (pain-)physician is most important when diagnosing a patient and in follow-up 
when looking for sensory abnormalities [75]. Patient sensory testing is the most important part (see 
bed-side examination). We advise that any clinical judgment is based on a comprehensive clinical 
assessment before classifying patients’ pain. 
Bedside examination: Bedside examination is an important method as it helps an individual patient 
clarify the disease and find the affected area corresponding to the injured nervous structure. Positive 
and negative signs and symptoms, location, quality and intensity of the pain should be tested 
together to assess a patient’s pain. This should also include the testing of touch, vibration, pinprick, 
cold and warmth. In patients suspected of an NePC, quantification and mapping of motor, sensory 
and autonomic phenomena is valuable when describing the signs of a neurological dysfunction (for 
the methods for the assessment of nerve function see table 1). Bedside examinations in patients 
suspected for NePC provides insights into the pain of individual patients based on neurological 
examination, where the sensory examination is of major importance. However, the validity of 
bedside examination for assessing patients with neuropathic pain has yet to demonstrated [76].
Screening tools: Currently, a number of tools are available to screen for or to assess the existence of a 
neuropathic pain component: NPS [77], LANSS [78], NPQ [79], NPQ-SF [80], NPSI [81], DN4 [82], DN4 
(interview, self-report) [82, 83], S-LANSS [84], PainDETECT [28], ID Pain [85], PQAS [86], StEP [87], SF-
MPQ-2 [88], FPQ [89] SCIPI [90], and the IT [91]. These instruments are translated or cross-culturally 
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adapted to different languages and are validated in different patient populations (partly) following 
the flow diagram in figure 2. For an overview of the objective and description of each instrument, see 
table 4. In a recently published systematic review regarding the measurement properties of these 
questionnaires, it was concluded that the Neuropathique Pain Questionnaire (NPQ) [79] and the DN4 
[82] were the most suitable for use in daily clinical practice [92]. Screening tools are considered to 
be useful in identifying patients with a possible neuropathic pain component, especially when used 
by a non-specialist, and to provide added-value for further diagnostic assessment of the patient [74, 
75]. This is their most important advantage; however, these screening instruments should never 
replace a thorough clinical assessment by a (pain-) physician.
NeuPSIG Grading system: In 2008, Treede et al. [10] presented a grading system for neuropathic 
pain suitable for both clinical and research purposes. This stepwise approach provides a working 
hypothesis for the origin of patient pain based on four evaluation criteria: 1) pain with a distinct 
neuroanatomically plausible distribution; 2) a history suggestive of a relevant lesion or disease 
affecting the peripheral or central somatosensory system; 3) demonstration of the distinct 
neuroanatomically plausible distribution by at least one confirmatory test; 4) demonstration of 
the relevant lesion or disease by at least one confirmatory test. A working hypothesis of ‘possible 
neuropathic pain is provided when both criteria 1 & 2 are answered with ‘yes’: when one of criteria 3 
& 4 is fulfilled, then the outcome is ‘probable neuropathic pain’. When both criteria 3 & 4 are fulfilled, 
the outcome is ‘definite neuropathic pain’ (see figure 3).
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Neuropathic pain is a clinical description*, not a diagnosis! 
 
* Gold standard for classification of patients’ pain does not exist, but is mostly based on  
the opinion of two physicians by proxy 
Cross-cultural adaptation of the developed screening tool 
Assessment of a Neuropathic Pain Component (NePC) 
Nociceptive Pain 
 
“Pain that arises from actual or threatened damage to 
non-neural tissue and is due to the activation of 
nociceptors” 
 
- Pain that affects the skin, muscles, joints, 
ligaments and/or bones 
 
- Generally well localized and restricted to a 
specific affected area 
 
- Responds well to classical analgesics 
Neuropathic Pain 
 
“Pain caused by a lesion or disease of the 
somatosensory nervous system” 
 
- Pain related to the central and/or 
peripheral somatosensory nervous system 
 
- Characterized as spontaneous pain with 
abnormal pain sensations 
 
- Poor response to current treatment 
Initial development of a screening 
tool for NePC  
Validation in a multidisciplinary pain practice group of patients with and 
without NePC 
Validation* in a pre-stratified group of patients 
 with and without NePC 
Mixed 
Pain 
Figure 2: The validation process of screening instruments for neuropathic pain until 2017
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Figure 3: The grading system. Adapted from Treede et al., Neurology, 2008 [10]
Quantitative Sensory testing (QST): QST is defined as “the analysis of perception in response to external 
stimuli of controlled intensity” [76]. The QST-method is based on the German research network of 
neuropathic Pain (DFNS) protocol and has been precisely described, and reference data are available 
[93-97]. The detection thresholds, pain thresholds, and pain tolerance thresholds are determined 
using stimuli applied directly to the skin. The major added-value in comparison with bedside 
examination is the use of well standardized instruments, such as von Frey filaments, weighted 
needles, and thermal testing instruments. QST is used in the early diagnosis of diabetic neuropathy 
as well as in small fiber neuropathies [98]. Moreover, QST may prove of value when describing 
painful neuropathic diseases and in explaining some of the underlying mechanisms. 
The Nijmegen-Aalborg Screening Quantitative Sensory Testing (NASQ) [99] protocol can be used 
to explore the underlying mechanisms of pain. NASQ screens for changes in pain processing based 
on a systematic mechanism-oriented approach [99, 100]. To gather information about the neural 
transmission of ‘noxious stimulation’, widespread hyperalgesia, and the multiple endogenous 
modulatory processes in the body, NASQ is used to make either anti-nociceptive or pro-nociceptive 
pain visible  [101]. The NASQ protocol can be used to measure static pain thresholds (making a 
stimulus response curve for sensory thresholds, pain thresholds and pain tolerance thresholds for 
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pressure algometry as well as electrical stimuli). Dynamic pain tests such as the Conditioned Pain 
Modulation (CPM) paradigm [102-104], also known as the “pain inhibits pain” phenomenon, measure 
an inhibitory mechanism like diffuse noxious inhibitory controls. This indicates that peripheral and 
central mechanisms play a role in the way the body handles nociception.
Currently, there is cumulative evidence that pain and sensitization play an essential role in the 
development of chronic pain [105]. An understanding of the pathophysiology of acute pain and 
of the development of chronic pain are essential to improving patient outcomes and in making a 
mechanism-based treatment. Both QST and NASQ are difficult to implement in daily clinical practice 
as they are time consuming and require expensive instrumentation. However, test-retest reliability 
and the interrater reliability are both classified as good if tests are performed by trained examiners 
[96].
Neurophysiological techniques: Following the definition of neuropathic pain and to fulfill the NeuPSIG 
grading criteria, confirmation of a lesion or disease affecting the central or peripheral nervous system 
is a prerequisite for the outcome ‘definite neuropathic pain’. Several techniques are described in the 
literature, such as nerve conduction studies via electromyography (EMG) testing large-fiber affection 
in, for example, patients with HIV. Skin wrinkle tests and quantitative sudomotor axon reflex testing 
(QSART) are used for testing small fibers, and somatosensory evoked potential testing (SSEP) is used 
to detect sensory abnormalities in, for example, the trunk or proximal limb regions. Nerve ultrasound 
has proved to provide reliable information for by example nerve entrapments during the diagnostic 
work-up of neuropathic pain. Positron emission topography (PET) is used to target specific ligands 
and to access detailed information about the neurotransmitters. Functional magnetic resonance 
imaging (fMRI) makes it possible to gather information about blood deoxygeneration and changes 
in metabolites via spectroscopy. Electrophysiological methods, such as the nociceptive withdrawal 
reflex, and electroencephalography (EEG) including (laser)-evoked potentials and resting-state EEG 
provide complementary information and reflect real-time activity in the neural system [29, 75, 106-
109]. 
REQUIREMENTS FOR A SCREENING TOOL TO ASSESS (NEUROPATHIC) 
PAIN
Screening tools for the assessment of NePC such as the PainDETECT and the DN4 are biopsychological 
measurements. These instruments screen for the presence of NePC via a set of items related to 
various pain descriptors. The individual items and the outcomes of the questionnaires reflect the 
patient’s perception of the pain. Instruments like the PainDETECT and the DN4 are in current use 
in daily clinical practice, research and education. Their popularity in daily clinical practice and in 
research is partly due to their simplicity and ease-of-use when identifying potential patients with 
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NePC and their immediate provision of information, in particular by non-specialists [47, 110]. BSE 
and NASQ are other biopsychological measures that examine the negative (loss of function) and 
positive (augmented excitation, for example hyperalgesia and allodynia) signs, and to gain insights 
into the underlying lesion or disease [29]. These observations rely, at least partly, on the patients’ 
evaluation of pain and on the physician’s experience with performing the tests [111]. 
 
It is hard to understand the manifestation, the time course and the impact of patients’ pain and 
therefore difficult to find the right solution or management for patients’ pain when symptoms 
of pain are not systematically documented. An effective diagnosis, prognosis and treatment of 
patient’s pain must be based on the underlying (pain) mechanisms. To achieve this, a number of 
valid, and reliable tools have been developed to assess chronic pain. The measurement of pain and 
the underlying pain systems is important to understand its origin, intensity, quality and the progress 
suffered by the patient during the treatment process, but it has to be accepted that the symptoms 
as provided by the patient and arising from the clinical examination by the physician only gives a 
few insights into the underlying pain mechanisms and the pain diseases resulting from a changing 
somatosensory system [112]. 
Assessing patients suffering from pain in daily clinical practice serves several goals: screening, 
diagnosis, therapy and monitoring. The goal of screening is the initial triage of patients, for example 
by referring them for more diagnostic research or by placing them in a specific clinical treatment 
trajectory. Individual patients can be classified in specific sub-groups with common underlying pain 
mechanisms to undergo, for example, a similar pain treatment. Differential diagnosis, prognosis, 
the prediction of the process and/or outcome of the disease; all these form an important part of 
the assessment of patients’ pain [112]. The choice of therapy is based on a patient’s diagnosis and 
the impact and course of the disease. Moreover, a patient’s diagnosis is also related to the disease 
mechanisms [29, 74, 75]. To increase the chance of a positive treatment outcome, it is necessary to be 
able to identify responders versus non-responders. However, this is not always possible for patients 
with pain: the mechanism(s) that underlie the presentation of pain are not always known, which 
therefore reduces the probability of a correct diagnostic profile and consequently an adequate 
management of treatment. Finally, the goal of monitoring is to follow the evolution, the treatment 
response and duration of the disease in patients [112].
Measuring pain 
A regular, structured and standardized documentation of the pain suffered by a patient is a 
prerequisite for an effective and timely treatment and follow-up. An important difference between 
the avaliable pain measurement instruments is whether the measurements are made in terms of 
quantity or quality and dimensionality. At a quantitative level, it is necessary to measure how much 
pain the patient is suffering from (pain intensity), how long the patient has been suffering from the 
pain (time), and where the pain is located. At a qualitative level the patient will be asked how much 
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the pain functionally limits the patient (disability), how much it affects the patient’s daily life (quality 
of life), and how the patient deals with the pain (coping). Patients’ pain quality can be characterized 
at a more qualitative level by describing feelings like the feeling of pins and needles, burning, 
stabbing or itching. Dimensionality reflects either uni-dimensionality, for example the amount of 
pain, and/or multi-dimensionality, where data comes from multiple perspectives, such as level of 
pain, experience of pain and behavior [112].
Requirements to measuring instruments
The value of a measurement instrument for pain is determined by its (clinimetrical) quality. This 
includes the quality of the measurement instruments as well as the performance of the actual 
measurement. Important indicators are the performance of the translation process, the reliability, 
validity, responsiveness, and sensitivity for change, as well as quality assurance [112].
Translation and cross-cultural adaptation: translation is the process of translating an instrument from 
one language into another. The term ‘cross-cultural adaptation’ is used when both language and 
culture are considered in the process of the preparation of an instrument that is to be used in another 
language and/or another country to provide equivalency, based on content, between source and 
target language [113-115]. After translation or cross-cultural adaptation, the instrument’s face 
validity can be assessed, the extent to which a test is subjectively viewed as covering the concept it 
purports to measure.
Reliability: the reliability of an instrument expresses the measure in which the instrument shows the 
same result if used again on the same person (test-retest reliability or inter-assessor reliability). The 
reliability can also be expressed as intra-assessor reliability: will two different assessors reach the 
same conclusion? The inter- and intra-assessor reliability are both only valid if no changes in the 
disease, conditions or the circumstances have occurred between the assessments [116]. 
Validity: the validity of an instrument is the way in which an instrument measures what it intends 
to measure. This is determined on the basis of a ‘gold standard’; an instrument or method for which 
it has been proven that it documents the presence or absence or the stage of the same condition, 
and for which people know beforehand that it is ‘true’, or that it is, at least, the best available test 
[117]. An instrument can be reliable without being valid, but a valid instrument must be reliable 
[116]. Important features for screening tools that assess NePC are the construct validity, content 
validity, criterion validity, and external validity. The theoretical embedding of the neuropathic pain 
concept is captured in the construct validity: how well does the test measure what it intends to 
measure. Construct validity consists of convergent and discriminant validity. Convergent validity 
is achieved when different tools that measure the same concept yield the same results (converge). 
On the other hand, an instrument must distinguish the concept which it intends to measure from 
other concepts (discriminate). Content validity refers to the question whether the content of the 
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instrument (asked questions, used measurement scales) represents all elements of the construct. 
The term criterion validity refers to the extent to which the outcome of the instrument is related to 
one or more criterion variables. Criterion validity is accessed via sensitivity, specificity and predictive 
value. External validity is important to assess and to see to which extent the outcomes obtained with 
the instrument are generalizable to other situations, other groups of patients, or to other concepts. 
Diagnostic procedures are used for clinical decisions, and therefore imply a certain risk for a patient 
as an incorrect diagnosis might harm the patient. From this perspective, it is important to assess the 
validity of a measuring instrument for each condition and per (sub-)population, as the fact that an 
instrument is valid for a specific group of patients with a certain diagnosis does not automatically 
mean that it is also valid for patients who suffer from another condition [112].
The sensitivity of a measuring instrument indicates which percentage of those suffering from 
certain diseases are (accurately) classified as ill by the measuring instrument [118]. The specificity 
of the measuring instrument indicates which percentage of a group of people not affected by the 
disease are (accurately) classified as not being ill [118]. The predictive value (also known as the 
diagnostic value) gives an indication for the chance that the person with the relevant test result will 
have the disease or condition now or in the near future [119]. A positive and/or negative predictive 
value refers to the chance that a disease or condition is present or absent in people with a certain 
test result. If an instrument has a high sensitivity, only a few patients suffering from the disease 
or condition are missed, it leads to a higher positive predictive value. If an instrument has a high 
specificity, only a few patients suffering from the disease or condition are incorrectly classified as 
suffering from this disease or condition, it results in a higher negative predictive value [119]. The 
number of people suffering from the disease or condition in the population on whom the measuring 
instrument is used at any given moment is called the prevalence. The prevalence influences the 
sensitivity, specificity and the predictive value. When the condition frequently occurs within a 
population, this will lead to a higher positive predictive value. At a lower prevalence, the number 
of false-positive test results will increase on the basis of coincidence [119]. For this, the (positive) 
likelihood ratio can be used which gives an indication of the value of an instrument for increasing 
certainty about a positive diagnosis [119]. However, as indicated by Altman and Bland [119], a high 
positive likelihood ratio might show that an instrument is useful, but that it cannot ensure that a 
positive test is a certainty for the presence of a disease [119].
Responsiveness: in (pain) measurement instruments that are used frequently over a longer period 
(for example for follow-up research), it is important to know whether the instrument shows any 
changes that have taken place in that time [116].
Quality of performance: The measuring instrument must be suitable for the situation for which 
it is to be used (practical applicability), for the purpose of the research (e.g. screening for an 
epidemiological study or serve as a diagnostic assessment by the physician), the population under 
General Introduction
37
1
investigation (number and composition of the group) and for the person performing the assessment 
(e.g. experience, time and costs) [116]. 
Quality control and assurance: the reproducibility of pain measurements is crucial and depends on 
the instruction of the patient and a correct measurement by the patient, the physician, the nurse or 
the researcher. Staff performing the measurements and /or interpreting the results must be trained 
in how to use the instrument(s) to ensure that these are used in a standardized and reproducible 
way following the applicable protocols. All staff involved should follow theoretical and/or practical 
refresher courses to guarantee continuation of equal measuring quality. Participation in regular 
quality circles also contributes to a consistent and reliable pain measurement and interpretation 
quality [112]. 
RESEARCH QUESTIONS IN THIS THESIS
A better characterization of patient pain based on a thorough assessment in daily clinical practice 
increases the chance of discovering the underlying (pain) mechanisms. This can lead to a better-
founded pain diagnosis and is a prerequisite for choosing an effective treatment for the individual 
patient, if available, as well as for the subpopulation of patients with pain. Screening tools help 
physicians to assess pain, but they are also valuable for monitoring the progress of patient treatment 
in research projects, as well as for assessing the incidence/prevalence of a disorder like neuropathic 
pain. At this moment, the DN4 has been translated into Dutch, whereas the PainDETECT is only 
validated in its (original) German version with an English translation. The interobserver reliability 
of the assessment of neuropathic pain in patients between two physicians in the Netherlands in 
specific patient populations is still unknown. 
This is of importance because a ‘true’ gold standard for the NePC assessment does not yet exist. 
A valid screening tool would therefore be of value for both family practice and for specialized 
(academic) pain centers to help and guide the classification of patient pain. Therefore, the aim 
of two of the studies in this thesis is to assess the psychometric properties of the two screening 
instruments (PainDETECT and DN4) to assess the neuropathic pain component in a consecutive, 
daily practice population of patients with low back and leg pain, neck-shoulder pain, or with pain 
due to a suspected peripheral nerve damage. Validation in a more general population and in a 
clinical setting is important as the outcome may differ from validation studies set in more controlled, 
experimental settings with selected patients. A second aim is to assess the possible benefits of BSE 
and NASQ to distinguish between clinically diagnosed patients with and without NePC.
Question 1: Is a cross-cultural adaptation a prerequisite for achieving a valid Dutch translation of a 
screening tool for neuropathic pain? 
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Question 2: What is the reliability of clinical judgment as a surrogate for the lack of an objective 
gold standard in diagnosing a neuropathic pain component in patients with chronic pain?
Question 3: What are the psychometric properties of the PainDETECT and the DN4 questionnaire 
when used as screening tools in a daily practice consecutive patient population (patients with 
low back pain, neck shoulder or arm pain, or pain from a suspected neuropathic origin), not pre-
stratified on target outcome, for NePC detection?
Question 4: What is the potential association between clinically diagnosed, via two independent 
and trained professionals, absent or present NePC, and bedside examination / screening quantitative 
sensory testing (NASQ) in patients with chronic pain?
OUTLINE OF THIS THESIS
In chapter 2 we discuss the process of the cross-cultural adaptation of the PainDETECT-questionnaire 
into Dutch for use in the Netherlands and Belgium. Chapter 3 describes the interobserver reliability 
in daily clinical practice for the assessment of neuropathic pain in patients with cancer. Chapter 
4 presents a detailed study protocol for the validation of screening instruments to assess a 
neuropathic pain component; this is then used for the studies in chapter 5, 6 and 7. In chapters 
5 and 6 we describe the validation of the PainDETECT questionnaire and the DN4 in a consecutive 
population of patients with chronic pain. In Chapter 7 we describe the added value of bedside 
examination and screening-QST to improve neuropathic pain identification in patients with chronic 
pain. In chapter 8 I discuss the results of our studies in this thesis in a broad, scientific context and 
provide suggestions for future directions in (validation) research and for the use of screening tools 
in daily clinical practice.
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ABSTRACT
Background
The PainDETECT-Questionnaire (PDQ) helps to identify neuropathic components in patients 
suffering from pain. It can be used by clinicians in daily practice and in clinical trials. 
Aim
The aim of this study is to perform a translation and cross-cultural adaptation of the PDQ for use in 
the Netherlands and Belgium. 
Methods
The first phase was to translate and cross-culturally adapt the PDQ to Dutch. The second phase was 
to assess the face validity in the Netherlands and Belgium using qualitative and quantitative data 
collection. 
Results
The length, the readability, and the clarity of the questionnaire were good for all patients. The 
questionnaire was judged to have a good layout and to be clearly organized. 
Conclusion
The PDQ Dutch language Version is a well translated and cross-culturally adapted questionnaire, 
which might be useful for screening for neuropathic components of pain in the Netherlands and 
Belgium. 
Key Words
Neuropathic pain, translation, cross-cultural adaptation, validation, PainDETECT-Questionnaire, PDQ 
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INTRODUCTION
Neuropathic Pain (NeP) is defined as ‘‘pain arising as a direct consequence of a lesion or disease 
affecting the somatosensory system’’ [1]. NeP is characterized by spontaneous pain and abnormal 
pain sensations [2]. Clinically, NeP is typically described as a constant burning pain with spontaneous 
sharp exacerbations and somatosensory abnormalities [3]. As a rule, NeP has a considerable impact 
on the quality of daily life [4]. The incidence of NeP in the Dutch general population is 0.81% or 
130.000 new patients in the Netherlands per year. NeP is 63% more common in women than in men 
and peaks between 70 and 79 years of age [4].
Medical history and (highly valid) screening tools may help to identify or differentiate between NeP, 
nociceptive pain (NoP), and mixed pain syndromes [5-7]. Since 1996, various questionnaires have 
been developed in different countries for the screening of neuropathic pain components based 
on verbal pain description, with or without physical examination or attention to quality of life [8-
17]. Such questionnaires have been translated or cross-culturally adapted into different language 
settings [18-25]. The term ‘‘cross-cultural adaptation’’ is used to define an important process that 
considers both language and culture in the process of preparing a questionnaire in another 
language and/or another country to provide equivalency between source and target language 
based on content [26]. For example, the Netherlands are Dutch speaking, and parts of Belgium are 
Flemish speaking (almost the same as Dutch, but interpretation and use of some words may vary). 
Because of slight differences in language and sociocultural characteristics between the Netherlands 
and Belgium, it is necessary to perform an adaptation in both countries. Moreover, it is useful to 
have this instruments in a well-adapted Dutch language version not only for national studies but 
also to permit participation in multinational studies [26-28]. 
The PainDETECT © Questionnaire (PDQ) (Pfizer GmbH, Berlin, Germany; 2005) was developed in 
Germany [13] and tested as a reliable screening tool with high sensitivity (85%), specificity (80%), 
and positive predictive accuracy (83%) for NeP. In the Spanish version of the PDQ sensitivity is 75%, 
specificity 84%, and the positive predictive value is 92% [25]. The PDQ is a questionnaire that can be 
filled in by the patients themselves and was devised to screen for neuropathic signs and symptoms 
without physical examination. 
The aim of this study is to achieve a cross-cultural adaptation of the PDQ for use in the Netherlands 
and Belgium. The PainDETECT © Questionnaire Dutch language version: PDQ-Dlv (Pfizer, GmbH, 
Berlin, Germany; 2008). Subsequently, this PDQ-Dlv will be used to assess face validity, as a first step 
in a validation trajectory for this questionnaire in the Netherlands and Belgium. 
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METHODS
The medical and ethical review board (CCMO Arnhem/Nijmegen, Nijmegen, the Netherlands) gave 
approval to conduct this study. All patients signed an informed consent form prior to participation 
in the study. 
Translation of the PDQ 
The process of cross-cultural adaptation of the PDQ to Dutch was based on the 10 steps as described 
in the ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Task Force guidelines 
[28] (Figure 1). The source questionnaire and the translations by translator 1 (T1), translator 2 (T2), 
back translator 1 (BT1), and back translator 2 (BT2) together with the preliminary Dutch version 
(Translation T1 to 2) were discussed item by item in a multidisciplinary expert committee review 
during the harmonization phase: (AW) a physician experienced in the treatment of (chronic) pain, 
(AE) a medical psychologist experienced in the translation, development and use of measurement 
instruments (German native speaker and fluent in Dutch), (RF) the developer of the PainDETECT-
questionnaire, physician and experienced in the treatment of (chronic) pain (German native speaker 
participating by telephone), and (HT) the project manager, in close contact with both the forward- 
and backward translators, to prepare the pre-PDQ-Dlv. Special attention was given to three kinds 
of equivalence: (1) Semantic equivalence / Idiomatic equivalence: The similarity of meaning of 
each word or colloquialism in each culture after translation, (2) Experiential equivalence: Assessing 
the experiences of daily life, and (3) Conceptual equivalence: In different cultures, words can have 
different conceptual meaning. The committee searched both the source and the (back-) translations 
for all such equivalences and adapted them to the most fitting meaning in Dutch [26-27]. In the 
cognitive debriefing phase, the authors used qualitative semi-structured interviews to ask the 
patients about the questionnaire and their understanding of the questions. It was performed by 
one researcher from the review committee (HT) in a group of randomly selected patients in an 
outpatient pain clinic (n = 10, seven women; mean age 58 years [± 16.2 years]) and in a group of 
researchers (n = 4, two women; mean age 32 [± 4 years]). 
Testing the PDQ 
After finalizing the translation, the quality of all the different versions in the cross-cultural adaptation 
process were assessed using a 3-point scale [29]. The items were categorized (Cat.) as (Cat. 1) ‘‘different 
meaning in each version’’, (Cat. 2) ‘‘almost the same meaning in both versions’’, or (Cat. 3) ‘‘exactly the 
same meaning in both versions’’. Comparison of items was performed between translation T1 and 
translation T2 by both forward translators, between back translation BT1 and back translation BT2 by 
both backward translators. Comparison between the backward translation BT1-2 and the source PDQ 
was performed by one of the developers of the questionnaire (RF). The final comparison was between 
the source PDQ and the PDQ-Dlv during the harmonization phase and the review of the cognitive 
debriefing results. After completion of the whole process, a quality control process was implemented. 
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Step 1: Preparation 
Preparation was performed by the project manager (HT).  
 
Step 2: Forward translation T1  
From source language into target language by a independent 
official translator: Dutch native speaker; Medical background and 
informed about the concept of the PDQ 
 
Step 4: Backward translation BT1 
From translation T1-2 into source language by a 
independent official translator: German native speaker; 
No medical background and not informed about the concept of 
the PDQ. 
concept of the PDQ 
 
 
Step 3: Reconciliation: Translation T1-2 
In a conference call with both translators and the project manager, both translations were discussed item by item (linguistically and 
culturally). The translators administered the items which had caused problems and the choices they made during the translation 
procedure. After discrepancies had been discussed, the translations were combined into a new version, translation T1-T2, which 
was thereafter checked by the translators. 
 
Step 5: Back translation review: BT1-2 
The translators administered the items which had caused problems and the choices they made during the translation procedure. In 
a conference call with both back-translators and HT, both translations were discussed item by item (linguistically and culturally). 
The best translation according to both backwards translators was adopted in the backwards translations. One of the developers 
(RF) was asked to read both backward translations and to compare them with the source questionnaire paying specific attention to 
conceptual equivalence. 
 
Step 8: Review of the cognitive debriefing results 
The project manager did the review and the first translator agreed with the revisions of the translation. The outcome of the 
interviews was used to modify the pre-PDQ-Dlv into the new Dutch version of the PDQ: the PDQ-Dlv. 
Step 2: Forward translation T2 
From source language into target language by a 
independent official translator: Dutch native speaker; 
No medical background and not informed about the 
concept of the PDQ 
 
Step 4: Backward translation BT2 
From translation T1-2 into source language by a 
independent official translator: German native 
speaker; No medical background and not informed about 
the concept of the PDQ. 
about the concept of the PDQ 
 
 
Step 7: Cognitive debriefing; identification of problem items 
The project manager asked patients with and without neuropathic pain and researchers not involved in the adaptation process to 
fill in the pre-PDQ-Dlv and interviewed them to paraphrase the clarity, readability and comprehensibility of the pre-PDQ-Dlv 
Step 6: Harmonization: T1, T2, T1-2, BT1, BT2, BT1-2, Source  
The source questionnaire, and the translations T1, T2, T1-2, BT1 and BT2 were discussed item by item in a multidisciplinary expert 
committee review (AW, AE, HT and RF). The committee searched both the source and all the translations for all equivalences and 
adapted them to the most fitting meaning in Dutch: the pre-PDQ-Dlv 
PainDETECT Questionnaire-Dutch language version (PDQ-Dlv) 
PainDETECT Schmerz Fragebogen (PDQ) 
Step 10: Final report  
The development of the translation was described in a report, containing every translation and the choices that were made.  
 
 
Step 9: Proofreading 
The PDQ-Dlv was checked for minor errors such as punctuation, spelling etc. 
 
 
 
Figure 1: Flow diagram of the cross-cultural adaptation process. 
  T1: forward translation 1; T2: forward translation 2; BT1: back translation 1; BT2: back translation 2; 
BT1-2: back translation based on BT1 & BT2; Source: original German PainDETECT-Questionnaire; pre-
PDQ-Dlv: preliminary PainDETECT-Questionnaire Dutch language version; PDQ-Dlv: PainDETECT-
Questionnaire Dutch language version. 
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by two researchers (TS: German native speaker, fluent in Dutch; and JO: Dutch native speaker, 
fluent in German) who had not been involved in the translation pprocessprocess until that point 
The face validity was assessed in the Netherlands (N = 30, Radboud University Nijmegen Medical 
Centre, Nijmegen, the Netherlands/general practice in the Netherlands) and in Belgium (N = 30; 
Ziekenhuis Oost-Limburg, Genk, Belgium) based on semi-structured interviews by patients with 
pain of different origins as diagnosed by a physician. Gender, age, and time necessary to fill in the 
questionnaire were recorded. The semi-structured interview was based on eight questions (as listed 
in Table 2 below). All the questions were answered on a Visual Analogue Scale (VAS) of 100 mm. 
After the patient filled in the VAS on an item, it was followed by an open question in which he or she 
was encouraged to explain his or her understanding of the item [30]. 
Statistical Analysis 
All data were entered and analyzed in the Statistical Package for the Social Sciences (SPSS version 
17.0; SPSS Inc., Chicago, IL, USA) and checked for completeness and normality using the Kolmogorov-
Smirnov test. A significance level of P ≦ 0.05 was chosen (two-sided). Descriptive statistics were 
computed, and comparisons between the Netherlands and Belgium at baseline were performed 
using the Mann-Whitney U-test. 
RESULTS
The PDQ consists of 62 items. During the harmonization and cognitive debriefing-phase textual 
amendments were made (Table 1). The items of the PDQ were linguistically and culturally assessed 
by the translators and the harmonization group by use of the 3-points scale (Figure 2). When 
comparing T1 and T2, three items were scored as ‘‘different meaning in each version’’ and 23 items as 
‘‘almost the same meanings in both versions’’. Comparison between the backward translation BT1 to 
2 and the source showed two items scored as ‘‘different meaning in each version’’ and two items as 
‘‘almost the same meaning in both versions’’. A multidisciplinary expert committee (AW, AE, HT, and 
RF), in close contact with both the forward- and backward translators, was used to prepare the pre-
PDQ-Dlv. During this harmonization phase, four items were changed based on commentary by one 
of the developers of the questionnaire and the choice for a more conceptual than literal translation, 
which would give a better understanding by the patient. In the last comparison, between the source 
and the PDQ-Dlv,there were only two items with almost the same meaning in both versions (these 
were the items which were changed according to the cognitive debriefing). The quality control of 
the translation was performed afterward by two researchers (JO & TS) who had not been involved in 
the translation process until that moment. No item was scored as having different meaning in each 
version between PDQ-Dlv and the source. Rater A scored 60 times ‘‘exactly the same meaning in 
both versions’’ (96.8%), rater B 53 times (87.1%) (Figure 3). 
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Figure 2: Translation process: degree of agreement. 
  T1: forward translation 1; T2: forward translation 2; BT1: back translation 1; BT2: back translation 2; BT1-
2: back translation based on BT1 and BT2; Source: original German PainDETECT-Questionnaire; PDQ-
Dlv: PainDETECT-Questionnaire Dutch language version; Cat.1: different meaning in each version; Cat. 
2: almost the same meaning in both versions; Cat. 3: exactly the same meaning in both versions. 
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Figure 3: Quality control after the translation process.
  A: rater A; B: rater B; T1: translation 1; T2: translation 2; BT1: back translation 1; BT2: back translation 2; 
BT1-2: back translation based on BT1 & BT2; Source: original German PainDETECT-Questionnaire; PDQ-
Dlv: PainDETECT-Questionnaire Dutch language version; Cat.1: different meaning in each version; 
Cat.2: almost the same meaning in both versions; Cat.3: Exactly the same meaning in both versions. 
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In total, 60 patients were asked to fill in the PDQ-Dlv to assess the face validity. Twenty-one of 60 
patients (35%) forgot to mark the main area of pain (‘‘drawing’’). Five patients (12%) forgot to tick 
the box whether the pain was radiating to other regions of the body or not. One patient did not 
fill in all the questions because there was no appropriate answer according to the patient. Patients 
gave their opinion about the usability of the questionnaire on a VAS-scale (0 to 100), in which ‘‘0’’ 
means totally not useable and ‘‘100’’ means very useable (Table2). Most Belgian and Dutch patients 
found the PDQ-Dlv a clear, readable, well organized, and useful instrument to assess their pain. The 
question ‘‘Are the questions stated in a clear way?’’ showed a significant difference in favor of the 
patients from Belgium (P = 0.03, Mann-Whitney U-test). The most common question in the group of 
sixty patients (n = 14; 23.3%) during the fillingin period was ‘‘Should I circle the number or tick the 
box?’’ in the questions about the pain at this moment, the strongest pain during the last 4 weeks 
and on average in the last 4 weeks. After answering the questions in the interview, the patients were 
challenged to give their thoughts and comments about the PDQ-Dlv in words. Most of the patients 
had no comment. The most frequent comment was that the kind of pain of the patient ‘‘did not fit in 
the questionnaire’’ (n = 4, 7%). Suggestions made by patients for a next version were the use of less 
color (n = 1) and increasing font size (n = 1). 
DISCUSSION
This study presents the results of the cross-cultural adaptation and face validation of the PDQ into 
the Dutch language for use in the Netherlands and Belgium. The PDQ was until this moment only 
published in a German, English, and Spanish language version [13,25]. The quality of a questionnaire 
used in research is expected to be dependent on the quality of the chosen method for translation 
[31]. There are many strategies to perform a cross-cultural adaptation [26-28,32,33]. The use of 
these guidelines improves the linguistic, structure, and cultural equivalence [34]. However, there 
is a lack of consensus and consistency in quality, methodology and application of these guidelines 
in healthcare literature [28,35]. The ISPOR guidelines [28] represent a consensus regarding the 
principles of good practice in translation and cultural adaptation. Their goal is to provide a more 
conceptual equivalent approach instead of a more literal translation. Because it provides clear 
recommendations and a detailed multistep approach, the ISPOR guidelines were chosen as method 
for the translation and cultural adaptation of the PDQ. This study consequently followed these 
guidelines in the choice of translators, the members of the multidisciplinary expert committee as 
well as the process of the adaptation. Decisions were discussed with the persons involved in the 
process either by conference call or by live meetings. 
Because differences in instrument formatting and administration may produce variations in 
response even if meticulous care is taken [36], we opted for the same layout as the original version. 
In the cognitive debriefing phase and during data collection before the face validity testing, some 
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patients indicated that in some questions they did not know where in the questionnaire they had to 
put their answer to that question. They found the questionnaire too colorful and that the colors were 
distracting. Another difficulty when using the original format was that Dutch translated questions 
were limited to the space the original developers used in the original version. 
Patient interviews were very useful to find out what the patient is thinking and how he interprets 
the questions in the questionnaire [37]. On the basis of these interviews, we changed two items to 
make them clearer to the patient and to reduce missing data: ‘‘Mark the picture that best describes 
the course of your pain’’ was changed into ‘‘Mark one picture that best describes the course of your 
pain’’. We also changed ‘‘If yes, please draw the direction in which the pain radiates’’ to ‘‘If yes, please 
draw the direction and the place into which the pain radiates’’. Thirty-five percent of the patients 
forgot to fill in this drawing but this is not of influence on the outcome score of the questionnaire. 
The question ‘‘Does the pain radiate to other regions of the body?’’ was not filled in by 7% of the 
patients. This has an influence on the outcome score. However, owing to the choice to use the same 
format as the original questionnaire, we were not able to change this item in a manner that there 
was more attention to the drawing and corresponding questions. 
A quality check based on a 3-step scale [29] during and after completion of all the steps recommended 
by ISPOR was added because during the translation process the comparison was performed only by 
the translators. Thus, after the translation was completed, two independent researchers were asked 
to check each step in the translation trajectory. Rater A scored almost the same meaning in both 
versions two times when comparing the source and the PDQ-Dlv, and Rater B, who took a more 
literal rather than a conceptual approach, scored nine items as almost the same meaning in both 
versions. On the basis of the outcome of all scores, it is clear that a good translation process consists 
of more than a forward translation and that the steps the authors took in this study are necessary to 
come to a good cross-cultural adaptation. 
The face validity of the PDQ-Dlv was assessed in Dutch and Flemish because of the slight differences 
in the interpretation and use of some words. Therefore, the understanding of questions in the 
questionnaire may not be equal. In the end, only one significant difference in favor of the patients 
from Belgium occurred (‘‘are the questions stated in a clear way?’’). No further differences were 
found. 
A valid adaptation (‘‘Are the questions easily understood by patients as well as by clinicians/
researchers and do they measure the same concept in different languages and countries?’’) of a 
questionnaire is necessary for its use in every day clinical practice and also in (inter-)national research 
to make the outcome comparable in different cultures. Furthermore, cross-cultural adaptation is 
cheaper, less labor-intensive and less time-consuming than to develop a whole new questionnaire. 
[27,38] 
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Publishing a cross-cultural adaptation has a value itself. First, it will help to prevent the existence of 
multiple versions of an instrument in a given language. Second, it ensures that the large amount of 
work involved will not be repeated unnecessarily [26]. Third, it gives a clear insight in which choices 
have been made during the translation process and thus provides important information about the 
strength of the translation [27]. On the basis of the method used, the reported patient outcome 
in the cognitive debriefing phase as well as in the face validity assessment and in the quality 
check, the PDQ-Dlv is a well translated and cross-culturally adapted questionnaire for screening on 
neuropathic pain components in patients in the Netherlands and Belgium. A validation study of the 
PDQ is now in progress to assess the psychometric properties (ie, sensitivity, specificity, predictive 
value, and reliability) for different groups of patients in the Netherlands. 
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ABSTRACT
Background
Neuropathic pain (NeP) is a burdensome problem in all stages of cancer. Although clinical judgment 
is accepted as a surrogate for an objective gold standard in diagnosing NeP, no publications were 
found about its reliability. 
Objectives
Therefore, levels of agreement on the clinical examination of NeP were estimated by calculating 
kappa-value (Κ) and percentage of pair wise agreement (PA) to determine the interobserver 
reliability of diagnosing NeP. 
Setting
The outpatient clinic of medical oncology of the Radboud University Nijmegen Medical Centre. 
Method
Patients with cancer with potential NeP complaints were recruited from the outpatient clinic of 
medical oncology. Physicians were recruited from the department of pain and palliative medicine. 
Physicians and patients were recruited for participation in an observational study in daily practice. 
Each patient (N = 34) was examined by 2 specialists via independent clinical assessment. All 
consultations were video recorded. After each assessment, physicians were asked to indicate the 
most adequate characterization of the pain: pure NeP, pure nociceptive pain (NoP), mixed pain 
(MiP), or no pain (NP). 
Results
Kappa (Κ) for the diagnosis of the most adequate pain characterization was 0.50, PA 64.7%. For 
diagnosing pure NeP K was 0.78 (PA 91.2%), for the NeP component (NeP + MiP) and NoP component 
(NoP + MiP), it was respectively 0.52 (PA 76.5%) and 0.61 (PA 82.4%). For the diagnosis on the basis 
of the grading system between physicians, Κ was 0.34 (PA 52.9%). The intrarater reliability for the 
diagnosis of an NeP component on the basis of clinical assessment and the NeP component on 
the basis of the grading system, for pain specialists Κ was 0.69 (PA 85.3%) and for palliative care 
specialists Κ was 0.61 (PA 79.4%). 
Limitations
The values of Κ and the PA for the existence of an NeP component are not satisfying and the clinical 
agreement between physicians around findings from physical examination should encourage a 
better standardization of the clinical assessment and classification of pain in patients with cancer in 
respect with the identification of NeP. 
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Conclusions
A substantial level of agreement was found for the diagnosis of pure NeP and a moderate level of 
agreement for the diagnosis of the NeP component was found, both with a PA ≥ 70%. There was 
only a fair agreement between the physicians regarding the grading system. However, there was a 
substantial level of (interrater) agreement for the diagnosis of an NeP component and the outcome 
of the grading system. The findings in this study also suggest that a better standardization of the 
clinical assessment and classification of pain in patients with cancer with respect to the identification 
of neuropathic pain is necessary. 
Key words
Neuropathic pain, diagnosis, interobserver reliability, agreement, cancer observational study, pain, 
clinical assessment, diagnostic test 
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INTRODUCTION
Pain is a burdensome symptom in all stages of cancer. Van den Beuken et al [1] found a prevalence 
of 55% in patients with cancer in the Netherlands. Of those, 44% suffered from moderate to severe 
pain [1]. As described in a review, 64% of the patients with metastatic, advanced, or terminal stages 
of cancer had pain, 59% of patients who were on anticancer treatment and 33% of patients who had 
been cured from cancer still suffered from pain [1,2]. In patients with cancer who were on opioid 
treatment by a pain specialist for their pain, almost 40% had neuropathic pain (NeP) alone or in 
combination with nociceptive or visceral pain [3]. In several other studies, the prevalence of NeP in 
patients with cancer varied between 17% and 36% [4-7]. This large variability in prevalence between 
studies can be explained by differences in populations, differences in diagnostic methodologies, 
and differences in definitions [8]. 
The International Association for the Study of Pain (IASP) defines NeP as “pain caused by a lesion 
or disease of the somatosensory nervous system” [9].The question arises when (part of ) the pain in 
patients with cancer can be diagnosed as NeP. Despite the attempts to specify the entity of NeP, still 
no gold standard for the diagnosis of NeP exists [10]. NeP is experienced by the patient and despite 
the characteristic signs and symptom complex that may be recognized by experienced doctors, 
it is still difficult to measure objectively. Several screening tools, like the DN4, LANSS, NPQ, and 
PainDETECT have been developed to indicate the possible existence of NeP [11-15]. Yet, screening 
tools are no substitute for history taking and physical examination, and they are not intended to 
be a diagnostic method [12]. Therefore, clinical judgment is the only recommended method to 
diagnose NeP [10,16]. When standardized diagnostic criteria are lacking, the reliability of diagnostic 
procedures is usually demonstrated by acceptable levels of agreement among physicians [17-19]. 
Interobserver reliability is an important measure to assess the agreement of categorical variables 
such as diagnosis or the interpretation of findings in physical examination [20]. Cohen’s kappa is a 
for chance corrected statistical outcome for interobserver reliability [21]. We used Cohen’s kappa 
and percentage of pair wise agreement to investigate the interobserver reliability and agreement of 
the diagnosis of NeP in patients with cancer. 
METHODS
Patients 
Patients were recruited from the outpatient clinic of the department of medical oncology of the 
Radboud University Nijmegen Medical Centre (RUNMC). Between September and November 2010, 
all patients who visited the outpatient clinic were screened for pain for another larger study. As part 
of a larger set of questionnaires, they were also asked to complete the 7-item DN4 questionnaire 
[13] about the quality of their pain. Inclusion criteria for enrollment in the kappa-study were (1) age 
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≥ 18 years; (2) diagnosed with cancer (regardless of the type and stage of cancer) or being cured 
from cancer; (3) at least 2 positive answers on the 7-item DN4 questionnaire in order to enrich the 
chance of including patients suffering from NeP in the research population. 
Exclusion criteria were (1) no consent to be contacted for further research; (2) no permission 
for video recording of the consultations. Eligible patients were phoned by the researcher (IH). 
Subsequently, the patients received information by mail. After verbal and written informed consent 
patient-volunteers were included in the study. They did not receive any benefit from the study; only 
costs for transportation were reimbursed. This study was approved by the local ethics committee: 
the Committee on Research Involving Human Subjects region Arnhem-Nijmegen, Nijmegen, the 
Netherlands. 
Patients were examined by experienced pain specialists (N = 4) and palliative care specialists (N 
= 2), recruited from the department of anesthesiology, pain, and palliative medicine of RUNMC. 
All 4 participating pain specialists, 2 men and 2 women, median age of 40 (range 32 – 47), had a 
background as an anesthesiologist. The 2 palliative care specialists, both male, were 58 and 63. One 
was a medical oncologist and the other an elderly care physician. Years of experience in their actual 
specialization (pain or palliative care) was 10 years for the pain specialists (range 1 – 18 years) and 
13 years for the palliative care specialists (7 and 18 years). All physicians worked full time, but, as a 
mean, they worked 19 hours per week (10 – 26 hours) in this specific field. 
Test Methods 
All physicians completed a questionnaire recording their age, gender, professional background, 
specialty, and number of weekly hours working as a pain specialist or as a palliative care specialist. 
They were also asked to provide a working definition of NeP, including symptoms and findings at 
physical examination they considered decisive for NeP. As a part of the preparation of the study, an 
inquiry was made among the physicians regarding the tools they wanted to use for the physical 
examination. There was no prearranged set of tools available in the examination rooms, only those 
recommended by one or more of the participating physicians: pieces of cotton wool, cotton buds, 
a tuning fork, and a reflex hammer. All physicians had access to the same set of tools. They were 
allowed to use the Electronic Patient Record (EPR), and instructed to diagnose NeP in the way they 
were used to in their daily practice. 
Before the consultation, each patient completed a set of questionnaires, consisting of repetition of 
the 7-item DN4 questionnaire [13], the Brief Pain Inventory-Short Form (BPI-SF) [22], and a question 
about duration and course of their pain over time. Subsequently the patients were randomly 
assigned to be seen first by the pain specialist or the palliative care specialist and underwent a 
second assessment by the other specialist after 30 minutes. The physicians were not informed about 
the selection procedure of the participating patient-volunteers, or about the outcome of the DN4 
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and BPI-SF. Each physician had 20 minutes for clinical assessment of the patient (history taking and 
physical examination). However, the physician was allowed to take more time when necessary. 
After the consultation, the physician had 10 minutes to complete a research form with a tick box 
for the diagnosis: “NeP,” “nociceptive pain (NoP),” or “mixed pain (MiP)” which was categorized as 
NeP together with NoP or no pain (NP). If there was more than one pain location, physicians were 
instructed to focus on the location of the worst pain. During the assessments, physicians were 
blinded to the results of their colleague and patients were instructed not to mention the findings of 
the other physician. In each session, 4 patients were seen in a row by each physician. 
Each assessment was videotaped and evaluated by 2 researchers (IH and AS). Regarding history 
taking, items of evaluation were words mentioned to characterize the pain, including items of 
the 7-item DN4 questionnaire, and whether a Numeric Rating Scale (NRS) was mentioned (yes/
no) for scoring intensity of pain. Regarding the physical examination, items of evaluation where 
performing a physical examination (yes/ no), comparison of affected and healthy body parts (yes/ 
no), and which tools were used. 
Statistical Methods 
Because there are no previous data regarding this research topic, it was not possible to perform 
a reliable power calculation. However, NeP prevalence in patients with cancer is 31%-36% [4-7]. 
To artificially create a higher probability of patients suffering from NeP, we included only patients 
who scored 2 or more items on the 7-item DN4 questionnaire during the previous screening study. 
We assumed NeP prevalence in this specific study group to be 0.5 during the actual study. With an 
assumed kappa of 0.7, a study power of 80%, and an alpha of 0.05, we estimated that 30 patients 
were needed. To be able to focus on agreement whether or not an NeP component exists in a 
patient, kappa’s aimed at this specific part were determined. Patients with NeP or with MiP were 
rated together as having an NeP component. Patients with NoP or with MiP were also rated together 
as NoP component present. The physicians were, afterwards, asked to rate Treede’s Grading System 
[23] for each patient they had seen. The outcomes “probable” and “definite” were regarded as an 
NeP component was present. Unlikely and possible were rated as no NeP component was present. 
To assess interobserver reliability and agreement of the diagnosis of NeP in patients with cancer, we 
calculated pair-wise Cohen kappa-values (Κ), the prevalence index (Pi), and pair-wise percentages 
of agreement (PA). Κ gives the proportion of agreement after chance agreement is removed [21]. 
The Κ-value can vary between -1.0 and 1.0 though it usually falls between 0 and 1 [20]. Landis and 
Koch [24] categorized values of kappa as: none beyond chance (Κ = 0.00), slight (Κ = 0.01 – 0.20), fair 
(Κ = 0.21 – 0.40), moderate (Κ = 0.41 – 0.60), substantial (Κ = 0.61 – 0.80), almost perfect agreement 
(Κ = 0.81 – 1.00). Pi is calculated to quantify the effect of prevalence to Κ. It is the absolute value of 
the difference between the number of agreements on positive and negative findings divided by 
the total number of observations [20,25]. PA represents the number of exact agreements divided 
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by the number of possible agreements [26]. A Κ ≥ 0.40 and a PA ≥ 70% is considered indicative of 
interobserver reliability acceptable for use in clinical practice [24]. Statistics were applied regarding 
diagnosis, outcome of the grading system [23], and the outcome of the DN4. All data were entered 
and analyzed in Statistical Package for the Social Sciences (SPSS version 18.0, SPSS Inc., Chicago, 
Illinois, USA). 
RESULTS
Patients 
Between September and November 2010, 340 patients visiting the outpatient clinic of the 
department of medical oncology of the RUNMC completed the pain questionnaire. Of them, 94 
scored 2 or more on the 7-item DN4 and gave their consent to be approached for a subsequent pain 
study (Figure 1). After 56 patients were approached we stopped the inclusion in this study. Eighteen 
patients refused to join the study due to personal reasons (mainly because of active ongoing 
chemotherapy schedules). Finally, 38 patients gave their written informed consent. Due to an acute 
intercurrent illness at the day of the assessments, 3 patients dropped out of the study. Therefore, 
35 patients participated in the kappa study. One patient was excluded afterwards, because the 2 
physicians had examined different pain locations. 
These 34 patients had a median age of 56 (range 36 – 76). There were 8 men (24%), of whom 2 
had testis carcinoma, 4 had tumors arising from the digestive system, one had a GIST tumor, and 
one had a carcinoid. Of the 26 women (76%), 92% had breast cancer (N = 24), one a GIST tumor, 
and one an angiosarcoma. The duration of the pain in months was at mean 64 months (± SD 100; 
range 1 – 568 months). Worst pain during the 24 hours before the consultations was experienced 
as severe in 5 cases (15%), moderate in 21 cases (63%), and mild in 7 cases (7%): mean 5.24 ± SD 
2.28; range 0 – 9 (NRS 0 – 10). The average pain in the last 24 hours was at mean 4.19 ± SD 2.15; 
range 0 – 9 (NRS 0 – 10). The outcome of the BPI-SF for the pain severity score at mean was 4.08 ± 
SD 2.23; range 0 – 8 (NRS 0 – 10) and for the pain interference score 3.67 ± SD 2.37; range 0 – 9 (NRS 
0 – 10). On the repeated 7-item DN4 questionnaire on the day of examination, one patient didn’t fill 
in the questionnaire, one patient scored 0 points, 8 patients scored 2 points, 11 scored 3 points, 10 
scored 4 points, 2 patients scored 6 points, and one 7 points. See Table 1 for more detailed patient 
characteristics. 
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94 eligible patients 
34 analyzed 
246 
18 
3 
1 
DN4 < 2 or no consent 
Excluded afterwards
1 
56 approached 
Total 340 
Drop out because of acute illness 
Refusal due to personal reasons 
1
 One patient was excluded afterwards, because the  
two physicians had examined different pain locations 
35 participated 
38 included 
Figure 1:  Flowchart for inclusion of patients
Physicians 
We asked the physicians, in an open question, to give their working definition of NeP: 2 of the 
pain specialists mentioned the definition suggested by Treede (23), one pain specialist mentioned 
the DN4-criteria, and the other physicians mentioned definitions containing the words “pain” and 
“the nervous system/ nerve damage.” To the question “what do you think is a decisive symptom 
for NeP,” 3 pain specialists answered that allodynia in general was the decisive symptom and 
one had the opinion that there was none. The palliative care specialists considered respectively 
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a changed sensibility and an annoying pain during night the decisive symptom. When asked for 
the decisive finding for NeP at physical examination, again allodynia was mostly mentioned by the 
pain specialists, while the palliative care specialists mentioned changed sensibility and hyperpathy 
(Table 2). 
Table 2:  Individual opinions from participating physicians about diagnosing neuropathic pain in 
general. 
Specialists Palliative Care Pain Specialists
Working definition 
for neuropathic pain 
Pain or troublesome experience of the 
patient that can be traced back to a 
possible or demonstrated change in the 
function of the nerve or central nervous 
system.
Pain arising as a direct consequence 
of a lesion or disease affecting the 
somatosensory system (Treede, 2008). 
(2x)
Pain related to the peripheral or central 
nervous system.
Pain as a consequence of nerve 
damage or neurological dysfunction 
including sensitization.
DN4-criteria.
Decisive symptom
for neuropathic pain
Changed sensibility (experienced as pain/ 
troublesome).
Pain at normal touch.
None.
Allodynia.
Especially pain during nighttime, mostly 
annoying.
Allodynia (dynamic and static) and 
abnormal sensations.
Decisive sign  
at physical examination 
for neuropathic pain
Changed sensibility in an area of pain 
experience.
Allodynia. (2x)
Allodynia static and dynamic.
Hyperpathy. Sensorial abnormality.
Test Results 
The Κ and PA between paired physicians for the characterization of pain (NeP, MiP, NoP, or NP) 
was 0.50 (64.7%) (P < 0.000). For diagnosing NeP Κ was 0.78, Pi 0.44, and PA 91.2%; for MiP it was 
respectively 0.53, 0.38, and 79.4%; and for NoP it was 0.31, 0.26, and 67.6%. The Κ for the NeP 
component (by summing the diagnoses of pure NeP and MiP) was 0.52 (P = 0.002), Pi was 0.18, and 
PA was 76.5%. For the NoP component (by summing the diagnoses of pure NoP and MiP) Κ was 0.61, 
Pi was 0.35, and PA was 82.4%. 
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The interobserver reliability and the pair-wise agreement between the pain specialist and the 
palliative care specialists regarding the grading system (unlikely, possible, probable, and definite 
neuropathic pain) showed a Κ of 0.34 and a PA of 52.9%. The comparison between the NeP 
component, following from the diagnosis of the physician and the outcome of the grading system 
(the outcomes probable and definite were regarded as an NeP component was present) gave for 
the pain specialists a Κ of 0.69, Pi 0.26, and PA of 85.3%. For the palliative care specialists it was 
respectively 0.61, 0.03, and 79.4%. The comparison between the NeP component, following from the 
diagnosis of the physician and the outcome of the DN4 (7-items, a “yes” on ≥ 3 items is considered 
as having NeP) gave for the pain specialists a Κ of 0.24, Pi 0.36, and PA of 66.7%. For the palliative 
care specialists it was respectively 0.16, 0.27, and 57.6%. The comparison between the outcome of 
the grading system (the outcomes probable and definite were regarded as an NeP component was 
present) and the outcome of the DN4 (7-items, a “yes” on ≥ 3 items is considered as having NeP) gave 
for the pain specialists a Κ of 0.34, Pi 0.42, and PA of 72.7%. For the palliative care specialists it was 
respectively 0.32, 0.15, and 63.6%. 
Secondly, items from history taking and physical examination were assessed by video recording 
and analyzed afterwards. In 27 out of 34 cases the palliative care specialists asked for a pain score 
and the pain specialists asked in 21 cases. Most frequently asked items of the DN4 during history 
taking were tingling (23 times by the palliative care specialists and 15 times by the pain specialists), 
numbness (18 times by both), and burning (12 versus 19 times). During physical examination, the 
cotton bud was most often used. The palliative care specialists used the sharp side of a cotton tip 
22 times and the pain specialists 18 times. The soft side of it was used 25 times by the palliative care 
specialists and 10 times by the pain specialists. Of the available tools, the cotton wool was used the 
least: 9 times by the pain specialists while the palliative care specialists did not use it at all. 
Table 3:  The kappa coefficient (Κ) and the percentage of pair-wise (PA) agreement between physicians 
calculated for the patients’ diagnosis. 
k-value Approx. 
Sig.
Categorized 
value of kappa
Pi PA-value 
(%)
Diagnosis (NeP, MiP, NoP, NP) 0.50 0.000* Moderate --- 64.7
NeP (NeP versus MiP + NoP + NP) 0.78 0.000 * Substantial 0.44 91.2
MiP (MiP versus NeP + NoP + NP) 0.53 0.001 * Moderate 0.38 79.4
NoP (NoP versus NeP + MiP + NP) 0.31 0.08 Fair 0.26 67.6
NePcomponent (NeP + MiP versus NoP + NP) 0.52 0.002* Moderate 0.18 76.5
NoPcomponent (NoP + MiP versus NeP + NP) 0.61 0.000* Substantial 0.35 82.4
k-value: Kappa value; 95% CI: 95% confidence interval; Approx. Sig.: Approximate significance; *: significant, P 
≤ 0,05; Pi: Prevalence index; Pavalue: Pair-wise Agreement-value; NeP: neuropathic pain; MiP: mixed pain; NoP: 
nociceptive pain; NP: no pain; Fair: ĸ = 0.21 – 0.40; Moderate: ĸ = 0.41 – 0.60; Substantial: ĸ = 0.61 – 0.80. 
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Table 4:  The kappa coefficient (Κ) and the percentage of pair-wise agreement (PA), calculated for the 
NeP component, grading system, and DN4. 
k-value Approx. 
Sig.
Categorized 
value of kappa
Pi PA-value 
(%)
Grading PS & Grading SPC  
(unlikely-possible-probable-definite)
0.34 0.001* Fair --- 52.9
PS: NePcomponent & Grading 
NePcomponent  
(NeP + MiP versus Grading probable + definite)
0.69 0.000* Substantial 0.26 85.3
SPC: NePcomponent & Grading 
NePcomponent 
(NeP + MiP versus Grading probable + definite)
0.61 0.000* Substantial 0.03 79.4
PS: NePcomponent & DN4  
(NeP + MiP versus DN4)
0.24 0.160 Fair 0.36 66.7
SPC: NePcomponent & DN4  
(NeP + MiP versus DN4)
0.16 0.475 Slight 0.27 57.6
PS: Grading NePcomponent & DN4  
(Grading probable + definite versus DN4)
0.34 0.053 Fair 0.42 72.7
SPC: Grading NePcomponent & DN4  
(Grading probable + definite versus DN4)
0.32 0.026* Fair 0.15 63.6
k-value: Kappa value; 95% CI: 95% confidence interval; Approx. Sig.: Approximate significance; *: significant, P ≤ 
0,05; Pi: Prevalence index; Pavalue: Pair-wise Agreement-value; PS: Pain Specialist; SPC: Specialist Palliative Care; 
DN4: Douleur Neuropatique en 4 Questions (Questionnaire); NeP component: Neuropathic pain component 
(diagnosis NeP or MiP); Grading NeP component: only “probable” and “definite” are counted as NeP component; 
MiP: mixed pain; NoP: nociceptive pain; Grading: Grading system by Treede et al [23]; Slight: ĸ = 0.10 – 0.20; Fair: 
ĸ = 0.21 – 0.40; Moderate: ĸ = 0.41 – 0.60; Substantial: ĸ = 0.61 – 0.80.
DISCUSSION
In this real-life type of study, we found a substantial level of interobserver reliability for diagnosing 
pure NeP and a moderate level of interobserver reliability for the diagnosis of an NeP component, 
between pain specialists and specialists in palliative care, both with a Κ ≥ 0.40 and a PA ≥ 70%. A 
Κ of ≥ .40 and a PA of ≥ 70% is indicative of interobserver reliability and acceptable for clinical use 
[25]. The reliability of the diagnosis of NeP by a physician is an important consideration in clinical 
practice because it has direct treatment implications for the individual patient. We performed this 
kappa study to see if the diagnosis of NeP is a reliable diagnosis because an objective gold standard 
for this diagnosis is lacking. As an example, in validation studies of questionnaires screening for 
NeP 2 physicians were both examining the same patient to serve as a substitute gold standard 
for diagnosis [13,14]. But until now no proof of this concept was given. According to the literature 
[20,25,27,28] we chose to use the kappa-value as well as the PA and Pi. The level of agreement for 
NeP component either as a part of MiP or as pure NeP appeared moderate. Regarding MiP we found 
a moderate but significant level of agreement which suggests that the clinical picture is less straight 
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forward. Probably, a combined pain syndrome is a less clear outcome, explaining the lower kappa. 
For pure NoP the physician pairs only had a fair, non significant level of agreement. The PA-value for 
NoP was below 70% and thus considered as not acceptable for clinical use. This might be due to the 
focus of the physicians: the instruction of the physician was to diagnose NeP in the way they were 
used to in their daily practice. Probably there was less attention to NoP. For NoP component the level 
of agreement was substantial. 
Although the participating physicians used different descriptions for NeP, a high consensus existed 
for the decisive symptom and sign for NeP, namely allodynia or a description of allodynia. However, 
allodynia is not a decisive symptom for NeP, because it might also be present in patients with 
nociceptive pain, especially in inflammatory conditions. 
The presented results indicate that the specialists used very different diagnostic criteria for 
neuropathic pain. This was confirmed most notably by the working definition used by the 
investigators, which corresponded to the IASP definition of neuropathic pain in only one third of 
the investigators (Table 2). In conclusion, the majority of the participating physicians didn’t know 
the current definition of neuropathic pain and use “personalized” inappropriate diagnostic criteria 
in their daily practice. 
In this study, we also have used the grading system by Treede et al [23], filled in by both physicians 
after the clinical examination of the patient. Comparing the diagnosis of the existence of an 
NeP component with the outcome of the grading system per physician, we found a substantial 
intraobserver reliability with a PA ≥ 70%, indicating a good reliability and useful in clinical practice. 
However, the comparison on the outcome of the grading system (unlikely, possible, probable, or 
definite) between both physicians gave a fair reliability and a low PA (< 70%), indicating a poor 
reliability between both physicians and therefore it might be less useful in clinical practice. 
Moreover, the grading system will not necessarily provide the right diagnosis. In a patient suffering 
from MiP, the NoP part may be paramount. The physicians’ diagnosis (NeP, MiP, NoP, or NP) had a 
moderate reliability, but also a low PA < 70%. All this indicates that it is difficult to categorize the 
kind of pain the patient is suffering from, as well with the physicians’ diagnosis as with the grading 
system. It can be questioned whether the clinical judgment should be regarded as a gold standard 
for the diagnosis of NeP because both clinicians might be wrong in their diagnosis even with values 
of Κ > 0.5 and a PA of 70%. 
Our study measured the interobserver reliability of 2 physicians diagnosing NeP in patients with 
pain from cancer and taking the grading system and the DN4 into account. The focus of the study 
was to diagnose the kind of pain and not on which specific diagnostic tests were used in the 
diagnostic process. Mostly, kappa studies are used to report the reliability of specific diagnostic 
tests in patients or from clinical data [18,29-31]. Comparing the outcome of the physicians diagnosis 
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on the existence of an NeP component with the outcome of the 7-item DN4 we found only a fair (Κ 
< 0.40) reliability for the pain specialists and a slight interobserver reliability for the palliative care 
specialists (both with a PA ≤ 70%). In the paper of Garcia de Paredes et al [7] it was described that 
only half of the patients with cancer suffering from NeP had a positive score on the DN4 compared 
with the clinicians diagnosis. They suggested investigating if a specific cut-off score for the DN4 for 
patients with NeP from cancer would fit better. The same was suggested in the study by Mercadente 
et al [32] for the LANSS, NPQ, and NPQ-SF. This study also indicates that the DN4, at this moment, is 
less valid and thus less useful in clinical practice for screening for NeP in patients with cancer pain. 
During the pain history taking, the pain specialists asked for a pain intensity score only 21 out of 
34 times and the palliative care specialists 27 times. A marginal comment should be made on this 
statement, as the physicians were only instructed to diagnose the type of pain. However, one expects 
a pain intensity score to be a standard item during a pain history taking. During the observation of 
the clinical examination of the patients, in 10 of 68 cases (Table 1), no clinical examination was 
performed, and in many cases only one sensory modality was tested. It has been recommended 
[16] that (a) clinical bedside (sensory) examination of a patient with suspected NeP includes testing 
of touch/vibration, cold, warmth, and pain sensibility (pinprick) and (b) the outcomes should be 
compared with the findings in the contra lateral region or in a region without pain (not performed 
in 21 of 68 cases). 
To our knowledge, this is the first study to determine the interobserver reliability of the diagnosis of 
NeP in patients with cancer. Participation of patients, examination rooms that were equipped as real 
consultation rooms, and instructing the physicians to perform the diagnosing procedure as they 
usually do, all contributed to collect reliable information about the current state of daily practice in 
this hospital. Besides, by using a video camera that was almost invisible to the physician and patient, 
the consultation was not disturbed by the researchers. 
While the patient number (N = 34) is sufficient for a reliable kappa study, the number of participating 
physicians was low and unequal: 4 participating pain specialists and 2 palliative care specialists. 
Another weak aspect was the fact that one of the palliative care specialists was a medical oncologist 
and the other an elderly care physician. Yet, both of them had palliative care as their main task for 
at least 7 years. However, both the pain specialists and the palliative care specialists will be more 
experienced than usual physicians in pain and NeP and our findings cannot be interpreted for a 
broader group of physicians. Furthermore, in the questionnaire, patients were asked about all sites 
of pain; whereas in the clinical examination, physicians were instructed to focus on the site of worst 
pain. The majority of patients had breast cancer. This high number is an adequate representation 
as breast cancer is the most frequent type of cancer among women in the Netherlands (www.
cijfersoverkanker.nl) and many of them suffer from chronic pain [33,34]. The incidence of NeP in 
this study is artificially high in comparison with the normal population in the oncology outpatient 
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clinic. Because we used a score of at least 2-points on the 7-item DN4 as an inclusion criterion for 
this study, the presence of NeP was more likely and thus enlarged the possibility of diagnosing 
NeP. For now it is not sure that in a situation of a lower incidence of NeP the kappa values will 
be the same. The physicians were also more triggered and focused on NeP than on NoP because 
we asked their working definition of NeP, the symptoms and findings at physical examination they 
considered decisive for NeP, and their self-efficacy in diagnosing NeP. This is probably the cause of 
a lower kappa-value in patients with NoP. Finally, the worst pain did not necessarily originate from 
the cancer or anti-cancer treatment. Patients sometimes had comorbidity causing the (worst) pain, 
for example rheumatoid arthritis. 
CONCLUSIONS
We found a substantial level of agreement for the diagnosis of NeP and a moderate level of agreement 
for diagnosing an NeP component, both with a PA ≥ 70%. This study shows preliminary evidence 
that the clinical judgment of NeP in patients with cancer is reliable. Implementation of the proposed 
criteria for categorizing NeP as definite, probable, possible, or unlikely might be a step forward [23] 
to come to more diagnostic clarity for NeP. As stated by Bennett et al [8] a standardized approach 
is essential for clinical assessment, for appropriate treatment, and for clinical research. Despite the 
lack of a gold standard for diagnosing NeP, our study shows that physicians have a good agreement 
in the diagnosis of pure NeP. For MiP however, the level of agreement is moderate but with a high 
PA. Based on these findings, in MiP we suggest the opinion of a second physician to enlarge the 
chance of a correct diagnosis and thereby of adequate pain treatment. Especially in more complex 
pain syndromes, the recognition of NeP component needs attention. Since the treatment of NeP 
and MiP or NoP is quite different according to the international guidelines, a strict delineation 
and certitude about the correct diagnosis is of upmost importance and will influence the result 
of consequent pharmacological treatment schemes [35]. Taking into account the different pain 
mechanisms of NeP and NoP and working mechanisms of the medications, it is important to have 
an adequate pain diagnosis for optimal pain treatment with the least side effects. The general value 
of the findings for validating physician assessment of neuropathic cancer pain in this study is limited 
to our centre and participating physicians in order to confirm their relevance and general interest. 
However, the findings in this study suggest that a better standardization of the clinical assessment 
and classification of pain in patients with cancer in respect to the identification of neuropathic pain 
is necessary. Moreover, we recommend a further study on how to improve the level of agreement 
in, and the validity of, the clinical diagnosis of NeP by systematically analyzing the history taking 
and the different (diagnostic) tools used in pain assessment and how standardizing the diagnostic 
process can improve the level of agreement and validity in clinical circumstances [16,23]. 
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ABSTRACT
Background
The presence of nerve damage plays a key role in the development and prognosis of chronic 
pain states. Assessment of the presence and severity of a neuropathic pain component (NePC) is 
key in diagnosing chronic pain patients. Low back pain (LBP) and neck and shoulder pain (NSP) 
are highly prevalent and clinically important medical and societal problems in which a NePC 
is frequently present. The more severe the NePC, the worse the course of the pain, its prognosis 
and the results of treatment. Reliable and standardised diagnosis of the NePC remains difficult 
to achieve. Standardized and validated screening tools may help to reliably identify the NePC in 
individual chronic pain patients. The aim of this study is to validate the Dutch language versions of 
the PainDETECT Questionnaire (PDQ-Dlv) and the ‘Douleur Neuropathique 4 Questions’ (DN4-Dlv) 
for use in primary and specialist medical care settings to screen for a NePC in patients with chronic 
pain due to (1) LBP, (2) NSP or (3) known peripheral nerve damage (PND). 
Methods / design
The study design is cross-sectional to assess the validity of the PDQ-Dlv and the DN4-Dlv with 2 
weeks follow-up for test-retest reliability and 3 months follow-up for monitoring and prognosis. 
438 patients with chronic pain due to (1) LBP, (2) NSP or (3) PND will be included in this study. Based 
on the IASP definition of neuropathic pain, two physicians will independently assess whether the 
patient has a NEPC or not. This result will be compared with the outcome of the PDQ-Dlv & DN4-Dlv, 
the grading system for neuropathic pain, bed side examination and quantitative sensory testing. 
This study will further collect data regarding prevalence of NePC, general health status, mental 
health status, functioning, pain attribution and quality of life. 
Discussion
The rationale for this study is to provide detailed information on the clinimetric quality of the PDQ-
Dlv and DN4-Dlv in Dutch speaking countries. Our innovative multi-factorial approach should help 
achieve more reliable diagnosis and quantification of a NePC in patients with chronic pain. 
Trial registration
The Netherlands National Trial Register (NTR3030). 
Keywords
PainDETECT questionnaire, PDQ, DN4, Validation, Low back pain, Neck-shoulder pain, Peripheral 
nerve damage 
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BACKGROUND
The International Association for the Study of Pain (IASP, 2011) defines Neuropathic Pain (NeP) as 
‘pain caused by a lesion or disease of the somatosensory nervous system’ (http://www.iasp-pain.
org/Education/Content.aspx?ItemNumber=1698 #Neuropathicpain). This definition will be used in 
this study because of its diagnostic specificity, anatomic precision and the usefulness in clinical as 
well as research conditions [1]. NeP plays an important role in the development and prognosis of 
chronic pain states. A relevant example is patients with low back pain (LBP) and neck-shoulder pain 
(NSP), which are both highly prevalent and clinically important medical and societal problems: In 
this context, the more severe the NeP, the worse the pain course, the prognosis and the results of 
treatment [2-5]. 
The incidence of NeP in the Dutch general population is 0.81% or 130.000 new patients in the 
Netherlands per year. NeP is 63% more common in women than in men and peaks between 70 
and 79 years of age [6]. LBP as well as NSP are among the top 10 health problems encountered 
in general practice. For men and women, respectively, the prevalence of LBP and/or NSP in the 
general practice is in the range of 55 – 86 and 24 – 113 per 1000 patients a year. In general practice, 
radiating pain from the low back or neck occurs in men and women in respectively 4 – 8 and 10 
patients per 1000 patients [7] (http://www.nationaalkompas.nl/gezondheid-en-ziekte/ ziekten-en-
aandoeningen/bewegingsstelsel-en-bindweefsel/ nek-en-rugklachten/ omvang/). The prevalence 
of chronic pain syndromes due to peripheral nerve damage (PND) is 3,3 per 1000 per year [8]. 
Strictly speaking, the diagnosis of neuropathic pain is a patho-anatomical diagnosis presuming 
knowledge regarding nerve injury which is difficult to obtain in the clinical situation. Thus in the 
clinical context it is better to speak of a neuropathic pain component (NePC), which is a clinical 
syndrome based on a typical set of clinical symptoms and signs. Clinically, a NePC is characterized 
by spontaneous pain and abnormal pain sensations [9]. NeP is typically described as a spontaneous 
ongoing burning or shooting pain with spontaneous sharp exacerbations and somatosensory 
abnormalities after a (non-) noxious stimulus [10]. 
As a rule, a NePC has a considerable impact on the quality of daily life [6]. Hence it is important for 
physicians in daily practice (specialist care as well as primay care) to diagnose the presence and 
severity of a NePC in individual patients. In clinical practice it is, however, often difficult to reliably 
diagnose a NePC in (sub)acute and chronic pain of the low back and neck shoulder region. The 
diagnosis of a NePC is at present primarily based on clinical examination by a physician including 
sensory examination. Quantitative sensory testing (QST) may provide extra information for selected 
clinical cases and in the research context [11,12]. 
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Because a reliable diagnosis of the neuropathic pain component is often difficult to accomplish in 
routine practice [2], it would be helpful to have a screening tool to detect such a component for 
clinical triage and epidemiological purposes [12,13]. Apart from optimal sensitivity and specificity, 
such a screening tool should be easy to use in clinical practice, not only for the first visit but also 
during follow up. The availability of such a simple, validated, Dutch language screening tool should 
improve diagnosis and quantification of a NePC and hence lead to better therapy. At present, no 
specific (validated) instrument to determine the neuropathic component in LBP, NSP and PND 
is available in the Dutch language. The PainDETECT-Questionnaire (PDQ) [2] and the Douleur 
Neuropatique 4 Questions (DN4) [14] were originally developed and validated in Germany and 
France, respectively. Both are considered to be reliable screening tools with a high sensitivity, 
specificity and positive predictive value. Recently, the DN4 and the PDQ have been translated into 
a Dutch language version (Dlv) by Van Seventer et al [15] and Timmerman et al [16], respectively. 
Validation of the Dutch versions of DN4-Dlv and PDQ-Dlv will improve the identification of a NePC 
in Dutch primary and specialist medical care, also facilitating remote follow up evaluation by 
telephone, internet or post for clinical and scientific purposes. We chose an innovative approach 
which should lead to a more reliable identification and quantification of a NePC in patients with 
chronic pain. This study will help define patient groups at risk for a NePC and will help to understand 
and assess the variability and burden of a NePC in individual patients. 
The aim of this study is to establish the clinimetric quality, including 2-weeks test-retest reliability, of 
the PDQ-Dlv and the DN4-Dlv for use in primary care and specialist medical care settings in Dutch 
speaking countries for patients with chronic pain due to LBP, NSP or known peripheral nerve damage 
(PND). Follow-up for monitoring and prognosis properties of DN4-Dlv and PDQ-Dlv for a NePC will 
be done over a period of 3 months. Additional data will be collected regarding NEPC prevalence, 
general health status, mental health status, functioning, pain attribution and health related quality 
of life in patients with chronic pain. 
METHODS
The medical and ethical review board Committee on Research Involving Human Subjects region 
Arnhem-Nijmegen, Nijmegen, the Netherlands, has given approval to conduct this study, Dossier 
number: 2008/348; NL 25343.091.08; The Netherlands National Trial Register NTR3030. 
Design 
In this study a cross-sectional, observational, research design with 3-months follow up will be used 
to study the clinimetric quality of the DN4-Dlv and PDQ-Dlv (Figure 1). 
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Specialized pain centers 
Departments of neurology 
General practices 
N=438 , 146 patients in each patient group 
Medical history: Date of birth; gender; duration of complaints; presence of diabetes mellitus; 
co-morbidity 
 
Examination by both physicians 
 
Questionnaires: 
 PDQ 
 DN4 
 DRI  
 HADS 
 SF-36 
 PAS 
Patient population: 
A. Patients with chronic Low Back Pain      
B. Patients with chronic Neck/Shoulder Pain 
C. Patients with chronic pain from Peripheral Nerve Damage 
20% QST measurement (n=88) 
2 weeks follow-up (PDQ & DN4 + PGIC) 
 Test-retest reliability 
 
3 months follow-up (PDQ & DN4 + PGIC) 
 Medical record control for patients with probable neuropathic pain component: Does the 
patient still have a probable neuropathic pain component or has it become a possible, 
unlikely or definite neuropathic pain component? 
 Prognostic value 
Figure 1: Flow-diagram of the study. 
  PDQ: PainDETECT questionnaire; DN4: Douleur neuropatique 4 questions; DRI : Disability rating index; 
HADS: Hospital anxiety depression scale; RAND-36: RAND 36-item health survey; PAS: Pain attribution 
scale; QST: Quantitative sensory testing; PGIC: Patients global impression of change.
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Setting 
Multicenter recruitment will be take place in academic pain centres, non-academic pain centres and 
non-academic departments of neurology. Patients will be seen by the two physicians during normal 
office hours, or when that is not possible during a special office hour for this study. Furthermore, 
patients willing to participate in this study from general practices will also be included in this 
study via a special office hour in the clinical trainings centre of Radboud university medical center 
(Radboudumc). 
Each patient will be seen by two physicians, independently of each other, working in the same 
institute. The medical background of the participating physicians is diverse (experienced pain 
specialists, pain specialist trainees, experienced neurologists and experienced general practitioners). 
Participants 
The patients will be recruited non-selectively and consecutively in the period from September 2009 
till July 2013. Inclusion criteria: Male and female adult patients (>18 years of age) with chronic (>3 
months) LBP or NSP radiating into respectively leg(s) or arm(s) or patients with chronic pain due 
to PND. Exclusion criteria: Patients diagnosed with malignancy, compression fractures, patients 
with painful syndromes of unknown origin or associated with diffuse pains (such as ankylosing 
spondylitis or fibromyalgia), severe mental illness, chronic alcoholism or substance abuse, inability 
to fill in the questionnaire adequately, or incapable of understanding Dutch. Subjects can leave 
the study at any time for any reason without any consequences. The investigator can decide to 
withdraw a subject from the study for urgent medical reasons. When an individual subject leaves 
the study all the information from the patient will be kept in the database, and possibly be used for 
data analysis or withdrawal analysis. Such patients will be replaced. 
Measurements 
At the first visit, each patient will be seen by two physicians who will question and examine the 
patients. They will then independently classify the patients’ pain as pain with or without a NePC, 
based in the IASP NeP criteria and supported by a standardized assessment form. Next, the patient 
will complete seven questionnaires (including the PDQ and the DN4). Twenty percent of the patients 
will additionally undergo QST measurement following the first visit. Two weeks and three months 
after the initial visit three follow-up questionnaires will be sent to the patient by mail. 
Demographics 
Date of birth, gender, weight (Kg), length (m), nationality, nationality of origin, pain medication, 
smoking (cigarettes a day), alcohol consumption (units per day) and education level will be assessed 
by use of a self completed questionnaire. Pain at this moment will be assessed by use of a numeric 
rating scale (0-10, NRS). Medical co-morbidity, duration of complaints (years/months), presence of 
diabetes mellitus (yes/no), presence of HIV (yes/no), presence of herpes (yes/no) and undergoing of 
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chemotherapy (yes/no) are based on interview by the physician and noted by the physician on the 
standardized assessment form. 
Pain classification 
At each centre participating patients will be examined by two (rater A and B) independent and 
trained pain physicians, two experienced neurologists or two experienced general practitioners, 
working independently of each other and blinded to the diagnosis of the other physician. To achieve 
standardization of the history and clinical examination all participating physicians will be trained at 
the sites. Both physicians will classify the pain regarding the presence or absence of a NePC based on 
history and clinical examination. Level of certainty of the physicians regarding the pain component 
classification will be assessed by use of a Visual Analogue Scale (VAS, range 0-100). The findings are 
noted on the standardized assessment form by the physician. To monitor the quality of the clinical 
examination random quality checks, by expected/ unexpected visits, will be used. 
Grading system 
The grading system for neuropathic pain as proposed by Treede et al. [1] will be used as a secondary 
comparison with the outcome of both the PDQ-Dlv and DN4-Dlv and with the outcome of the 
original pain classification by the two physicians. This system provides a working hypothesis for the 
origin of patients’ pain. The criteria are graded on basis of history and testing in medical examination 
[1]: (1) Pain with a distinct neuroanatomically plausible distribution; (2) A history suggestive 
of a relevant lesion or disease affecting the peripheral or central somatosensory system; (3) 
Demonstration of the distinct neuroanatomically plausible distribution by at least one confirmatory 
test; (4) Demonstration of the relevant lesion or disease by at least one confirmatory test lesion or 
disease explaining NeP. When the criteria 1-4 are all fulfilled the pain will be graded as possessing 
a ‘definite NePC’. Criteria 1 and 2 and either 3 or 4 will be graded as ‘probable NePC’. Criteria 1 & 2 
without criteria 3 or 4 will be graded as ‘possible NePC’. The pain is ‘unlikely to have a NePC’ when 
no criteria, or only criteria 1 or 2, are graded as present (Table 1). The answers (yes or no) to the four 
criteria are noted by the physician on the standardized assessment form. Three months after the first 
consultation by the two physicians the medical record of patients with ‘probable NePC’ according 
to the grading system will be controlled: i.e. does the patient still have probable NePC, or does he 
now have definite NePC?. 
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Bedside examination 
Bed-side examination of the patient is performed by both physicians. The aim of this examination is 
to find possible abnormalities suggestive for a relevant lesion or disease which affects the peripheral 
or central somatosensory system [17]. The value of bed-side examination within the clinical 
examination is that it will give insight in the pathology and the localization of the lesion or disease 
which is causing the pain. Touch, pin prick, pressure, cold, heath, vibration and temporal summation 
were included in the examination to provide proof of a NePC [10,12,18]. This evaluation will be 
assessed in a standardized way. The location indicated by the patient as the one with maximum 
pain will be compared with the mirrored location on the contra lateral side. If the pain has a double 
sided character a location without pain as close as possible to the original mirror site will be tested 
for comparison. The outcome is noted by the physician on the standardized assessment form: a) Is 
there a sensation b) is the sensation unpleasant or c) is the sensation painful (all scored as Yes, No or 
Unclear). The response of the patient will be noted on the assessment form. The following tests will 
be performed in all patients: Mechanical static allodynia by blunt pressure with a finger at a force 
which normally doesn’t evoke pain; Dynamic mechanical allodynia by stroking the skin with a Soft 
Brush (SENSElabTM, Brush-05, Somedic AB, Hörby, Sweden), one movement of 1-2 centimeter and 
three movements of 1-2 centimeters (wind-up response); Mechanical pinprick allodynia by touch 
of the skin with a plastic safety pin and a Von Frey hair (TOUCH TESTR, 5.07, 10.0 g, North Coast 
Medical Inc., Gilroy, USA). Heat allodynia by using TipThermR (TipTherm, Brüggen, Germany) in a 
baby-bottle warmer (ISI mini Baby Bottle Warmer, Assen, the Netherlands) set at 45 degrees Celsius; 
Cold allodynia with an ice cube placed on the skin for 2 seconds and Vibration with a Tuning fork 
(128 Hz; Medipharchem, Wormerveer, the Netherlands) applied to joint, bone or soft tissue in the 
region of the pain. 
Quantitative sensory testing 
Over the last two decades, QST has been developed to complement traditional neurological 
bedside examination in the analysis of somatosensory aberrations [19,20]. In theory, greater 
precision in assessing the functionality of the somatosensory systems is the main advantage of 
QST over standard bedside examination. QST improves diagnostic procedures and can be helpful 
for treatment monitoring [11,21]. The protocol we chose is the Nijmegen Aalborg Screening QST 
Paradigm (NASQ Paradigm) [22]. This maps pain sensitivity at multiple sites by measuring the 
responses (i.e. painful sensations) evoked by mechanical and electrical non invasive stimuli and 
measures the patient’s capacity to modulate pain using the Conditioned Pain Modulation [23], 
previously termed Diffuse Noxious Inhibitory controls (DNIC) or Heterotopic Noxious Conditioning 
Stimulation (HNCS) [24]. In this study the QST is used to quantify alterations in sensory processing 
due to the NePC (sensory profiling) in a sub-sample of patients with LBP, NSP and PND (20% of the 
total population under study, n = 88, equally but randomly divided over all three pain syndromes). 
Instructions are standardized and will be read to the patient from an instruction sheet. Pressure 
Pain Thresholds (PPT) will be tested by use of an pressure algometer (Somedic sales AB, Hörby, 
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Sweden). PPT will be measured on the left and right bodyside once at each location: Thenar (middle 
part), musculus trapezius pars median (middle part), musculus rectus femoral (15 cm above patella) 
and m. abductor hallucis (middle part). Electrical pain thresholds (EPT) will be tested by use of the 
QST-3 device (JNI Biomedical ApS, Klarup, Denmark) on the left and right body side. Measurement 
locations are the musculus trapezius pars median (middle part) and the musculus rectus femoris 
(20 cm above patella). Electrical pain thresholds (EPT) are assessed and expressed in milli-Ampère. 
Single pulse evoked pain measurement is performed by one pulse at 150% of the EPT and assessed 
on a VAS. Summation (i.e. Electric Wind-Up response (E-WUR)) is measured by a train of five pulses 
at 150% of the EPT and assessed on as VAS. Conditioned Pain Modulation (CPM) [23,25] will be 
assessed. Electrical Pain Tolerance Thresholds (EPTT) (test stimulation) are assessed and expressed 
in milli-Ampère on the m. Rectus femoris contralateral to the dominant hand. The noxious stimulus 
(conditioning stimulation) is to immerse the dominant hand until the wrist in a bucket filled with 
water and icecubes (‘Ice water bucket test’) [24] for ‘as long as possible, until the moment that the 
sensation becomes unbearable and you want to stop directly”. The pain will be recorded every 
10 seconds on a NRS. The duration of the immersion (with a maximum of three minutes) will be 
recorded and the pain at the end of the immersion will be asked. Afterwards, again the EPTT and the 
PPT on the contra lateral m. rectus femoris are assessed. 
Douleur neuropathique 4 questions (DN4) 
The DN4 [14,15] (© Pfizer bv. Capelle a/d Ijssel, the Netherlands) consists of 10 items in total, divided 
in two questions and two physical examination tests, and is developed to screen components of 
NeP resulting in a yes/no answer for the presence of NeP. Questions 1 & 2 are sensory descriptors 
and have to be filled in by the patient or assessed by the physician by interview; questions 3 & 4 
are based on a sensory examination by the physician. Question 3 includes two items related to 
sensory deficits: ‘Is the pain located in an area where the physical examination may reveal one or 
more of the following characteristics? Touch hypoesthesia and/or pricking hypoesthesia. Question 
4 includes 1 item related to evoked pain: ‘In the painful area, can the pain be caused or increased by 
brushing? Examination of sensitivity to touch (one movement) will be performed with the use of a 
soft brush (SENSElabTM, Brush-05, Somedic AB, Hörby, Sweden). The soft brush will also be used to 
evaluate tactile (i.e. dynamic mechanical) allodynia (wind-up, with three movements). Examination 
of sensitivity to touch and pricking will be performed with the use of a Von Frey hair (TOUCH 
TESTR, 5.07, 10.0 g, North Coast Medical Inc., Gilroy, USA). Pressure allodynia (i.e. static mechanical 
allodynia) is tested by blunt pressure with a finger at a pressure that does not provoke pain in a 
normally sensitive area [14]. The findings in the physical tests are noted by the physician on the 
standardized assessment form. The cut-off score for the diagnosis of NeP for the 10-item’ DN4 was 
determined on 4 times ‘yes’ out of 10 (score range 0-10). This score gave the highest percentage 
of correctly identified patients (86%), sensitivity (82,9%) and specificity (89,9%). The 7-item’ DN4-
interview (score range 0-7) has a cut-off score of 3 times ’yes’ out of 7 which resulted in a percentage 
of correctly identified patients of 79, 5%, 78% sensitivity and 81,2% specificity [14]. 
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PainDETECT-Questionnaire (PDQ) 
The PDQ (© Pfizer Pharma GmbH 2005, Pfizer bv 2009. Cappelle a/d IJssel, the Netherlands) was 
developed in Germany [2,16]. The questionnaire can be filled in by the patients themselves and was 
devised to screen for the presence of a NePC without physical examination. Scoring is performed 
using a scoring manual and results in a final screening score for the presence of a NePC: ‘negative,’ 
a NePC is unlikely (<15%, score range 0-12); ‘unclear’, result is ambiguous, however a NePC can be 
present (score range 13-18); or ‘positive’, a NePC is likely (>90%, score range 19-38). The PDQ was 
tested as a reliable screening tool with a percentage of correctly identified patients of 83% for NeP, 
sensitivity of 85% and a specificity of 80% [2]. 
Additional questionnaires 
Functioning: Disability Rating Index (DRI) [26]. The self- administered DRI inquires, in a clinical 
setting, in 12 items about specified activities (Dressing, Out-door walks, Climbing stairs, Sitting 
longer time, Standing bent over a sink, Carrying a bag, Making a bed, Running, Light work, Heavy 
work, Lifting heavy objects, Participating in exercise/sports). Score range is from 0 to 100 for each 
item on a Visual Analogue Scale (VAS). A higher score indicates more disability. The DRI has a good 
responsiveness (p = 0,0001) and a good test-retest correlation of 0,95. The inter- and Intra-rater 
reproducibility were respectively 0.99 and 0.98 [26]. Mental health status: The Hospital Anxiety 
Depression Scale (HADS) [27] will be used to assess the presence of anxiety and depressive states 
of patients. This self-administered questionnaire is divided into an anxiety subscale (HADS-A) and 
a depression subscale (HADS-D), both containing 7-items with a score range of 0-21. The HADS-Dlv 
[28] has a good test-retest reliability for HADS-A, HADS-D and the total HADS (respectively 0.89; 
0.86 and 0.91 p =0.001). The correlation between the anxiety and the depression subscale was 
high (0.43 to 0.73) [28]. Based on the review by Bjelland [29] a cut-off score for both the HADS-A 
and the HADS-D of 8+ gives the best balance in sensitivity and specificity (approximately 0.80 for 
sensitivity and specificity). Pain Attribution: Pain Attribution Scale (PAS) Additional questions to 
study the attribution of the pain in patients. On a 5-point Likert-scale the patient is asked to rate 
the influence of several items on the pain complaints. Rating is from ‘totally not of influence on 
the pain complaints’ to ‘very much of influence on the pain complaints’. Quality of life: The RAND 
36-item Health Survey (RAND-36) [30] is developed to investigate the health related quality of life. 
The short, self-administered questionnaire consists of 8 different scales: Physical functioning, social 
functioning, role limitations (physical problem), role limitations (emotional problem), mental health, 
pain, general health perception and health change. The psychometric quality of the RAND-36-Dlv 
was studied by van der Zee [31,32]. Change (Follow-up, 2 weeks and 3 months): The Patients Global 
Impression of Change (PGIC) is a patient rated instrument which measures changes over time on 
a seven-points scale. Score range is from 1 (very much worse) to 7 (very much improved) [33-35]. 
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Power calculation 
In an unselected cohort of chronic LBP patients, 37% had a high probability of a NePC [2]. Sensitivity 
and specificity of the PDQ is respectively 85% and 80% [2] and the sensitivity and specificity of 
the DN4 are respectively 83% and 90% [14]. The expected sensitivity and specificity of the Dutch 
versions of both questionnaires is set at 80% with an prevalence of 37% and the required lower 95% 
confidence limit > 0.55. According to Flahault et al the N cases is 40. From the equation in the first 
formula by Flahault, the Ncontrols = 68 [36]. Without prior knowledge of the individual case-control 
status, the sample size must be determined such that, with high probability (e.g. 95%), the sample 
contains sufficient numbers of cases and controls. According to the second formula by Flahault et 
al: Ntotal = 132, in each group. Thus in each group 146 patients will be included (10% drop out). It 
is expected that this recruitment will be achievable in the 10 general practices, 4 pain treatment 
centres and 2 departments of neurology chosen. 
Data 
All data will be collected from the patients and the physicians on paper and stored by Radboudumc. 
Data management and monitoring will be performed within MACRO (MACRO, version 4.1.1.3720, 
Infermed, London, United Kingdom). 
Statistical analysis 
To establish the clinimetric quality of the PDQ-Dlv and the DN4-Dlv a comparison will be made 
between the outcome of both the screening questionnaires and the original pain classification, 
the Grading system by Treede at al. [1], the bedside examination and the QST measurements. 
The prevalence of a NePC in patients with LBP and NSP in the Netherlands will be assessed by 
extrapolating the outcome of this study to the Dutch population. The monitoring and prognosis of 
the patient over a period of three months by use of the PDQ-Dlv and the DN4-Dlv will be recorded. 
Data analysis and statistics will be performed by use of Statistical Package for the Social Sciences 
(SPSS version 18.0, SPSS Inc., Chicago, Illinois, USA). All statistical tests will be two-tailed, for all 
statistical analysis the type 1 error will be set on 5%. 
Descriptive statistics: The quantitative variables will be described using mean, standard deviation 
(SD) and range; Qualitative variables will be described using frequency and percentages. To assess 
central position, dispersion and distribution of variables, the Kolmogorov-Smirnov test will be used. 
Univariate analysis: Both the physicians assessments (by rater A and B) will serve as the ‘gold standard’ 
to assess the presence of a NePC. The internal consistency of both the physicians assessments and the 
physical examination tests of the DN4 will be separately established for rater A and B by calculating 
Cronbach’s α that assesses the contribution of each item to the precision of the measurement by 
both the physicians assessments and the examination items of the DN4 questionnaire. 
Study protocol
97
4
Inter-rater reliability: will be assessed by the agreement of the results obtained by raters A and B for 
both the physicians assessments and the examination items of the DN4. Agreement was determined 
by calculating the Cohen’s kappa coefficient. 
Test-retest reliability: will be assessed for the PDQ and DN4, after two weeks of completion of the 
questionnaires during the first visit. Stability of the questionnaire will be analyzed by measuring the 
intra-class correlation coefficient and by use of Cohen’s kappa coefficient of agreement. 
Prognosis and monitoring: will be assessed for the PDQ and DN4, after three months of completion of 
the questionnaires during the first visit. Stability of the questionnaire will be analyzed by measuring 
the intra- class correlation coefficient and by use of Cohen’s kappa coefficient of agreement. 
Correlations: will be calculated between scores and continuous variables using Pearson correlation 
coefficient (i.e. correlation between DN4, PDQ and both the physicians assessments). A students-t 
test for independent groups or a Mann-Whitney’s U test (non-normal distribution) will be used 
to compare respectively continuous or ordinal variables between patients with and without a 
neuropatic pain component 
Multivariate analysis: Sensitivity and specificity percentage of well classified observations and 
Youden index (i.e. sensitivity + specificity-1) will be calculated for different values of the score of 
the questionnaire by logistical regression analysis. Positive and negative predictive value for both 
instruments will also be calculated. The corresponding ROC (receiver operating characteristics) 
curves will be plotted and AUC calculated using the trapezoid method. Discriminant analysis will be 
used to analyze complementarily of PDQ and DN4 to each other. 
DISCUSSION
The rationale for this study is to provide detailed information on the clinimetric quality, including 
test-retest reliability, of the PDQ-Dlv and DN4-Dlv in patients with LBP, NSP or PND regarding 
of diagnosing a NePC. A validation of these questionnaires is necessary for its use in everyday 
clinical practice and also in (inter-)national research to make the outcome comparable in different 
countries. The key question of this study is whether a NePC as assessed by the physician is reflected 
in the outcome of the PDQ-Dlv and DN4-Dlv. In already published articles both questionnaires 
have proven to be useful in daily clinical practice and for research purposes with good clinimetric 
qualities [2,14]. 
This study chose an innovative and wide ranging approach to diagnose a NePC in patients in based 
on a more reliable identification and qualification of a NePC. In the absence of an internationally 
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accepted ‘gold standard’ [12] the challenge was to find a method to examine the patients in a 
standardized manner to assess a NePC. The opinion of two physicians about a NePC, the most 
frequently used standard, will be used in this study and is also used in the original validation studies 
by Freynhagen et al [2] and Bouhassira et al. [14]. Together with the grading system [1], sensory 
bed-side examination and QST we will aim to confirm the diagnosis of a NePC, also following the 
NeuPSIG guidelines for the assessment of neuropathic pain [12]. Screening for nerve damage on 
basis of sensory bed side examination will be performed by both the physicians. The aim of this 
examination is to find possible abnormalities suggestive for a relevant lesion or disease which 
affects the peripheral or central somatosensory system [17]. The value of bed-side examination 
within the clinical examination is that it will give insight into the pathology and the localization of 
the lesion or disease which is causing the pain. Touch, pin prick, pressure, cold, heath, vibration and 
temporal summation were included in the examination to assess the NePC of pain [10,12,18]. For 
heat allodynia we use a Tip-ThermR in a baby-bottle warmer at 45 degrees Celsius. To our knowledge 
we are the first to use this method. Because a bottle warmer has a reasonably good thermostat, the 
temperature of the water inside, and thus the TipThermR, will be kept at the set temperature. In this 
study we did not use the DFNS sensory testing protocol [19,20] but our own NASQ-protocol. This 
because we were interested in using QST to assess the altered pain processing, including changes 
in function of endogenous pain modulation, that may underlie chronic pain conditions, instead of 
testing small and large nerve-fibre function and the nerve damage related sensory changes [21]. 
This study will aim to try to define patient groups at risk and to understand and assess the variability 
and burden of a NePC in individual patients. The PDQ [2] outcome is an ordinal scale, ranging from 
zero to thirty-eight (a neuropathic pain component is unlikely-neuropathic pain component is 
likely) and thus the question logically arises whether the PDQ is suitable for the assessment of the 
amount of nerve damage. 
By the choice for a non-selective consecutive patient recruitment in specialized pain clinics, 
neurology clinics as well as general practices this study aims to validate the PDQ-Dlv and DN4-Dlv 
in a general, unselected chronic pain population. To date, almost all screening questionnaires are 
validated in a defined, restricted, population, recruited in specialized pain clinics and pre-selected by 
precise medical diagnosis (lumbar radicular pain, diabetic polyneuropathy, postherpetic neuralgia 
etc.). Our choice of a non-selcted population might lead to a lower sensitivity and specificity of the 
PDQ-Dlv and DN4-Dlv in this study than published in the original validation studies [2,14]. However, 
the choice for a non-consecutive population has the advantage of providing more information 
relevant to ordinary clinical practice, in that it is relevant to the unselected ‘general population’. 
In conclusion, this study seeks to identify the association between patient’ symptoms, the signs as 
found in the bedside examination and outcome of the QST measurements, the general and mental 
Study protocol
99
4
health status, functioning, pain attribution and quality of life with regard to the outcome of the 
PDQ-Dlv and DN4-Dlv in patients with chronic pain due to LBP, NSP or PND. 
TRIAL STATUS
This study is ongoing. The expected end date of patient recruitment in this study is July 1, 2013. 
ABBREVIATIONS
CPM: Conditioned pain modulation; DN4: Douleur neuropathique 4 questions; DN4-Dlv: Douleur 
neuropathique 4 questions dutch language version; DNIC: Diffuse noxious inhibitory control; 
DRI: Disability rating index; HADS: Hospital anxiety depression scale; LBP: Low back pain; NASQ 
paradigm: Nijmegen otali screening QST paradigm; NeP: Neuropathic pain; NePC: Neuropathic 
pain component; NRS: Numeric rating scale; NSP: Neck shoulder pain; PAS: Pain attribution scale; 
PDQ: PainDETECT questionnaire; PDQ-Dlv: PainDETECT questionnaire dutch language version; 
PGIC: Patients global impression of change; RAND-36: RAND 36-item health survey; Radboudumc: 
Radboud University medical center; QST: Quantitative sensory testing; VAS: Visual analogue scale. 
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ABSTRACT
Background
Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory nervous 
system and is a major therapeutic challenge. Several screening tools have been developed to help 
physicians detect patients with neuropathic pain. These have typically been validated in populations 
pre-stratified for neuropathic pain, leading to a so called “Catch-22 situation:” “a problematic situation 
for which the only solution is denied by a circumstance inherent in the problem or by a rule”. The validity of 
screening tools needs to be proven in patients with pain who were not pre-stratified on basis of the 
target outcome: neuropathic pain or non- neuropathic pain. This study aims to assess the validity of 
the Dutch PainDETECT (PainDETECT-Dlv) in a large population of patients with chronic pain. 
Methods
A cross-sectional multicentre design was used to assess PainDETECT-Dlv validity. Included where 
patients with low back pain radiating into the leg(s), patients with neck-shoulder-arm pain and 
patients with pain due to a suspected peripheral nerve damage. Patients’ pain was classified as 
having a neuropathic pain component (yes/no) by two experienced physicians (“gold standard”). 
Physician opinion based on the Grading System was a secondary comparison. 
Results
In total, 291 patients were included. Primary analysis was done on patients where both physicians 
agreed upon the pain classification (n = 228). Compared to the physician’s classification, PainDETECT-
Dlv had a sensitivity of 80% and specificity of 55%, versus the Grading System it achieved 74 and 46%. 
Conclusion
Despite its internal consistency and test-retest reliability the PainDETECT-Dlv is not an effective 
screening tool for a neuropathic pain component in a population of patients with chronic pain 
because of its moderate sensitivity and low specificity. Moreover, the indiscriminate use of the 
PainDETECT-Dlv as a surrogate for clinical assessment should be avoided in daily clinical practice 
as well as in (clinical-) research. Catch-22 situations in the validation of screening tools can be 
prevented by not pre-stratifying the patients on basis of the target outcome before inclusion in a 
validation study for screening instruments. 
Trial registration
The protocol was registered prospectively in the Dutch National Trial Register: NTR 3030. 
Keywords
PainDETECT questionnaire, Reliability, Validity, Sensitivity, Specificity, Screening tool, Neuropathic 
pain, Pain, Clinical assessment, Low back pain, Neck shoulder arm pain, Peripheral nerve damage 
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BACKGROUND
The International Association for the Study of Pain defines neuropathic pain as “pain caused by 
a lesion or disease of the somatosensory nervous system” and states that “neuropathic pain is not a 
medical diagnosis but a clinical description which requires a demonstrable lesion or a disease that 
satisfies established neurological diagnostic criteria” [1]. In the clinical context it is better to speak 
of a present or an absent neuropathic pain component (present- or absent NePC) with respect to 
so called mixed-pain conditions [2, 3] in which neuropathic pain and nociceptive pain both exist. 
Clinically, NePC is considered to manifest specific symptoms and signs [4, 5]. The classification of 
NePC is usually based on history and physical examination including (bedside-) sensory testing [6, 
7]. The correct classification of NePC is important for patients because NePC has a considerable 
impact on the quality of daily life [8] and for physicians since the treatment differs strongly from that 
of patients without NePC [6, 9, 10]. 
An easy to use and validated screening tool for clinical triage and epidemiological purposes could 
aid uniform classification and quantification of NePC and hence lead to better therapy, particularly 
when used by non-specialists [6-8, 11-15]. 
The PainDETECT is such a patient friendly screening tool for the screening for neuropathic pain. It 
was originally developed and validated in Germany [2] based on two groups of patients (patients 
with pain of predominantly neuropathic origin or of predominantly nociceptive origin) with at 
least a 40% score on a visual analogue scale for pain (VAS; 0-100). The gold standard used in this 
study was the assessment of the pain type based on the examination by two experienced pain 
specialists. This resulted in a percentage of correctly identified patients of 83% for neuropathic 
pain, a sensitivity of 85 and 80% specificity [2]. Subsequently, validation studies were performed 
in Spain [16], Turkey [17], Japan [18], India (Hindi) [19] and Korea [20]. Since the introduction of the 
PainDETECT this instrument has been used in many clinical and epidemiological studies [21]. In a 
Danish study, based on PainDETECT outcome, NePC was present [22] in about 40% of the patients 
with musculoskeletal pain. 
In the above-mentioned validation studies [2, 16-20], the validity of the PainDETECT as a screening 
tool was performed in pre-stratified groups of patients based on the target outcome (pain of 
predominantly neuropathic origin or of predominantly nociceptive origin and limitation to pain 
scores). The inclusion of only patients with a known pain classification on forehand might lead 
to a prerequisite for the determination of validity of the PainDETECT. For this situation, the term 
“Catch-22” is used in the English language for “a problematic situation for which the only solution is 
denied by a circumstance inherent in the problem or by a rule” [23]. It was firstly described in Joseph 
Heller’s novel Catch-22 which describes a general situation in which an individual has to accomplish 
two actions that are mutually dependent on the other action that must be completed first. 
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The objective of this study is to further validate the PainDETECT as a screening tool for use in daily 
outpatient practices for detecting a NePC. The current validation study is being conducted in 
a general patient population having common chronic pain syndromes, not pre-stratified on the 
target outcome: low back with leg pain (LBLP), neck-shoulder-arm pain (NSA pain) or a suspected 
peripheral nerve damage pain (suspected PND pain).
METHODS
The study was conducted in a cross-sectional, observational, research design with two weeks and 
three months follow up to study the clinimetric quality (i.e. reliability and validity) of the PainDETECT. 
This study, to detect a NePC in patients suffering from chronic pain, was approved by the medical 
and ethical review board Committee on Research Involving Human Subjects region Arnhem-
Nijmegen, Nijmegen, the Netherlands, Dossier number: 2008/348; NL 25343.091.08 and conducted 
in accordance with the declaration of Helsinki and the declaration of the World Medical Association. 
As required, written informed consent was obtained from patients prior to study participation. The 
protocol is registered in the Dutch National Trial Register: NTR 3030. The PainDETECT was translated 
and cross-culturally adapted into the Dutch language (PainDETECT –Dlv) (© Pfizer Pharma GmbH 
2005, Pfizer bv 2008. Cappelle a/d Ijssel, the Netherlands) in a separate study [24] before the 
commencement of the present validation study. In this study, the same methodology was used as 
in the previously published protocol [25] and as employed in a simultaneous study regarding the 
validity of the DN4 [26] . 
Patients 
The patients were recruited from October 2009 until July 2013. Multicenter recruitment took place 
in the Netherlands in three academic centers specialized in pain medicine, three non-academic 
centers specialized in pain medicine and one non-academic department of neurology. The question 
to participate in the study was asked by the patients’ own physician. At that moment they only 
had a provisional diagnosis: LBLP, NSA pain or pain due to a suspected PND (Conditions associated 
with a lesion of the peripheral somatosensory system). These three groups of patients include a 
majority of the patients referred towards an academic or peripheral pain clinic from the general 
practitioner. Patients had to be diagnosed for the initial cause of the pain as classified according 
to the International Statistical Classification of Diseases and Related Health Problems 10th Revision 
(ICD-10)-2015-WHO Version 2015 [27]. Importantly, patients were not pre-stratified on the target 
outcome: the existence of NePC yes or no [28]. Patients, when willing to participate, were included 
when they met the following inclusion criteria: Male or female adult patients (> 18 years of age) 
with chronic (≥3 months) LBLP or NSA pain radiating into leg (s) or arm (s) respectively or patients 
with chronic pain due to a suspected PND. Exclusion criteria were: Patients diagnosed with an 
active malignant disorder, compression fractures, patients with diffuse pains (pains with an origin 
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in muscles, bones or joints: such as fibromyalgia or ankylosing spondylitis), severe mental illness, 
chronic alcoholism or substance abuse, inability to fill in the questionnaire adequately or incapable 
of understanding the Dutch language. 
Physicians’ assessment
Patients were examined for the presence of NePC by two physicians which was considered to 
be the “gold standard” in this study. The physicians (pain specialists, pain specialist in training or 
neurologists always operated in differently composed pairs) worked independently from each other 
and were blinded to the classification made by the other physician. The physicians were not selected 
on basis of age, years of experience as a physician or other criteria. A full medical history was taken 
followed by a thorough clinical examination. A bedside examination (touch, pin prick, pressure, 
cold, heat and temporal summation) to assess patients’ pain [25] was based on the European 
Federation of Neurological Societies (EFNS) guidelines [29, 30], the IASP Neuropathic Pain Special 
Interest Group (NeuPSIG) guidelines on neuropathic pain assessment [6] and the guidelines for 
assessment of neuropathic pain in primary care [7]. Patients’ pain was classified by the physician as 
pain with present- or absent-NePC. The NeuPSIG Grading System for neuropathic pain as proposed 
by Treede et al. [31] was used as a secondary comparison with the outcome of the PainDETECT-Dlv. 
The assessment of the Grading System was implemented in the standardized assessment protocol 
and thus included in the diagnostic work-up of the patients [25]. The outcomes “probable” and 
“definite” were regarded as “present-NePC”. “Unlikely” and “possible” were rated as “absent-NePC” 
[32-34]. All participating physicians underwent standard medical training, belonging to the classic 
medical curriculum, and examination of the (central) nervous system in particular. To achieve 
standardization of history and assessment of NePC presence in patients included in this study all 
participating physicians underwent a training in the performance of the clinical examination of the 
patients (including sensory (bedside) examination and use of the NeupSIG Grading System) [25]. 
Training of the physicians took place at the participating center. During the execution of the study, 
the study coordinator (HT) visited the participating centers on a regularly basis to answer questions, 
to see if the necessary equipment was always available and to keep an eye on the inclusion of 
patients. Based on the order of assessment, the physician who performed the first assessment was 
called physician A and the physician who performed the assessment as a second physician was 
named physician B. However, the order of the physicians was based on availability during the study. 
PainDETECT-Dlv and other questionnaires 
The PainDETECT-Dlv (© Pfizer Pharma GmbH 2005, Pfizer bv 2008. Cappelle a/d Ijssel, the 
Netherlands) [2, 24] was designed as a simple, patient self-administered screening tool to screen 
for the presence of neuropathic pain without physical examination. This instrument consists of one 
item about the pain course pattern, one about radiating pain and seven items about the gradation 
of pain. An overall score is generated and ranges between -1 and 38. Additionally, there are three 
items about pain severity (current, worst and average pain) included in the PainDETECT. For the 
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original German version [2] the outcome was as follows: ‘-1 – 12: negative’, neuropathic pain is 
unlikely; 13-18: ‘unclear’; result is ambiguous, however neuropathic pain can be present; 19-38 
‘positive,’ neuropathic pain is likely. 
The patient completed five questionnaires (including the PainDETECT-Dlv directly after the clinical 
assessment by the participating physicians but without any interference by the physicians. The 
researcher (HT) was available for help via telephone or in person when it was not clear how to fill 
in the questionnaires. Besides screening for NePC via the PainDETECT-Dlv [24], the disability of the 
patient was assessed via the Disability Rating Index (DRI) [35]. The existence of an anxiety disorder 
and/or depression were assessed via the Hospital Anxiety Depression Scale (HADS) [36-38] and the 
Pain Attribution Scale (PAS) was used to assess patients attribution of his or hers pain. Quality of 
life was determined via the RAND 36-item Health Survey (RAND-36) [39-41]. Two weeks and three 
months after the initial visit the follow-up questionnaires (the Patients Global Impression of Change 
(PGIC) [42-44] and the PainDETECT-Dlv) were sent to the patient by mail. 
Data 
All data gathered from patients and physicians was collected on paper and stored at the 
Radboudumc, Nijmegen, The Netherlands. Data management and monitoring were performed 
within MACRO (MACRO, version 4.1.1.3720, Infermed, London, United Kingdom). 
Statistical methods 
Power calculation for this study was based on an expected NePC prevalence of 37% in an unselected 
cohort of patients with chronic low back pain [2]. Sensitivity and specificity of the PainDETECT were 
assessed in the original validation study as respectively 85 and 80% [2]. The sensitivity and specificity 
of the PainDETECT-Dlv was, on forehand, expected to be 80% with a prevalence of 37%. The lower 
95% confidence limit was required to be >0.55. According to the calculations following the formulas 
by Flahault et al. [45] 132 patients with LBLP, NSA pain or suspected PND pain were needed so that 
the sample size contained a sufficient numbers of cases and controls [25]. 
Qualitative variables were presented as frequencies and percentages. The quantitative variables 
were presented as mean and standard deviation (SD) or as median and inter quartile range (IQR). 
Based on the classifications of the two physicians, all patients were categorized as absent-NePC, 
NePC or ‘undetermined’ (i.e. the classification by both physicians jointly was not equal). 
One-way ANOVA (with additional Tukey’s studentized range post-hoc test) or Kruskal-Wallis test 
were used to study differences between the three groups (NePC, absent-NePC, Undetermined). 
Intraclass correlation (ICC) was used to assess reproducibility (‘test-retest reliability’) of the 
PainDETECT-Dlv between the fixed time points (baseline versus two weeks & baseline versus three 
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months). The ICC and responsiveness of the PainDETECT-Dlv were assessed between each point of 
measurement. 
A receiver operating characteristic (ROC) curve was calculated and the area under the curve (AUC) 
with 95% confidence interval is presented to indicate the discriminatory power of the PainDETECT-
Dlv to discriminate patients classified as with or without a NePC. The classification was based on 
the physicians’ assessment outcome or based on the Grading System outcome, respectively. The 
theoretical maximum of the AUC is 100%, indicating a perfect discrimination and 50% is equal to 
tossing a coin. The optimal cut-off point of the PainDETECT-Dlv – sum score was calculated under the 
condition of equal-costs of misclassification, using the Youden-index. Sensitivity, specificity, positive 
and negative predictive values and the likelihood ratio in the population in this study was calculated 
at this cut-off point. Also, the ‘number needed to diagnose (NND)’ was assessed [46] by use of the 
formula: NND = 1/ [Sensitivity – (1-specificity)]. A clinical screening tool for the demonstration of a 
neuropathic pain component is considered valid if it has a high sensitivity, specificity and a high 
positive predictive value. For the measurement of the usefulness of the screening tool the likelihood 
ratio will be used [47]. 
The agreement between the pain classification by the physicians, the NeuPSIG Grading Systems 
and the PainDETECT-Dlv (yes: ≥11, no:< 11) outcome was evaluated by using Cohen’s kappa (K), 
prevalence index (Pi) and percentage of pair wise agreement (PA) [25]. A Κ ≥ 0.40 and a PA ≥ 70% is 
considered indicative of interobserver reliability which is acceptable for use in clinical practice [48].
 
Data analysis and statistics were performed by use of Statistical Package for the Social Sciences 
(SPSS version 20.0, SPSS Inc., Chicago, Illinois, USA). Two-tailed p-value below 0.05 was considered 
statistically significant. 
RESULTS
Patient population 
In this study 330 patients, not pre-stratified on the target outcome, with chronic LBLP, NSA pain or 
suspected PND pain were assessed for eligibility. Two patients did not give their informed consent. 
Exclusion (n = 37) was due to not fulfilling the in- and exclusion criteria (n = 13); not returning the 
baseline questionnaires by the patient (n = 16); missing pain classification by one physician (n = 
5) or both physicians (n = 3). In eight patients the assessment of the grading system (secondary 
comparison) was missing by one or both physicians. Finally, 291 patients participated in the study 
between October 2009 and July 2013. According to the international classification of diseases 
(ICD-10, version 2015) [27] these patients were classified as follows: 8 patients suffered from pain 
related to endocrine, nutritional and metabolic diseases (chapter IV); 75 patients from diseases of 
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the nervous system (chapter VI); 1 patient from diseases of the circulatory system (chapter IX); 189 
patients from diseases of the musculoskeletal system and connective tissue (chapter XIII); 1 patient 
from diseases of the genito-urinary system (chapter XIV); 3 patients from symptoms, signs and ill-
defined conditions, and 14 patient from injury, poisoning or other consequences of external causes. 
Numbers of recruitment in the different participating hospitals (all in the Netherlands) were 
as follows: Reinier de Graaf Gasthuis, Delft n = 86; ErasmusMC, Rotterdam n = 62; Radboudumc, 
Nijmegen n = 59; Bernhoven Ziekenhuis, Oss n = 56; Rijnstate Ziekenhuis, Arnhem n = 15; St. Anna 
ziekenhuis, Geldrop n = 12 and UMC Utrecht, Utrecht n = 1. 132 patients had LBLP with radiation in 
one or two legs (45.4%), 51 NSA pain with radiation into one or both arms (17.5%) and 108 (37.1%) 
had suspected PND pain. The group of patients with suspected PND consisted of 86 patients with 
pain who were treated because of breast cancer (surgery and/or radiation and/or chemotherapy 
and/or hormonal therapy). The remaining 22 patients had pain because of various reasons: 
peripheral nerve damage (n = 12), polyneuropathy (n = 3), central post stroke pain (n = 2), Complex 
Regional Pain Syndrom (n = 2) and spinal radicular pain (n = 3). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No informed consent: n = 2 
Excluded: n= 37 
Patients 
 LBLP or NSA pain without radiating pain: n = 1 
 less than 3 months pain complaints: n = 2  
 pain with an oncological cause: n = 2 
 painful syndromes  of unknown origin or associated with diffuse pains: n = 7  
 severe mental illness: n = 1 
 
Missings  
 baseline measurements due to not returning questionnaires by the patient: n = 16 
 assessment  by second physician: n = 8 
 grading system by one or both the physicians: n = 8 
PainDETECT Questionnaire (Dutch language version) 
NePC present when outcome ≥ 11 (range -1;38) 
 
Absent-NePC  
PA: n = 32 
GS: n =  43 
Present-NePC  
PA: n = 26 
GS: n = 50 
Absent-NePC  
PA: n = 32 
GS: n = 17 
 
Present-NePC  
PA: n = 31 
GS: n = 34 
Absent-NePC  
PA: n = 34 
GS: n = 36 
 
Present-NePC 
PA: n = 136 
GS: n = 103 
 
Present-NePC  
PA: n = 170 
GS: n = 139 
 
Absent-NePC  
PA: n = 58 
GS: n = 93 
 
Undetermined  
PA: n = 63 
GS: n = 51 
 
Patients with chronic pain  
assessed for eligibility 
n = 330 
Classification of NePC 
PA: n = 291 
GS: n = 283 
 
Figure 1:  Flow diagram for the validation of the PainDETECT-Dlv. 
  PA: Physicians’ assessment; GS: Neuropathic pain special interest group Grading System; Present-
NePC: Neuropathic pain component present; Undetermined: both physicians disagree with each 
other about the presence of a neuropathic pain component; Absent-NePC: No neuropathic pain 
component present; n = number of patients in analysis
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After assessment by physicians A and physicians B, 170 patients were classified as having 
present-NePC, 58 as absent-NePC. In 63 patients the two physicians made a non-concordant pain 
classification, so the outcome based on the physicians assessment was classified as ‘undetermined’. 
Based on the NeuPSIG Grading System in 139 patients NePC was classified as present, in 93 patients 
NePC was absent and in 51 patients the two physicians made a non-concordant pain classification 
in which the outcome was classified as ‘undetermined’ (see Figure 1: Flow Diagram). 
Social-demographic and clinical details of the 291 patients were analyzed and divided from each 
other based on the pain classification (see Table 1). No statistically significant differences were found 
between absent-NePC, present-NePC and undetermined for gender, age, height, weight, body 
mass index (BMI), education, medication, duration of pain, quality of life, disability, pain attribution, 
anxiety disorder and depression. Moreover, no statistically significant differences were observed 
between absent-NePC and present-NePC for pain (current, worst and average pain). 
Physicians 
During this study 62 various physicians (pain specialist, pain specialist-fellow or neurologist), from 
seven different hospitals, assessed all included patients. All patients were assessed two times by 
two different physicians. Of all participating physicians, 21 physicians assessed ≤2 patients during 
the execution of the study, 23 physicians saw ≤9 patients, 10 physicians saw ≥10 patients and 8 
physicians saw ≥20 patients. 
Evaluation of the PainDETECT-Dlv 
The mean score of the PainDETECT-Dlv (Range – 1;38) for patients classified as absent-NePC was 
10.7 (SD± 5.7); for patients classified as present-NePC it was 15.7 (SD ± 6.3) and for patients with an 
undetermined outcome it was 11.8 (SD ± 5). As calculated based on a one-way ANOVA with Tukey’s 
studentized range post-hoc test, there was a statistical significant difference between absent-
NePC and present-NePC (P < 0.001) and between present-NePC and undetermined (P < 0.001). No 
significant difference was seen between absent-NePC and undetermined (P = 0.57). Patients pain 
course pattern and if the pain was radiating to other regions of the body were not significantly 
different between the three groups. Pain descriptors (burning, tingling or prickling, painful light 
touching, sudden pain attacks, temperature evoked pain, numbness sensation and pressure evoked 
pain) were all statistically significant discriminators for the presence of NePC (P ≤ 0.005) except for 
pressure evoked pain (P = 0.07). See Table 2 for the PainDETECT-Dlv outcomes divided according to 
the pain classification by the physicians (presentNePC, absent-NePC or undetermined) (See Table 2). 
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Table 1:  Socio-demographic and clinical characteristics of the patients related to physicians 
agreement for the existence of a NePC 
NePC Absent Present Undetermined
N
n (%) 
Mean (±SD) 
Median [IQR] N
n (%) 
Mean (±SD)
Median [IQR] N
n (%) 
Mean (±SD)
Median [IQR]
Gender
Male
Female 
58
25 (43%)
33 (57%)
170
56 (33%)
114 (67%)
63
17 (27%)
46 (73%)
Age (Years) 58 55 ± 12 170 56 ± 11 63 58 ± 13
Height (cm)
Weight (kg)
BMI (kg/m2 )
55 
55 
54
 
172 ± 9
84 ± 25
28 ± 8
164 
167 
164
 
172 ± 8
80 ± 17
27 ± 5
62
62 
62
170 ± 9
80 ± 16
27 ± 5
Education 
Functional illiterate
Primary education
Secondary education
Postgraduate
56
(0%)
2 (3.6%)
32 (57.1%)
22 (39.3%)
164
(0%)
14 (8.5%)
98 (59.8%)
52 (31.7%)
63
2 (3.3%)
6 (9.8%)
38 (62.3%)
15 (24.6%)
Medication (% yes) 55 31 (56.9%) 168 111 (66.1%) 61 35 (57.4%)
Pain (NRS; 0-10)
Current pain
Worst pain (past four weeks)
Average pain (past four weeks)
Duration of pain (months)
57
57
57
57 
5 [3 – 7]
8 [5 – 9]
6 [3.5 – 7]
72 ± 90
167
167
167
169
6 [3 – 7]
8 [7 – 9]
6 [5 – 8]
60 ± 76
61
61
61
62
4 [1 – 7]
7 [5 – 8]
6 [3 – 7]
49 ± 46
Quality of life
Physical functioning 
Role functioning physical 
Role functioning emotional 
Social functioning 
Bodily pain
Mental health 
Vitality
General health
Health change
58
58 
58 
58
58 
58 
58
57 
58
57 ± 27
43 ± 42
80 ± 35
43 ± 14
55 ± 24
60 ± 6
51 ± 10
58 ± 14
38 ± 24
170
170
169
170
170
170
170
165
170
51 ± 25 
35 ± 41
70 ± 43
44 ± 11
56 ± 25
61 ± 10
49 ± 12
57 ± 14
40 ± 26
62
61
61
62
62
61
61
60
63
55 ± 29
41 ± 45
73 ± 42
46 ± 10
46 ± 25
62 ± 7
50 ± 11
55 ± 12
42 ± 27
Disability Total 53 46 ± 27 158 48 ± 24 57 40 ± 26
Pain attribution
Somatic 
Psychological 
Social
53
58 
57
5.2 ± 4.3
2.0 ± 2.9
1.6 ± 2.2
156
164
163
6.0 ±4.0
2.2 ± 3.2
2.0 ± 2.6
58
60
61
5.2 ± 3.9
2.9 ± 3.0
2.4 ± 2.6
Anxiety disorder 
Depression 
57
57
14 (24.6%)
14 (24.6%)
167
166
46 (27.5%)
46 (27.7%)
60
61
18 (30.0%)
11 (18.0%)
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Classification for the existence of NePC is based on physicians assessment of the patients. NePC: 
neuropathic pain component; Absent: NePC is absent; Present: NePC is present; Undetermined: both physicians 
disagree with each other about the existence of a neuropathic pain component; N: total number of patients in 
analysis; n: number of patients; %: percentage; SD: Standard deviation; IQR: Inter quartile range.
Table 2:  The median (IQR) of the items of the PainDETECT by physicians agreement for the existence of 
a NePC 
NePC   Absent     Present    Undetermined
PainDETECT item
N
n (%) 
Median [IQR]
Mean (±SD) N
n (%) 
Median [IQR]
Mean (±SD) N
n (%) 
Median [IQR]
Mean (±SD)
Pain course pattern 58
19 (33%)
14 (24%)
16 (28%)
9 (16%)
162
53 (33%)
58 (36%)
32 (20%)
18 (11%)
59
17 (29%)
17 (29%)
20 (34%)
5 (9%)
Persistent pain with slight fluctuations 
Persistent pain with pain attacks 
Pain attacks without pain between them 
Pain attacks with pain between them
Radiating pain (% yes) 51 41 (78%) 154 112 (73%) 57 38 (67%)
Gradation of pain
55
55
55
55
54
56
55
0 [0 – 2] 
1 [0 – 3] 
0 [0 – 1] 
2 [0 – 3] 
0 [0 – 1] 
2 [0 – 3] 
2 [1 – 3]
170
170
169
167
170
170
170
1 [0 – 3] 
2 [0 – 3] 
1 [0 – 2] 
3 [1 – 4] 
1 [0 – 2]
3 [2 – 4]
3 [1 – 4] 
62
63
63
62
63
63
63
0 [0 – 2.25] 
1 [0 – 3] 
0 [0 – 1] 
2 [0 – 3] 
1 [0 – 1] 
3 [1 – 4] 
2 [1 – 3] 
Burning 
Tingling or prickling  
Painful light touching  
Sudden pain attacks   
Temperature evoked pain 
Numbness sensation  
Pressure evoked pain  
Total sum score PainDETECT 58 10 [6.75 – 15.25]
10.7 (± 5.75)
170 16 [11 – 20]
15.7 (± 6.3)
63 10 [8 – 15]
11.8 (± 5)
Classification of NePC is based on physicians assessment of the patients. NePC: neuropathic pain 
component; Absent: NePC is absent; Present: NePC is present; Undetermined: both physicians disagree with 
each other about the existence of a neuropathic pain component; N= total number of patients in analysis; n= 
number of patients; IQR: inter quartile range; SD: standard deviation; Range: 0 = never; 1 = hardly noticed; 2 = 
slightly; 3 = moderately; 4 = strongly; 5 = very strongly; Total sum score PainDETECT: Sum score calculation of 
the PainDETECT.
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Validity 
The gold standard for presence of the NePC in this study was the concordant opinion of both 
physicians. On basis of this gold standard, patients with an identical pain classification were 
included in the initial analysis (n = 228): 58 patients were classified as absent-NePC (25.4%) and 170 
were classified as present-NePC (74.6%)(see Table 3 and Additional file 1: Table S1). A ROC-curve 
was constructed for PainDETECT-Dlv (see Figure  2). Based on the gold standard, PainDETECT-Dlv 
sensitivity was (at maximal Youden-index) 80%, specificity 55.2%, positive predictive value 84% and 
the positive likelihood ratio was 1.78. Based on the neuropathic pain Grading System, the sensitivity 
was 74.1%, specificity 46.2%, positive predictive value 67.3%, and positive likelihood ratio of 1.38. 
 
1-Specificity 
S
e
n
s
it
iv
it
y
 
Figure 2:  Receiver operating characteristics and area under the curve (AUC) for the total score of the 
PainDETECT-Dlv versus the presence of a neuropathic pain component as classified by two 
physicians (n = 228; undetermined patients are not included).
 X-axis: 1-Specifity; Y-axis: Sensitivity 
We also constructed ROC-curves for the classification by solely physicians A or B and according 
to the neuropathic pain Grading System by physicians A or B and all the combinations. Except 
for classification of patients’ pain based on the description of physicians A and the outcome of 
the Grading System by physicians B all cut-off scores were calculated at 11-points out of 38: The 
sensitivity ranges from 57.6-86.1% and specificity from 43.9-59.2%. The classification of patients’ pain 
based on the classification of physicians A resulted in a cut-off score of 9-points: Sensitivity 86.1% 
and specificity 45.8%. The classification of patients’ pain based on the Grading System according to 
physicians B resulted in a cut-off score of 14-points: Sensitivity of 57.6% and specificity of 59.2%. 
In Table 3 and Additional file 1: Table S1 we present the number of patients with LBLP, NSA pain or 
suspected PND pain, in total and per group based on physicians’ assessment and/or the Grading 
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System. Values of the AUC, cut-off value, sensitivity and specificity are provided (see also Additional 
file 1: Table S1 for a more detailed analysis of the diagnostic accuracy of the PainDETECT-Dlv: AUC, 
cut-off value, sensitivity, specificity positive and negative predictive values, positive likelihood ratios 
and the number needed to diagnose (NND). 
Patients were screened on a NePC (positive outcome) by two physicians, two times the Grading 
System, and the patient completed the PainDETECT-Dlv. All the possible outcome combinations 
were computed based on the outcome: Is a NePC present, or not? In 283 patients all the five 
outcome variables were available and are displayed in a Venn-diagram [49] (see Figure 3). In 92 
patients (32.5%), five times a positive outcome variable was found, indicating presence of NePC. 
In 23 patients all outcome variables were negative (8.1%), thus indicating absence of NePC. One 
positive outcome was detected in 39 patients (13.8%), two positive outcomes in 28 patients (9.9%), 
three in 49 patients (17.3%), and four in 52 patients (18.4%). 
 
Absent-NePC: n = 23 
 
Assessment B 
(n = 251) 
(n=251) 
Grading A 
(n=246) 
Grading B 
(n=244) 
PainDETECT 
(n=219) 
Assessment A 
(n=204) 
Figure 3: VENN-Diagram of all the five outcomes per patient. 
  Physicians A: classification of a neuropathic pain component (NePC) exists; Physicians B: NePC exists; 
Grading A: NePC exists according to the Grading System by physicians A; Grading B: NePC exists 
according to the Grading System by physicians B; PainDETECT-Dlv: Outcome of the PainDETECT-Dlv 
indicates the existence of a NePC. Absent-NePC: No NePC exists according to physicians, Grading 
Systems and the PainDETECT-Dlv 
CT
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Reliability 
To determine the interobserver reliability between the physicians, the Grading System and 
the outcome of the PainDETECT-Dlv for the classification of a (absent-) NePC, Cohen’s kappa (K) 
and percentage of pair wise agreement (PA) were assessed (see Table 4). K for the classification 
of patients’ pain (absent-NePC or NePC) by the physicians was 0.49, with a PA of 78.4% (Pi=0.38; 
n=291). The K for the classification of patients’ pain based on the Grading System was 0.63 and PA 
was 82% (Pi = 0.16; n = 283). The outcome of K and PA regarding the PainDETECT-Dlv compared to 
the classification of physicians A was respectively 0.34 and 74.6% (Pi = 0.48; n = 291). Compared to 
physicians B it was 0.27 and 67.7% (Pi = 0.33; n = 291). Comparing the outcome of the PainDETECT-
Dlv to the outcome of the Grading System, was 0.18 and 61.5% (Pi = 0.27; n = 286) for physicians A, 
and 0.17 and 58.3% (Pi = 0.05; n = 288) for physicians B. 
Table 4:  The kappa coefficient between the classification on basis of the assessment by the physicians, 
the Grading Systems and the PainDETECT 
PainDETECT
(yes / no)
Grading 
A
Grading 
B
Assessment 
B
Assessment A n
K 
PA 
Pi
291
0.34
74.6
0.48
286
0.48
76.2
0.32
288
0.32
67.4
0.26
291
0.49
78.4
0.38
Assessment B n
K 
PA 
Pi
291
0.27
67.7
0.33
286
0.38
71.0
0.28
288
0.48
75.0
0.22
Grading A n
K 
PA 
Pi
286
0.18
61.5
0.27
283
0.63
82.0
0.16
286
0.38
71.0
0.28
Grading B n
K 
PA 
Pi
288
0.17
58.3
0.05
Classification of NePC is based on physicians’ assessment of the patients and on the Grading Systems. N 
= number of patients in the analysis; K = Cohen’s kappa coefficient; PA (%) = percentage of agreement between 
two outcome variables; Pi = Prevalence index
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Stability and responsiveness of the PainDETECT-Dlv over time was assessed over a period of two 
weeks. The mean sum score of the PainDETECT-Dlv at baseline for the total group was 13.8 ± 6.3. 
The mean sum score after two weeks was 14.1 ± 6.1. Test-retest reliability via ICC was 0.83 (95%CI 
0.79-0.87; n = 268). Taking into consideration the fact that patients’ pain should not have changed 
(outcome based on the PGIC), because otherwise the ICC would not reflect the consistency of the 
PainDETECT-Dlv, and a time gap of 7-21 days was allowed (to rule out the early or delayed return of 
questionnaires) between the first and second PainDETECT-Dlv, the ICC was 0.87 (95% CI 0.81-0.91; n 
= 123). After three months, with no change in the degree of patients’ pain and a time gap of 60-120 
days between the first and third PainDETECT-Dlv, ICC was 0.86 (95% CI 0.79-0.91; n = 102). 
DISCUSSION
This study demonstrates the clinimetric quality of the PainDETECT-Dlv, a screening instrument for 
the presence of a NePC, on a large population of patients, with chronic pain due to low back with 
leg pain, neck-shoulder-arm pain or pain due to a suspected peripheral nerve damage as normally 
present in a physician’s daily practice. Because the patients were included without pre-stratification 
on the target outcome, previous Catch-22 situations in the assessment of the validity of screening 
instruments were avoided. Under these conditions, the PainDETECT-Dlv failed to be predictive for 
the existence of a NePC due to a moderate sensitivity and low specificity, irrespective of comparison 
with the expert opinion via the classification by two physicians (gold standard) as well as with the 
outcome of the NeuPSIG Grading System. Moreover, the predictive values were also not indicating 
that the PainDETECT-Dlv is a valid screening tool for the assessment of a NePC. The likelihood ratios 
were also not suggestive for the usefulness of this instrument. 
Validation studies with patients pre-stratified for NePC 
We found an optimal cut-off score for the PainDETECT-Dlv of ≥11 points corresponding to a 
sensitivity of 80% and a specificity of 55%. In the original development and validation study of the 
PainDETECT by Freynhagen et al. [2] a sensitivity and specificity of 84% was found. The gold standard 
in their study was the examination by two experienced pain specialists. The study was performed at 
ten different specialized pain centers. Only patients with ‘typical’ neuropathic or nociceptive entities 
(i.e. no ‘unclear’ outcome) and only patients with a VAS of >40 mm (0 – 100 mm) were included. In 
the Spanish validation study by De Andrés et al. [16] only patients with a VAS ≥40 mm and a known 
classification (by one experienced specialist) of neuropathic pain, mixed pain or nociceptive pain 
were included. It revealed a sensitivity and specificity of 81% when patients with the classification 
of neuropathic pain or nociceptive pain were included. The inclusion of patients with mixed pain 
in the neuropathic pain group resulted in a sensitivity of 84% and specificity of 78%. The Korean 
version of the PainDETECT [20] was validated based on the study by De Andrés [16] in patients with 
chronic pain and with a NRS ≥ 3 (NRS 0-10). The gold standard was the independent diagnosis of 
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the patient by two experienced pain physicians. It revealed a sensitivity of 82% and a specificity of 
92% based on a cut-off score of ≥19 (range – 1; 38). In the validation of the Turkish version of the 
PainDETECT [17] patients were included with the classification of pain type (i.e. NePC) being assessed 
beforehand (based on the opinion of two expert pain physicians) and patients suffering from pain 
of three centimeters or more (VAS 0-10 cm). Sensitivity and specificity were respectively 78 and 
83%. The Hindi version of the PainDETECT [19] was validated in patients with neuropathic and in 
patients with non-neuropathic pain based on a conventional single assessment by one physician. 
At a optimal cut off point of ≥18 sensitivity was 83% and the specificity was 84%. 
In a cohort of patients with a spinal cord injury for more than one year, pain lasting more than six 
months and a pain intensity of more than three on a NRS (0-10) a sensitivity was found of 68% and 
specificity of 83% [50]. 
The present study included patients with chronic pain without limits to the minimal pain intensity 
or other limitations. At the moment of inclusion in the study our patients had only a provisional 
diagnosis (LBLP, NSA pain, suspected PND pain) established in primary or secondary care without 
further refinement or confirmation. Then, after referral to a (non-) academic pain clinic, they were 
assessed as to their complaints for the first time at study inclusion. Thus this was a ‘real-life’ clinical 
out-patient population. Avoiding patient selection due to pre-stratification to the outcome target 
makes our study unique and clinically more relevant as compared to other studies on the same topic 
and is crucial for the validation of a screening instrument. 
Validation studies with patients not pre-stratified for NePC 
In a study by Gauffin et al. [51] in patients diagnosed with fibromyalgia (n = 158) a cut-off score 
of 17 was found with a sensitivity of 79% and specificity of 53% (Gold standard: the classification 
by one experienced physician). This study, like ours, did not pre-stratify patients according to the 
pain classification either, and patients were not excluded because of a low pain level. The outcome 
of Gauffin’s sensitivity analyses in this fibromyalgia study was comparable to our study. Tampin et 
al. [34] found, based on the examination by a physical therapist, a sensitivity and specificity of the 
PainDETECT of respectively 64 and 62% (cut-off score 18.5) in a population of patients with neck/
upper limb pain (n = 122). In our study, the outcome for patients with neck-shoulder-arm pain was 
83 and 44% respectively (cut-off score of ≥9). 
Grading system 
In this study the physicians assessed patients for the presence of a NePC according to the Grading 
System [31]. Probable neuropathic pain and definite neuropathic pain were combined as present-
NePC, and non neuropathic pain and possible neuropathic pain were combined in absent-NePC. 
Sensitivity and specificity of the PainDETECT-Dlv resulted to be 74 and 46% respectively (Cut-off score 
11 out of 38, n = 232). Using the classification of patients’ pain based solely on the Grading System 
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by one physician results in a lower validity than based on the physicians assessment. This might 
suggest that the classification of patients’ pain based on the Grading System is less accurate than 
the classification based on the physicians’ assessment in respect to the outcome of the PainDETECT-
Dlv. However, the grading system was assessed by the same physician who also performed the 
physician’s assessment so it is also possible that the physician had difficulties to classify patients 
pain based on the Grading System or vice versa. When using the physicians’ assessments as well as 
the Grading Systems of both physicians (n = 161), sensitivity was 78%, specificity was 53% and the 
cut-off score was 11: The same poor result as for the gold standard. In the papers by Vaegter et al. 
[33] and Tampin et al. [34] the PainDETECT was also compared with the NeuPSIG Grading System. In 
both papers, like in ours, the outcome of the Grading System was not comparable to the outcome 
of the PainDETECT. As stated by Finnerup et al. [52] the PainDETECT (and other screening tools for 
the assessment of neuropathic pain) is only to alert the physician to further assess the patient who 
may have a NePC. 
NePC classification 
The initial classification of patients’ pain in our study was based on an interview and (clinical/
physical) examination by trained (pain-) physicians. There is a lack of consensus with respect 
to the classification of a NePC in patients with pain of different origins [53]. Moreover, a lack of 
standardization of assessment methods increases the number of undetected or poorly classified 
patients which leads to a variation in the classification accuracy (i.e. sensitivity and specificity) of 
screening tools caused by differences in strategy and patient population [15, 54]. Bouhassira and 
Attal recently stated that neuropathic pain is “a consistent clinical entity, but it is multidimensional 
in terms of its clinical expression, with different sensory profiles, potentially reflecting specific 
pathophysiological mechanisms” [55]. As stated by Scholz et al. [53] physical tests are more useful 
to identify patients with neuropathic back pain than interview questions. To reach a more unified 
classification system to differentiate between present-NePC and absent-NePC a standardized 
assessment of symptoms and signs is necessary [53]. However, these tests are not able to confirm the 
relation between the potential lesion or disease of the nerve and the pain directly: The classification 
of neuropathic pain should be based on clinical examination and the interpretation should be 
placed in the clinical context of patients’ pain [55]. 
In this study we used a mandatory standardized assessment [25] in addition to the medical history 
and physical examination which were performed according to the physicians’ standards. The clinical 
assessment and the use of the Grading System showed that in 18-22% of the patients a non-
consistent assessments was present resulting in an ‘undetermined’ status. In Freynhagens paper 
[2] it was 5%. This difference might be due to the inclusion of patients with a less clear absent or 
present NePC in our study which might reflect what happens in the assessment of a NePC in usual 
clinical care. Moreover, this also might occur in the treatment of patients with chronic pain. Based 
on both the physician’s assessments, almost 75% of the patients in this study had a neuropathic pain 
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component. This might be due to several facts. (1) Patients with LBLP or NSA pain were only included 
when the pain was radiating into the leg(-s) respectively the arm(-s) and were not removed from this 
study when they had mixed pain. Moreover, patients with radiating pain are more suspected to have 
a NePC. (2) There is a possibility that neuroplastic changes are interpreted as neuropathy in patients 
with chronic LBLP. (3) Patients were recruited in secondary and tertiary pain clinics. This might have 
led to a inclusion of patients who were more difficult to treat in primary care and (4) we included 108 
patients with suspected peripheral nerve damage. Almost 60% of the patients after treatment for 
breast cancer has pain [56]. Based on the recent review by Ilhan et al. [57], in patients who reported 
pain following breast cancer treatment the pooled prevalence of neuropathic pain from screening 
questionnaires ranged from 32.6 to 58.2%. Following the NeuPSIG Grading System the prevalence 
ranged from 29.5 to 57.1%. Based on these numbers, patients after breast cancer can be regarded as 
patients suspected of neuropathic pain due to peripheral nerve damage. However, the PainDETECT-
Dlv (compared to the gold standard and the NeuPSIG Grading System) as used in our study seems 
not valid for the assessment of patients with neuropathic pain based on a suspected PND in which 
the majority of patients was suffering of pain after treatment for breast cancer. 
Strengths and weaknesses 
There are several strengths in this study. Firstly, we included a large population of patients with 
diagnoses who are regularly seen in daily clinical practice. Secondly, there was no pre-stratification 
on the target outcome, clear inclusion criteria and almost no exclusion criteria. Thirdly, we used 
the NeuPSIG Grading System [31, 52] as a secondary comparison. The main purpose of the Grading 
System is to help in the classification of the pain as neuropathic [52]. In our study, the Grading 
System was added to the standardized assessment form which had to be filled in by the physician. 
There are also some weaknesses in this study. The use of the Grading System within the clinical 
assessment (including bed-side examination) is a strong aspect of our study, but the outcome of 
the clinical examination as well as the outcome of the Grading System might be influenced by 
each other. However, combining the physicians’ assessment with the Grading System might have 
made the ‘gold standard’ even stronger but also might have led to a cross-contamination. Secondly, 
diagnosing NePC by assessing patients’ pain by two separate physicians in our and in other 
studies is considered as the ‘Gold Standard’. However, classifying patients’ pain may be done more 
objectively by establishing a damaged nerve and by diagnosticating in a more detailed clinical way. 
Moreover, the breakdown of clinical grounds for in- and exclusion could also have been assessed 
and captured in more detail. Thirdly, 62 physicians participated. This might have led to the inclusion 
of younger, less clinical experienced physicians. However, it reflects ‘real life’ practice and limits the 
risk of systematic bias in the classification of patients’ pain and bias based on assumptions about 
the existence of a NePC. Moreover, all physicians followed the standardized training as described. 
Fourthly, almost only patients with peripheral causes of pain were selected. This can be considered 
as a methodological drawback. Moreover, because we did not include patients with, by example, 
low back pain without irradiation to the leg who would probably be diagnosed as absent-NePC the 
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specificity might decrease. Fifthly, there is an apparent lack of objective tests to determine whether 
the somatosensory fibers were affected, in particular the small fibers. This can be seen as crucial 
since objective data are mandatory to reach a definite neuropathic pain classification in the grading 
system. Lastly, in a following study we would collect data from the patients who were not able to 
participate in the study to prevent inclusion bias. In this study this was not possible because of 
ethical regulations. 
CONCLUSIONS
The PainDETECT-Dlv has a good internal consistency and test-retest reliability but is not an effective 
screening tool for the assessment of a neuropathic pain component in a population of patients with 
chronic pain, irrespective of the chosen comparison because of its moderate sensitivity and low 
specificity. However, the agreement by both the physicians and the agreement with the grading 
systems (performed by the physicians) were also not impressive. Moreover, the differences in the 
cut-off scores for the different comparisons reflects the fact that agreement in a not pre-stratified 
to the target outcome patient population is not easy to accomplish. Using the PainDETECT-Dlv (for 
screening purposes or as a surrogate for clinical assessment) may result in unreliably separating 
NePC presence from non-presence in patients with chronic pain in clinical outpatient practices and 
in research settings. Catch-22 situations in the validation of screening tools can be prevented by not 
pre-stratifying the patients on basis of the target outcome before inclusion in a validation study for 
screening instruments. For now, classifying patients pain still needs the clinical assessment based 
on history and physical examination including bed-side sensory testing by the physician and cannot 
be replaced by the use of the PainDETECT. 
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ABSTRACT
Neuropathic pain is clinically described as pain caused by a lesion or disease of the somatosensory 
nervous system. The aim of this study was to assess the validity of the Dutch version of the DN4, in a 
cross-sectional multicentre design, as a screening tool for detecting a neuropathic pain component 
in a large consecutive, not pre-stratified on basis of the target outcome, population of patients 
with chronic pain. Patients’ pain was classified by two independent (pain-)physicians as the gold 
standard. The analysis was initially performed on the outcomes of those patients (n = 228 out of 
291) in whom both physicians agreed in their pain classification. Compared to the gold standard 
the DN4 had a sensitivity of 75% and specificity of 76%. The DN4-symptoms (seven interview items) 
solely resulted in a sensitivity of 70% and a specificity of 67%. For the DN4-signs (three examination 
items) it was respectively 75% and 75%. In conclusion, because it seems that the DN4 helps to 
identify a neuropathic pain component in a consecutive population of patients with chronic pain in 
a moderate way, a comprehensive (physical-) examination by the physician is still obligate. 
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INTRODUCTION
Neuropathic pain is described as pain caused by a lesion or disease of the somatosensory nervous 
system and requires a demonstrable lesion or a disease that satisfies established neurological 
diagnostic criteria [1]. Moreover, neuropathic pain is a clinical description and not a diagnosis [1]. 
In daily clinical practice it is to our opinion more appropriate to speak of a present neuropathic 
pain component (present NePC) or absent neuropathic pain component (absent NePC) [2, 3]. 
This because the pain experienced by the patient in the clinical context may be caused by both 
neuropathic- as well as nociceptive mechanisms (also known as ‘mixed pain’) [2, 4-6]. The main 
features of neuropathic pain components are, in clinical practice, the painful signs and symptoms in 
a region of altered sensations (numbness or increased sensitivity) [6]. The assessment of neuropathic 
pain is nowadays primarily based on history and physical examination including (bedside-)sensory 
testing [7-9] to assess patients’ pain. 
Since current pharmacological treatment of patients with and without a NePC differs strongly, a 
correct pain classification is imperative [7, 10]. The availability of a simple and validated screening 
tool to determine the presence of NePC for clinical triage and epidemiological purposes can assist 
in detection of NePC [7, 8, 11-16]. This is especially true when this tool can be used by non pain 
specialists. 
The original French validation study of the ‘Douleur Neuropathique en 4 Questions’ (DN4) [17] was 
performed in patients with neuropathic pain resulting from, for example, nerve trauma or post 
herpetic neuralgia. Patients with non-neuropathic pain were, amongst other diagnoses, suffering 
from osteoarthritis. All included patients had pain of at least a moderate severity (≥ 40 on a 100mm 
visual analogue scale). Pain classification in this study was based on medical history, physical 
examination, electromyography and/or imaging by two independently working physicians. DN4 
application resulted in a sensitivity of 83% and a specificity of 90% [17]. As indicated in a systematic 
review by Mathieson et al [16] the classification of a NePC may differ between clinicians and may 
be more difficult when there are patients included with mixed pain and with all levels of pain. This 
reflects the patient population in a daily clinical practice, but might have an influence on the validity. 
Moreover, the accuracy of screening tools is dependent on the standardization of the assessment 
strategy [18]. Translation/ cross-cultural adaptation and/or validation of the DN4 was performed in 
more than 75 languages [19-31]. 
The neuropathic pain special interest group (NeuPSIG) grading system [32] is developed by Treede 
et al in 2008 and updated in 2016 [33]. It is a system to help the clinician to determine the certainty 
of the pain classification for the existence of a NePC in an individual patient: non-neuropathic pain; 
possible, probable or definite neuropathic pain. The grading system is suggested to be helpful in the 
assessment of the pain classification in clinical practice [34-38]. 
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The aim of this study was to assess the validity and reliability of the DN4 as a screening tool for 
use in daily outpatient practices to detect a NePC in a, not pre-stratified on the target outcome, 
consecutive patient population having chronic pain syndromes due to low back and leg pain (LBLP), 
neck-shoulder-arm-pain (NSAP) or pain of suspected neuropathic origin (PSNO).
 
METHODS
This validity and reliability study had a cross-sectional, longitudinal, research design with a 2-weeks 
and 3-months follow-up period. Comparisons were made between the DN4 (as a whole and for 
the symptom questions and signs tests separately) and the classification of patients’ pain by two, 
independently working, physicians (the gold standard) as well as with the grading system. 
The study was approved by the Committee on Research Involving Human Subjects region Arnhem-
Nijmegen, Nijmegen, the Netherlands, (dossier number: 2008/348; NL 25343.091.08) which 
counts for participation of the Dutch academic pain centers (Radboud University Medical Center, 
Nijmegen; Utrecht University Medical Center, Utrecht; Erasmus Medical Center, Rotterdam), Dutch 
non-academic pain centers (Bernhoven Ziekenhuis, Oss; St.Anna Ziekenhuis, Geldrop) and a Dutch 
non-academic department of neurology (Rijnstate Ziekenhuis, Arnhem). Participation of Dutch non-
academic pain center in Delft, the Netherlands (Reinier de Graaf gasthuis) was approved by Medisch 
Ethische Toestings Commissie Zuidwest Holland (dossier number: 10-145). The study protocol was 
registered in the Dutch National Trial Register (NTR3030). 
We used the same methodology as in the published protocol [39] and as employed in a simultaneous 
study regarding the validity of the PainDETECT (Timmerman et.al / Under review by BMC Neurology). 
Participants 
Consecutive patients (first time visitors of the participating centers) without pre-stratification based 
on the target outcome [40] were included in the study between October 2009 until July 2013. 
Patients were asked to participate by their doctor. Each patient signed informed consent before 
participation in the study. 
At that time, there was only a rough diagnosis: LBLP, NSAP or PSNO. Inclusion criteria: Male and female 
adult patients (≥18 years of age) with chronic (≥3 months) LBLP or NSAP radiating into respectively 
leg(s) or arm(s) or patients with chronic pain due to a PSNO (pain associated with a lesion or disease 
of the peripheral somatosensory system). Exclusion criteria: Patients diagnosed with malignancy; 
compression fractures; patients with diffuse pains (such as fibromyalgia or ankylosing spondylitis); 
severe mental illness; chronic alcoholism or substance abuse; inability to fill in the questionnaire 
adequately or incapable of understanding the Dutch language. 
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Physicians 
The physicians (pain specialists, pain specialist fellows or neurologists always operating in 
differently composed pairs) participating in this study were not selected on basis of age, experience 
as a physician or any other criteria. Classification of patients’ pain was based on the NeuPSIG 
guidelines on neuropathic pain assessment [7] and recorded as absent NePC or present NePC. Pain 
classification was performed consecutively on the same patient by two physicians and categorized 
afterwards in three groups: absent NePC, present NePC or ‘undetermined’ (i.e. the pain classification 
of the two physicians was not the same). A full medical history and clinical examination including 
sensory bedside examination (touch, pinprick, pressure, cold, heath and temporal summation) was 
taken [7, 8, 39, 41, 42] and was considered to be the gold standard when assessed by two physicians. 
The NeuPSIG grading system [32, 33] was used as a secondary comparison with the outcome of the 
DN4 and was assessed by both the physicians separately. The outcomes “probable” and “definite” 
were regarded as present NePC. “unlikely” and “possible” as absent NePC [38, 43, 44]. The physicians 
worked independently of each other and were blinded to the pain classification of the other 
physician. Each physician was allowed to perform the clinical examination in the way he or she 
is used to do but were supported by a standardized assessment form [39]. In this form, the pain 
score, a body map to indicate the localization of patients pain, the sensory examination and the four 
questions of the grading system had to be filled in by the physician. The participating physicians 
were trained in a standardized way (presentation about the study and the outcome parameters 
and a practical training on how to use the (measurement) instruments), by the investigator (HT) or 
by a designated person on location before participation in the study. Practical training was focused 
on the classification of NePC, the assessment of the grading system, the performance of bed-side 
examination tests and the performance and assessment of the examination items of the DN4. 
In this study, 62 physicians (pain specialist, pain specialist-fellow or neurologist) participated. The 
physicians who were classifying patients’ pain at the first session were called ‘Physicians A’. The 
physicians who performed the classification at the second session, were called ‘Physicians B’. 
Measurements 
Douleur Neuropathique en 4 questions (DN4). The DN4 [17, 20, 25] (Pfizer bv. Capelle a/d Ijssel, the 
Netherlands) consists of 10 items in total and is developed to screen for symptoms and signs of 
neuropathic pain resulting in a yes/no answer for the presence of neuropathic pain. This instrument 
is divided into two questions (seven answers, DN4-symptoms: score range 0-7) and two physical 
examination tests (three answers, DN4-signs: score range 0-3). The examination items of the DN4 
regarding the signs (hypoesthesia to touch, hypoesthesia to prick and brushing) were incorporated 
in the sensory examination part of the standardized assessment form and were carried out 
according the original publication by Bouhassira et al [17]. This assessment form was filled in by 
both physicians separately. The seven symptom items are consisting of characteristics (Burning, 
painful cold, electric shocks) and symptoms (Tingling, pins and needles, numbness, and itching). 
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The patient completed the DN4-symptoms directly after the clinical assessments by the physicians 
but without interference. The researcher (HT) or a nurse was available for help in person or via 
telephone when it was not clear fort the patient how to fill in the questionnaires. 
The items of the DN4 are scored based on a yes (1 point) /no (0 points) answer. This leads to a score 
range of 0-10 when the symptoms (range 0-7 points) as well as the signs (range 0-3 points) items are 
included. Values in the DN4 who were not filled in were considered as ‘no’ (0 points). However, in the 
reliability analysis these data were not incorporated. 
Patient global impression of change (PGIC). The Patients Global Impression of Change (PGIC) [11, 
45-47] was used to assess the change of pain complaints, based on the patients’ own impression 
of change over time, during the follow-up period (7-points scale: Very much improved-very much 
worse). Follow-up took place two weeks and three months after the initial visit. To compare the 
outcome of the DN4 in the follow-up period the pain complaints as addressed by the patient had 
to be unchanged. 
Time-line 
All baseline measurements (the assessment by the physicians, the grading system by both physicians 
as well as filling in the questionnaires by the patient) took place on preferably the same day. The 
PGIC [45-47] and the DN4-symptoms (sensory testing for the DN4-signs was not performed) were 
sent to the patient after two weeks and three months with instructions how to fill them in by mail. 
Also for the follow-up measurements help was available in person or via telephone when it was not 
clear how to fill in the questionnaires. 
Data 
All data was collected on paper and stored by Radboudumc, Nijmegen, The Netherlands. Data 
management and monitoring were performed within MACRO (MACRO, version 4.1.1.3720, Infermed, 
London, United Kingdom). Data analysis and statistics was performed by use of Statistical Package 
for the Social Sciences (IBM SPSS statistics 22, SPSS Inc., Chicago, Illinois, USA). 
Statistical analysis 
According to the power-calculation in the protocol 132 patients with LBLP, NSAP or PSNO were 
needed such that the sample size contains adequate numbers of cases and controls [39]. Qualitative 
variables are presented as frequencies and percentages. The quantitative variables are presented as 
mean and standard deviation (SD) or as median and inter quartile range (IQR). 
The agreement between any of the two combinations of the two observers (pain classification 
by the physician and the outcome of the grading system) to establish a present NePC or 
absent NePC, and of the DN4 (DN4 / DN4-symptoms / DN4-signs outcome) was evaluated 
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by use of Cohen’s kappa (K), prevalence index (Pi) and percentage of pair wise agreement 
(PA). The categorization of the kappa values are, according to the categorization of observer 
agreement by Landis and Koch [48], none beyond chance (K ≤ 0.00); slight (K = 0.01-0.20); fair 
(K = 0.21-0.40); moderate (K = 0.41-0.60); substantial (K = 0.61-0.80) and (almost) perfect agreement (K 
= 0.81-1.00). A K ≥ 0.40 and a PA ≥ 70% is considered indicative of interobserver reliability acceptable 
for use in clinical practice [48]. Moreover, also the interobserver reliability of the examination items 
in the DN4-signs were tested. 
Based on the classifications of the two phyicians, all patients were categorized as absent NePC, 
present NePC or ‘undetermined’ (i.e. the pain classification of the two physicians was not the same). 
Statistical significant differences between absent NePC and present NePC were determined by 
use of students t-test (Interval scales), Mann-Whitney U-test groups (ordinal scales) or via Chi2-test 
(nominal scale). The statistical significant differences between present NePC, absent NePC and the 
Undetermined group was assessed by use of One-way ANOVA (with additional Tukey’s studentized 
range post-hoc test) or Kruskal-Wallis test. Chi2 test was also used to analyze the nominal outcome 
scale of the DN4 regarding the three groups. 
A factor analysis was used to study the structure of the DN4 in such a way that variables that were 
thought to reflect a smaller number of underlying variables were observed. This method was 
performed for all three versions of the DN4 (DN4; DN4-symptoms and DN4-signs). Principal axis 
factoring was used as the extraction method. The varimax rotation with Kaiser normalization was 
used. Extraction of the factors was based on Eigenvalues being greater than 1.0. Cronbach’s alpha 
was used to calculate the internal consistency of the factors constructed. The results are only shown 
for the Physicians A (the assessment of the patient by the first physician). The outcomes by the 
Physicians B (the assessment of the patient by the second physician) are shown in S1 Table. However, 
the conclusions, which are drawn, are identical for physicians A and for physicians B. 
A receiver operating characteristic (ROC) curve was calculated for the DN4 and the DN4 signs by 
both the physicians A and B and for the DN4-symptoms as filled in by the patient. The area under 
the curve (AUC) with 95% confidence interval was presented to indicate the discriminatory power 
of the DN4 to discriminate patients by present NePC or absent NePC. This dichotomy was based 
on the physicians’ assessment outcome or based on the grading system outcome, respectively. 
The theoretical maximum of the AUC is 100%, indicating a perfect discrimination and 50% is equal 
to tossing a coin. An AUC between 0.9 and 1 is considered to be excellent, an AUC between 0.8 
and 0.9 is good and between 0.7 and 0.8 is fair. An AUC between 0.6 and 0.7 is considered to be 
poor. Between 0.5 and 0.6 the AUC is considered to be failed [49-52]. The optimal cut-off point of 
the DN4 was calculated under the condition of equal-costs of misclassification using the Youden-
index. Sensitivity, specificity, positive and negative predictive values and the likelihood ratio in the 
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population in this study was calculated at this cut-off point. The outcome results were averaged 
between both physicians and the 95% confidence intervals were noted with respect to the lowest 
and highest level. 
Clinimetrics of the DN4 based on both the physicians assessment and/or both the grading system 
outcome were assessed for the DN4, the DN4-symptoms and for the DN4-signs items. A screening 
tool for the presence of a NePC is considered valid if it has a high sensitivity, specificity, high positive 
predictive value and a high positive likelihood ratio [53]. Intraclass correlation (ICC) was used to 
assess reproducibility (‘test-retest reliability’) of the DN4-symptoms between the predetermined 
time points (baseline versus two weeks & baseline versus three months). Based on the guidelines 
by Cicchetti et al. [54, 55] an ICC <0.40 indicates poor level of clinical significance. The level is fair 
when the ICC is between 0.40 and 0.59, good between 060 and 0.74 and excellent when the ICC is 
between 0.75 and 1.00. To assess the test-retest reliability patients’ pain should not have changed 
(outcome based on the PGIC) because otherwise the ICC would not reflect the consistency of the 
DN4. Test-retest reliability was assessed for those questionnaires returned within 7-21 days for the 
two weeks test-retest reliability and 60-120 days for the three months test—retest reliability. The ICC 
and responsiveness of the DN4-symptoms was assessed at each point of measurement. 
Two-tailed p-value below 0.05 was considered statistically significant. 
RESULTS
Patients 
In this study 330 consecutive patients were assessed for eligibility (Figure 1). Of these, 291 
participated in the study between October 2009 and July 2013. Two patients did not give their 
informed consent. Exclusion (n = 37) was because of not fulfilling the in- and exclusion criteria (n 
= 13): patients with LBLP or NSAP without radiating pain: n = 1; patients with less than 3 months 
pain complaints: n = 2; patients with pain with an oncological cause: n = 2; patients with painful 
syndromes of unknown origin or associated with diffuse pains: n = 7; patients with severe mental 
illness: n = 1; missing baseline measurements due to not returning questionnaires by the patient: 
n = 16; missing pain classification based on the grading system by one physician (n = 5) or both 
the physicians (n = 3). 132 patients had LBLP with radiation in one or two legs (45.4%), 51 NSAP 
with radiation in one or both arms (17.5%) and 108 patients (37.1%) had PSNO: 86 patients with 
pain after treatment for breast cancer (surgery and chemotherapy and/or radiation therapy and/
or hormonal therapy). Twenty-two patients had pain for various reasons: peripheral nerve damage 
(n = 12), radicular pain (n = 3), polyneuropathy (n = 3), CRPS (n = 2) and post stroke pain (n = 2). 
The gold standard for presence of the NePC in this study was the concordant clinical opinion of 
both physicians. After pain classification by two physicians, 170 patients were classified as present 
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NePC, 58 as absent NePC and in 63 patients the two physicians made a different pain classification: 
‘undetermined’. Using the grading system, 139 patients were assigned as having a present NePC, 
93 patients as absent NePC and 51 patients were assigned as undetermined. The DN4 was full filled 
by the patients at a median of one day (IQR 0-5 days) following the assessments by the physicians. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chronic pain patients assessed for 
eligibility 
n = 330 
Classification of NePC by: 
- Physicians assessment (PhA) 
- NeuPSIG Grading System (GS) 
n=328 
Excluded with reasons: n= 37 
 
 
No informed consent: n = 2 
Present-NePC  
PhA: n = 170 
GS: n = 139 
Undetermined  
PhA: n = 63 
GS: n = 51 
 
Absent-NePC  
PhA: n = 58 
GS: n = 93 
 
Figure 1: Flow diagram for the outcome of the physicians assessment and the NeuPSIG grading system. 
  Present NePC: present neuropathic pain component; Undetermined: Both physicians disagree with each 
other about the existence of a neuropathic pain component; Absent NePC: absent neuropathic pain 
component; n = total number of patients in analysis PhA: Physicians assessment; GS: Neuropathic pain 
special interest group grading system (missing pain classification based on the grading system: n = 8). 
Clinical and social-demographic details of the 291 patients were analyzed based on their pain 
classification. No statistically significant differences were found between present NePC and absent 
NePC for gender, age, height, weight, BMI, medication and duration of pain. Also no statistically 
significant difference was observed between absent NePC and present NePC regarding current- 
,worst – and average pain (Table 1). 
The proportion of agreement after chance agreement is removed (Cohen’s Kappa, K) for the 
classification of patients’ pain (absent NePC or present NePC) by the physicians was 0.49 
(moderate), with a PA of 78.4% (Pi = 0.38; n = 291). For the classification of patients’ pain on 
basis of the grading system K was 0.63 (good) and PA was 82% (Pi = 0.16; n = 283). The outcome 
of K and PA regarding the DN4 compared to the outcome of the assessment by physicians 
A was respectively 0.34 (fair) and 69.8% (Pi = 0.33; n = 275). Compared to the outcome of
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Table 1:  Clinical and socio-demographic characteristics of the patients related to physicians 
agreement for the existence of a neuropathic pain component. 
NePC Absent Present Undetermined
N N P N P
Total number of patients 58 170 63
Gender
Male
Female 
25 (43%)
33 (57%)
56 (33%)
114 (67%)
0.163c
17 (27%)
46 (73%)
0.164c
Age (Years) # 58 55 ± 12 170 56 ± 11 0.594a 63 58 ± 13 0.522d
Height (cm) #
Weight (kg) #
BMI (kg/m2 ) #
55 
55 
54 
172 ± 9
84 ± 2
28 ± 8
164 
167 
164 
172 ± 8
80 ±17
27 ±5
0.845a
0.382a
0.436a
62
62 
62
170 ± 9
80 ± 16
27 ± 5
0.250d
0.461d
0.593d
Medication use^ 55 56.9% 168 66.1% 0.414c 61 57.4% 0.423c
Duration of pain (months)# 57 72 ± 90 169 60 ± 76 0.327a 62 49 ± 46 0.247d
Pain* 
(NRS; 0-10)
Current pain 
Worst pain during the 
past four weeks 
Average pain during 
the past four weeks
57
57
57
5 (3-7)
8 (5-9)
6 (3.5-7)
167
167
167
6 (3-7)
8 (7-9)
6 (5-8)
0.577b
0.371b
0.233b
61
61
61
4 (1-7)
7 (5-8)
6 (3-7)
0.084e
0.053e
0.018e
Classification for the existence of NePC is based on physicians assessment of the patients. 
NePC: neuropathic pain component; Absent: NePC is absent; Present: NePC is present; Undetermined: both 
physicians disagree with each other about the existence of a neuropathic pain component; N: total number 
of patients in analysis; n: number of patients; ^ percentage; # Standard deviation; * Inter quartile range. A: 
physicians A; B: Physicians B; P value for significant difference between groups (P ≤ 0.05) by use of different 
analyse methods: a: Students t-test; b: Mann-Whitney U test; c: Chi-square; d: One-Way ANOVA; e: Kruskal-Wallis 
test.
the assessment by physicians B it was 0.33 (fair) and 69.2% (Pi = 0.30; n = 263). Comparing 
the outcome of the DN4 to the outcome of the grading system, it was 0.35 (fair) and 69.1% 
(Pi = 0.22; n = 272) for physicians A, and 0.32 (fair) and 67.3%(Pi = 0.19; n = 260) for physicians B (Table 
2). The interobserver reliability for ‘hypoesthesia to touch’ as well as for ‘brushing’ was respectively K 
= 0.59 (moderate) (PA = 79.7%) and K = 0.53 (moderate)(PA = 76.6%). The interobserver reliability for 
‘hypoesthesia to prick’ was K = 0.21 (fair); PA = 87% (Table 3). 
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Table 2:  The kappa coefficient between the classification on basis of the assessment by the physicians, 
the grading systems, the DN4 and the kappa coefficient between both physicians regarding 
the DN4-signs. 
Classification 
physician B
Grading 
A
Grading
B
DN4 
A
DN4 
B
DN4-
Symptoms
DN4-
Signs 
A
DN4-
Signs 
B
Classification 
physician A
n
K 
PA 
Pi
291
0.49
78.4
0.38
286
0.48
76.2
0.32
288
0.32
67.4
0.26
275
0.34
69.8
0.33
263
0.34
70.0
0.31
288
0.32
67.4
0.26
279
0.37
70.3
0.30
266
0.26
64.4
0.30
Classification
physician B
n
K 
PA 
Pi
286
0.38
71.0
0.28
288
0.48
75.0
0.22
275
0.33
69.1
0.29
263
0.33
69.2
0.30
288
0.21
62.8
0.25
279
0.39
71.0
0.26
266
0.37
70.7
0.28
Grading A n
K 
PA 
Pi
283
0.63
82.0
0.16
272
0.35
69.1
0.22
259
0.31
67.2
0.23
283
0.14
58.6
0.19
276
0.54
77.5
0.19
262
0.31
67.2
0.21
Grading B n
K 
PA 
Pi
272
0.29
65.4
0.18
260
0.32
67.3
0.19
285
0.13
57.2
0.14
276
0.53
76.8
0.14
263
0.45
73.4
0.16
DN4 A n
K 
PA 
Pi
257
0.76
88.7
0.21
275
0.62
81.8
0.19
275
0.52
76.7
0.17
257
0.29
65.8
0.19
DN4 B n
K 
PA 
Pi
263
0.65
82.9
0.18
257
0.40
71.2
0.21
263
0.45
73.4
0.17
DN4-
symptoms
n
K 
PA 
Pi
276
0.15
58.7
0.17
263
0.10
56.3
0.16
DN4-
Signs A
n
K 
PA 
Pi
260
0.55
78.4
0.18
n = total number of patients in the analysis; K = Cohen’s kappa value; PA (%) = percentage of agreement between 
two outcome variables; Pi = Prevalence index
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Table 3: The kappa coefficient between both physicians regarding the DN4-signs. 
Hypoesthesia to touch
DN4-signs B
Hypoesthesia to prick
DN4-signs B
Brushing
DN4-signs B
Hypoesthesia to touch 
DN4-signs A
n
K 
PA 
Pi
222
0.59
79.7
0.10
Hypoesthesia to prick 
DN4-signs A
n
K 
PA 
Pi
244
0.21
87.3
-0.82
Brushing 
DN4-signs A
n
K 
PA 
Pi
222
0.53
76.6
0.11
n = total number of patients in the analysis; K = Cohen’s kappa value; PA (%) = percentage of agreement between 
two outcome variables; Pi = Prevalence index
In 253 patients all the six outcome variables (two times the physicians’ assessment, two times the 
grading system and The DN4 by physician A and DN4 by physician B was available. In 83 patients 
(32.8%), the pain was classified as present NePC in all outcomes and in 22 patients (8.7%) it was six 
times negative, indicating absent NePC, so the agreement on all the six measures was 41.5% (the 
percentage of agreement based on both the gold standards and both the grading systems only was 
56.9%). 
Factor analysis 
Table 4 shows the loading factor of the items of the DN4 according to the rotated component matrix 
factor analysis with Kaiser normalization. The analysis was performed by use of the 10 questions in 
the DN4 and revealed a 4-factor solution explaining 59.3% of the variance for the first physicians’ 
assessment (physicians A): Factor 1 included two items (hypoesthesia to touch, brushing) indicating 
that there was an inter-relation between those items (Cronbach’s α: 0.87). Factor 2 included three 
items (painful cold, tingling, hypoesthesia to prick) (Cronbach’s α: 0.37). Factor 3, consisted of four 
items (burning, electric shocks, pins and needles, numbness); Cronbach’s α: 0.51). Factor 4 consisted 
of one item (itching) (Table 4). In the S1 Table we provided the factor analysis for both the physicians 
assessments (A & B), the DN4 symptoms solely and the DN4signs for both physicians’ assessments 
(A & B). Internal consistency of all the components of the DN4 for the physicians A at baseline was 
assessed via Cronbach’s α: 0.57; for the physicians B it was 0.55. Cronbach’s α for DN4-symptoms was 
0.52. Cronbach’s α for the DN4-signs for A and B were respectively 0.68 and 0.66. 
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Table 4:  Loading factors of the items of the DN4 according to the rotated component matrix factor 
analysis.
DN4 Component (Physicians A)
1 2 3 4
Burning 0.25 0.28 0.29 0.15
Painful cold 0.62
Electric shocks 0.72
Tingling 0.68
Pins and needles 0.35 0.45 0.27
Numbness 0.71
Itching 0.86
Hypoesthesia to touch 0.87
Hypoesthesia to prick 0.38 0.63
Brushing 0.90
Cronbach’s alpha 0.81 0.37 0.51
Loading factors < 0.25 are omitted to improve readability
Items of the DN4 
The DN4-symptoms (pain descriptors) burning, electric shocks, tingling, pins and needles, and 
numbness were statistically significant associated (Chi2) with the classification by the physicians 
(absent NePC, present NePC or undetermined), p<0.05. The descriptors ‘painful cold’ (p = 0.210) 
and ‘itching’ (p = 0.409) were not associated with the outcome of the classification. The DN4-signs 
(examination items) hypoesthesia to touch, pricking and brushing were statistically significant 
associated (Chi2) with the classification by the physicians (absent NePC, present NePC or 
undetermined), p<0.05. 
The median of the total sum score of the DN4 for patients classified as absent NePC was 2, the 
median for the DN4-symptoms items was 2 and for the DN4-signs items the median was 0; for 
patients classified as present NePC it was at median 5, 3 and 2, respectively. As calculated based 
on the Kruskal-Wallis test there was for the sum scores of the DN4, the DN4-symptoms items and 
the DN4-signs items a statistical significant difference between absent NePC and present NePC 
(P<0.001), between present NePC and undetermined (P<0.001) and between absent NePC and 
undetermined (P<0.001). In Table 5 the outcomes for all individual items and the three DN4 scales 
(for physicians A as well as for physicians B) are presented according to the pain classification by the 
physicians (Table 5). 
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Table 5:  The median (IQR) and percentages of the items of the DN4 by physicians agreement of a 
NePC.  
NePC Absent Present Undetermined
N N P N P
Total number of patient 58 170 63
DN4-
Symptoms^
Burning 56 12 (21%) 161 77 (48%) 0.001a 57 22 (39%) 0.002a
Painful Cold 54 6 (11%) 154 34 (22%) 0.078a 53 11 (21%) 0.210a
Electric Shocks 55 18 (33%) 162 87 (54%) 0.007a 55 19 (35%) 0.005a
Tingling 55 29 (53%) 160 110 (69%) 0.032a 57 28 (49%) 0.011a
Pins and Needles 52 19 (37%) 157 101 (60%) 0.000a 58 27 (47%) 0.001a
Numbness 54 29 (54%) 165 131 (79%) 0.000a 59 42 (71%) 0.001a
Itching 51 10 (20%) 149 25 (17%) 0.646a 56 14 (25%) 0.409a
DN4-signs^ Hypoesthesia to touch A 42 9 (21%) 153 102 (67%) 0.000a 60 16 (27%) 0.000a
B 41 11 (27%) 151 101 (67%) 0.000a 49 18 (37%) 0.000a
Hypoesthesia to prick A 47 0 (0%) 162 20 (12%) 0.011a 58 3 (5%) 0.017a
          B 48 0 (0%) 159 21 (12%) 0.008a 53 1 (2%) 0.002a
Brushing A 43 9 (21%) 157 110 (70%) 0.000a 55 14 (25%) 0.000a
B 43 13 (30%) 151 99 (66%) 0.000a 52 19 (37%) 0.000a
Total sum score DN4 A* (0-10) 47 2 (1-3) 166 5 (3-6) 0.000b 62 3 (2-4) 0.000c
Total sum score DN4 B* (0-10) 48 2 (2-3,75) 159 5 (3-6) 0.000b 56 3 (2-4.75) 0.000c
Total sum score DN4 symptoms* (0-7) 57 2 (1-3) 168 3 (2-5) 0.000b 63 2 (2-4) 0.000c
Total sum score DN4 signs A* (0-3) 49 0 (0-0) 168 2 (1-2) 0.000b 62 0 (0-1) 0.000c
Total sum score DN4 signs B* (0-3) 49 0 (0-1) 161 2 (0-2) 0.000b 56 0 (0-2) 0.000c
Classification for the existence of NePC is based on physicians assessment of the patients. 
NePC: neuropathic pain component; Absent: NePC is absent; Present: NePC is present; Undetermined: both 
physicians disagree with each other about the existence of a neuropathic pain component; N: total number of 
patients in analysis; n: number of patients; ^ percentage; * Inter quartile range. A: physicians A; B: Physicians B; P 
value for significant difference between groups (P _ 0.05) by use of different analyse methods: a: Chi-Squared; b: 
Mann-Whitney U test; c: Kruskal-Wallis test.
Validity 
We constructed ROC-curves for the DN4, the DN4-symptoms and the DN4-signs with respect to the 
classification by physician A or B and according to the neuropathic pain grading system by physician 
A or B and all the combinations (Concordant assessment by physicians A and B together, concordant 
grading system by Physicians A and B together and concordant grading system for Physicians A 
and B together with the concordant grading system by physicians A and B). This because of the 
chosen gold standard and the grading system in which patients were classified by two different 
physicians. This might have lead to differences in the outcomes relative to the individual outcome 
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by the physician. In Figure 2 the ROC-curve is displayed for the DN4 (physicians A and physicians B), 
DN4-symptoms and the DN4-signs (physicians A and physicians B) (Figure 2). 
 
 
 
 
 
 
 
DN4 A:   AUC = 0.829 
DN4 B:   AUC = 0.807 
DN4 symptoms: AUC = 0.713 
DN4 signs A:   AUC = 0.781 
DN4 signs B:   AUC = 0.738 
Figure 2:  The ROC curve of the DN4, DN4 symptoms and the DN4 signs to the probability of the 
presence of NePC as classified based on the assessment by the physicians (A and B). 
  DN4: Doleur Neuropathique en 4 questions; DN4-symptoms: the items filled in by the patient; DN4 
A: DN4-symptoms filled in by the patient and DN4-signs as assessed by physicians A; DN4 B: DN4-
symptoms filled in by the patient and DN4-signs as assessed by physicians B; DN4 signs A: DN4-signs 
as assessed by physicians A; DN4 signs B: DN4-signs as assessed by physicians B. 
Based on the gold standard the sensitivity of the DN4 was on average (at maximal Youden- index, cut 
off point: 4/10) 75% (95% CI 0.68-0.81), specificity 76% (95% CI 0.61-0.86), positive predictive value 
92% and the positive likelihood ratio was 3.09 (95% CI 1.82-5.39) (Table 5; S2 Table). For patients with 
LBLP the sensitivity was on average 75% and specificity was on average 81%. For patients with NSAP 
the averaged sensitivity was 73% and the specificity was on average 72%. For patients with pain 
due to a PSNO it was respectively, on average, 70% and 78%. The sensitivity of the DN4-symptoms 
was, in respect to the gold standard, 70% (95% CI 0.63-0.77) and the specificity was 67% (95% CI 
0.54-0.78) (at maximal Youden-index, cut off point 3/7). Analysis of the DN4-signs solely resulted in 
an average sensitivity of 75% (95% CI 0.66-0.82) and an average specificity of 75% (95% CI 0.58-0.87) 
(at maximal Youden-index, cut off point 1/3). With the outcome based on the grading system the 
sensitivity was on average 76% (95% CI 0.68-0.82) and the specificity was 64% (95% CI 0.51-0.74) (at 
maximal Youden-index, cut off point 4/10). (Table 6; S2 Table). 
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In Table 6 and S2 Table we present the number of patients per group, values of the AUC, Youden index, 
cut-off score, true positives, false positives, false negatives, true negatives, sensitivity, specificity, 
positive and negative predictive values, positive and negative likelihood ratios, the diagnostic odds 
ratio, the a-priori chance for the existence (or not) of a NePC and false positive and negative ratios 
for all validity outcomes (DN4 A & B, DN4-symptoms, DN4-signs A & B) divided according to the pain 
classification and divided into LBLP, NSAP and PSNO (Table 6 and S2 Table). 
Test-retest reliability 
Stability and responsiveness of the DN4-symptoms over time was assessed over a period of two 
weeks. The median sum score (IQR) of the DN4 at baseline for the total group was 3 (2-4), after two 
weeks it was 3 (2-4). Taking into consideration the fact that patients’ pain should not have changed 
(outcome based on the PGIC) because otherwise the ICC would not reflect the consistency of the 
DN4, test-retest reliability via ICC was 0.84 (excellent) (95%CI 0.80-0.87; n = 265). For the time gap 
of 7-21 days (to rule out the early or delayed return of questionnaires) between the first and second 
DN4-symptoms the ICC was 0.85 (excellent) (95% CI 0.79-0.90; n = 122). After three months, with no 
change in patients pain and a time gap of 60-120 days between the first and third DN4-symptoms, 
ICC was 0.79 (excellent) (95% CI 0.70-0.86; n = 102). 
DISCUSSION
The DN4 seems, in this study, to help to identify a neuropathic pain component in a consecutive 
population of patients with chronic pain in a moderate way. 
Reliability 
We used the concordant opinion about the classification of patients’ pain by two physicians as the 
gold standard. It is disputable if the term gold standard is practicable. However, as written by Versi 
[56, 57] “the gold standard is not the perfect test but merely the best available test. . .. Against which newer 
tests can be compared”. There are studies regarding the validity of the DN4 using only one physician’s 
opinion [21, 30]. To our opinion it is preferable to use two physicians as the gold standard, which is 
also performed in the original validation study of the DN4 [17]. This might lead to less false positive 
or false negative outcomes which, of course, will lead to a more accurate validity outcome. The 
physicians in this study agreed on pain classification in 78% of the patients. In other studies without 
pre-stratification of patients on the target outcome the results for the physicians agreement were 
53% [25] and 89% [27]. The kappa coefficient between the DN4 as filled in by physician A compared 
to the DN4 by physician B was ‘good’ with a high percentage of agreement. Test-retest reliability of 
the DN4-symptoms in this study was excellent. Based on these results DN4 seems to be reliable. 
However, it is possible that an instrument is reliable without being valid [58]. 
The validity of the DN4 in patients with chronic pain
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Validity 
To quantify the screening ability of the DN4, for the existence of a NePC, sensitivity and specificity 
can be used [59]. However, in clinical practice we want to know how many patients with a positive 
score on the DN4 really does have a NePC. To report this, the positive and negative predictive values 
are important because they give the proportion of patients with positive or negative test results 
which are correctly diagnosed [60]. The predictive value depends on the prevalence of NePC in the 
group of patients under study [60]. In our study the prevalence of NePC was high, 75%. The higher 
the prevalence of NePC in the group under study the more sure it is that a positive outcome of the 
DN4 indicates the presence of a NePC, but the less sure it is that a negative DN4 outcome indicates 
absent NePC [60]. The likelihood ratio gives an indication of the value of the DN4 for increasing 
certainty about a positive diagnosis [60]. A higher likelihood ratio might indicate that the DN4 is 
useful, but is still not sure that a positive outcome of the DN4 is a good indicator for the presence of 
a NePC [60]. In the literature there are, as far as we know, no ‘cut-off’ scores for the validity indices. In 
our study we found a sensitivity of 75% (DN4-symptoms 70%), a specificity of 76% (DN4-symptoms 
67%), positive predictive value of 92%, negative predictive value of 46% and the positive and 
negative likelihood ratios were respectively 3.09 and 0.34. In the original study by Bouhassira et al. 
[17] patients with only ‘typical’ neuropathic or nociceptive entities and a VAS of ≥40 mm (0-100mm) 
were included. They found a sensitivity of 83% and a specificity of 90%. For the DN4-symptoms 
the sensitivity was 78% and the specificity 81%. The Dutch version of the DN4 [20] was validated 
before in a consecutive group of patients suffering from chronic pain for more than three months 
with a pain score of 5 or higher on a 0-10 numeric rating scale (NRS) [25]. For the DN4 a sensitivity 
of 75% and a specificity of 79% was found. For the DN4-symptoms version sensitivity was 74% and 
the specificity 79%. Van Seventer et al. concluded that the DN4 was a diagnostic tool with a good 
ability to discriminate between neuropathic pain and nociceptive pain [25]. However, the paper 
by Bouhassira et al. [17] and the paper by Van seventer et al. [25] both didn’t report the predictive 
values and likelihood ratios. Inappropriate screening might result in higher health care costs due to 
more diagnostic testing or even lead to a harmful treatment for the patient [61]. It seems that the 
validity indices in our study are resulting in a lower score for the DN4 as in the original publication 
[17] and than in other studies [4, 21, 23-28, 30, 31, 62-67]. This might have several reasons. At first, we 
did not pre-stratify on the target outcome. In studies, besides the original validation study [17] with 
pre-stratification on the target outcome [23, 24, 26, 28, 31] (neuropathic or non-neuropathic pain), 
the sensitivity of the DN4 was ranging from 90% [26] till 100% [24], the specificity from 93% [24]-
97% [23, 28]. In studies where there was no pre-stratification on the target outcome (neuropathic 
or non-neuropathic pain), the sensitivity of the DN4 was ranging from 80% [21] till 100% [30], the 
specificity ranges from 78% [21, 27] till 87% [30]. These results are showing that the validity of the 
DN4 is lower in studies without pre-stratification than in studies were patients were stratified based 
on their pain classification before entering the study. In studies with specified diseases as spinal cord 
injury [64]; diabetes [63, 64]; leprosy [65, 66]; FBSS [67], chronic low back pain [4] and in patients with 
cancer before starting with chemotherapy [68], the sensitivity (62%-100%) and specificity (44%-
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93%) ranges were much wider. Our results, also when separated into results for LBLP, NSAP and 
PSNO, falls within these ranges. This indicates that the neuropathic pain component is not always 
clear and/or easy to classify by use of the DN4 in the different medical conditions. Secondly, in our 
study we did not have a minimum level of pain as an inclusion criteria. In seven studies a minimal 
level of pain (on a rating scale of 0-10) was not an inclusion criteria [21, 23, 31, 62, 63, 65, 66]. In 
other studies a level ≥ three [64, 67], ≥ four [4, 17, 24, 26, 28, 30] or ≥ five [25, 27] is set as an inclusion 
criterium. As shown by Perez et al [21], pain severity has a major influence on the sensitivity and 
specificity of the DN4. A severity of < 40 mm on a 0-100mm VAS resulted in a sensitivity of 56% and 
a specificity of 67%. For moderate pain (between 40mm en 70mm on a 0-100mm VAS) it was 85% 
and 84% respectively, and >70 mm sensitivity was 80% and specificity was 74% [21]. In a study by 
Marksman [67] in patients after FBSS it was showed that the presence of neuropathic characteristics, 
as determined by the DN4, was associated with a higher pain intensity. These facts are crucial for 
the validation of a screening instrument because such a tool must be valid for use in daily clinical 
out-patient practice and/or for epidemiological purposes. 
As a second comparison, we validated the DN4 in comparison with the grading system [21, 32]. 
In this study, we combined ‘unlikely’ and possible neuropathic pain as absent NePC and probable 
and definite as present NePC, which resulted in an average sensitivity for the DN4 of 76% and an 
average specificity of 64%. In patients with a failed back surgery syndrome [67], the validation of 
the DN4 resulted in a sensitivity of 62% and a specificity of 44%. In a study by Sadler et al [69] where 
patients with neuropathic pain were compared to musculoskeletal pain the sensitivity was 76% and 
the specificity was 70%. However, in patients with a more mixed pain the sensitivity and specificity 
descended to 59% and 70% respectively. Abdallah et al [36] compared the DN4 with the grading 
system in patients after breast tumor resection with and without paravertebral blocks. This resulted 
in a sensitivity of 90% and a specificity of 60% to identify patients with chronic neuropathic pain 
based on the outcome of the grading system. However, this outcome was not validated by (expert) 
physicians. The distinction between possible neuropathic pain and probable or definite neuropathic 
pain is of high importance because the outcome forms the basis for selecting a different treatment 
strategy [34]. The combination of outcomes in our study might have resulted in a lower sensitivity 
and a bit higher specificity in comparison with the classification in the study of Abdallah et al [36]. 
Bouhassira [17] presented the DN4 as a clinician-administered questionnaire. In different studies not 
a physician but a research coordinator [30], a nurse [25] or the patient self [25, 70] filled in the DN4. 
In our study we gave the patient the questionnaire with the 7-items (DN4-symptoms) to fill them 
in after the physical examinations. The three examination-items (DN4-signs) were incorporated in 
the standardized assessment form which should be filled in by the physician. We presented the 
DN4 total sum score as well as the DN4-signs score separately for physicians A and B. This is due to 
the fact that it is only possible to have one outcome when the sign-items were performed by one 
physician. 
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Strength and weaknesses 
There are several strengths in this study. At first, this study reflects daily clinical practice. In this 
study, we included a large cohort of patients irrespective of the predominant origin of the pain 
and level of pain which corresponds to a typical daily clinical patient population. These patients 
were associated with the most common specified medical conditions for pain (i.e. LBLP or NSAP or 
PSNO) and classified by two, independently working, physicians. Moreover, patients were referred 
from primary care to secondary and tertiary pain clinics and were assessed for their complaints 
for the first time at the time of inclusion in this study. This limits the risk of systematic bias and 
also reflects daily clinical practice. Secondly, we used a standardized assessment form in which the 
bedside examination and the grading system [32, 33] and the DN4-signs were incorporated. This 
might, however, have led to an influence on each other which made the physician more sure about 
the final classification of patients pain and thus made the gold standard stronger. There are also 
some weaknesses in this study. As said before, we have not used the DN4-symptoms as a interview 
by a physician but as a questionnaire which has to be filled in by the patient. This might have had 
an influence on the reliability and validity. In the revised EFNS guidelines on neuropathic pain 
assessment [42] it is suggested that “The seven sensory descriptors can be used as a self-report 
questionnaire with similar results”. Moreover, above the official Dutch version [20, 25] of the DN4 is 
written in Dutch: “To be completed by the patient”. In the paper by van Seventer et al the agreement 
between the patient administered and a nurse administered was good till very good for the first 
seven items [25]. It would be of interest to see if there are differences in the outcome when the DN4 
is filled in by the patient himself or as an interview by the pain physician. Questions by the patient 
to the nurse of via telephone to the researcher regarding the DN4 were very rare. However, we 
didn’t keep track of the questions. Another limitation is the fact that we only tested the test-retest 
reliability regarding the DN4-symptoms and not the DN4-signs to prevent the patient to come back 
to the hospital only for these test-items. Another weakness is the gold standard which is, for now, 
the best measure for the existence of a neuropathic pain component but the result is still open for 
discussion. 
Suggestions for the validation of neuropathic pain screening tools 
Validation of screening tools should be performed in a standardized manner and described in detail, 
but performed in a setting which is comparable to a daily clinical practice. A research setting might 
be different from a clinical setting and thus might have influence on the patient and on the study 
results. The group of patients as well as the physicians under study should be comparable to the 
patients/physicians for who the tool is intended. Pre-stratification on the target outcome must be 
avoided (especially the exclusion of the so called mixed pain), because this will lead to a non-clinical 
situation and thus decreases the validity and generalizability of the instrument [16, 71]. 
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CONCLUSION 
The validity of DN4-signs is equal to the DN4 outcome and, importantly, both are more valid than 
the DN4-symptoms alone. It seems that the patients’ symptoms and signs doesn’t reliably reflect the 
underlying mechanisms, indicating there is a need for a more objective way to assess patients’ pain 
to facilitate improvement in the treatment of patients with pain. The physicians’ assessment cannot 
be replaced by a screening tool as the DN4, but gives the physician a little hint towards the (non-) 
existence of neuropathic pain component. 
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SUPPLEMENTARY MATERIAL
Supplement Table S1:  Loading factors of the three versions of the DN4 according to the rotated 
component matrix factor analysis
DN4 Component 
(Physicians A)
Component  
(Physicians B)
1 2 3 4 1 2 3
Burning 0.251 0.279 0.292 0.149 0.542
Painful cold 0.616 0.497
Electric shocks 0.719 0.287 0.649
Tingling 0.676 0.425 0.418
Pins and needles 0.353 0.445 0.271 0.636
Numbness 0.709 --- 0.262 0.602
Itching 0.857 0.484
Hypoesthesia to touch 0.872 0.905
Hypoesthesia to prick 0.375 0.630 0.297 0.579
Brushing 0.896 0.907
Cronbach’s alpha 0.809 0.370 0.509 0.836 0.482 0.236
Loading factors < 0.25 are omitted to improve readability
DN4-symptoms Component
1 2
Burning 0.439
Painful cold 0.515
Electric shocks 0.715
Tingling 0.654
Pins and needles 0.529 0.347
Numbness 0.625
Itching 0.684
Cronbach’s alpha 0.476 0.368
Loading factors < 0.25 are omitted to improve readability
DN4-signs Component (Physicians A) Component (Physicians B)
1 1
Hypoesthesia to touch 0.881 0.912
Hyopoesthesia to prick 0.515 0.405
Brushing 0.880 0.895
Cronbach’s alpha 0.675 0.663
DN4-examination via component matrix; One component extracted, the solution couldn’t be rotated.
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ABSTRACT
Background
The assessment of a neuropathic pain component (NePC) to establish the neurological criteria 
required to comply with the clinical description is based on history taking, clinical examination, 
and quantitative sensory testing (QST) and includes bedside examination (BSE). The objective of 
this study was to assess the potential association between the clinically diagnosed presence or 
absence of an NePC, BSE, and the Nijmegen-Aalborg screening QST (NASQ) paradigm in patients 
with chronic (≥3 months) low back and leg pain or with neck shoulder arm pain or in patients with 
chronic pain due to suspected peripheral nerve damage. 
Methods
A total of 291 patients participated in the study. Pain (absence or presence of neuropathic pain) was 
assessed independently by two physicians and compared with BSE (measurements of touch [finger, 
brush], heat, cold, pricking [safety pin, von Frey hair], and vibration). The NASQ paradigm (pressure 
algometry, electrical pain thresholds, and conditioned pain modulation) was assessed in 58 patients 
to generate new insights. 
Results
BSE revealed a low association of differences between patients with either absent or present NePC: 
heat, cold, and pricking sensations with a von Frey hair were statistically significantly less common 
in patients with present NePC. NASQ did not reveal any differences between patients with and 
without an NePC. 
Conclusion
Currently, a standardized BSE appears to be more useful than the NASQ paradigm when 
distinguishing between patients with and without an NePC.
Keywords
quantitative sensory testing, NASQ, Nijmegen-Aalborg screening QST, clinical assessment, 
diagnostic accuracy
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INTRODUCTION
Neuropathic pain is defined by the International Association for the Study of Pain (IASP) as “pain 
caused by a lesion or disease of the somatosensory nervous system”. It is a clinical description rather than 
a clinical diagnosis which would require “a demonstrable lesion or disease that satisfies the established 
neurological diagnostic criteria” [1]. In the general population, 6%-8% suffer from neuropathic pain 
[2-4]. Nociceptive pain is defined as “pain that arises from actual or threatened damage to non-neural 
tissue and is due to activation of nociceptors”. This allows us to distinguish between patients with 
neuropathic pain (classification based on an abnormally functioning somatosensory nervous 
system) and nociceptive pain (classification based on a normally functioning somatosensory nervous 
system). Because co-existence of both conditions (mixed pain condition) is frequently observed in 
daily clinical practice, La Cesa et al. suggest using the presence or absence of a neuropathic pain 
component (absent or present NePC) [5]. NePC assessment is based on history taking, clinical 
examination, and (quantitative) sensory testing and includes bedside examination (BSE) [6-8].
Clinical examination alone can never offer proof that a specific pain is of neuropathic origin, but it 
provides supporting evidence for alterations in the functioning of the nervous system [6]. According 
to the IASP neuropathic pain special interest group (NeuPSIG), abnormal sensory findings should be 
neuroanatomically plausible when an NePC is present, and the sensory signs should be associated 
with the neuroanatomically plausible distribution compatible with an underlying relevant lesion 
or disease of the somatosensory nervous system [9,10]. As part of a bedside clinical neurological 
examination, sensory testing can identify negative sensory symptoms such as hypoalgesia or 
hypoesthesia and/or positive sensory symptoms such as allodynia and hyperalgesia [5]. According 
to Haanpää et al. [6] BSE can possibly identify where the pathology causing the pain can be found 
in the central nervous system. 
In the last decades, quantitative sensory testing (QST) has complemented traditional neurological 
BSE tests. QST uses psychophysical tests defined as stimuli with predetermined physical properties 
based on specific measurement protocols for the analysis of somatosensory aberrations [11-13]. 
QST measures responses to sensory stimuli and can be used to assess somatosensory system 
function [11-12], the measurement of the altered peripheral and/or central pain sensitivity [14-16], 
and descending pain modulation [17,18]. QST is thought to offer greater precision and reliability 
when assessing somatosensory system functionality than a standard BSE [19,20] because of the 
use of controlled automated devices. There is evidence that QST improves the diagnostic process 
of patients with pain, and that it may be valuable when monitoring for a specific anti-neuropathic 
treatment [21,22]. Moreover, an altered pain modulation can be assessed on the basis of signs and 
symptoms of peripheral and central sensitization [17,23-25] and by the use of conditioned pain 
modulation (CPM) [19,26]. CPM is a physiological phenomenon that can be used to assess the quality 
of the endogenous pain inhibitory pathway, also known as the “pain inhibits pain” phenomena 
[27]. The Nijmegen-Aalborg screening QST (NASQ) [15,16,24,28] measures pain and central pain 
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processing under standardized conditions using defined stimuli and experienced intensity ratings. 
There is no “gold standard” for the diagnosis of NePC, and the association between NePC and BSE/
NASQ has not yet been fully evaluated. There is a need for studies to more objectively identify the 
presence of an NePC and to assess the diagnostic accuracy of BSE and NASQ for NePC [5].
The objective of this study was to assess the potential association between clinically diagnosed 
absent or present NePC and BSE and NASQ in patients with chronic (≥3 months) low back and leg 
pain (LBLP) or with neck shoulder arm pain (NSAP) radiating into the leg(s) or arm(s), or in patients 
with chronic pain due to suspected peripheral nerve damage (sPND). 
METHODS
This study is based on a cross-sectional, observational research design to generate new insights 
into the clinical assessment of NePC. It is a sub-analysis of a study approved by the medical and 
ethical review board Committee on Research Involving Human Subjects, region Arnhem-Nijmegen, 
Nijmegen, the Netherlands, dossier number: 2008/348; NL 25343.091.08. 
In the original study conducted between October 2009 and June 2013, we validated the Dutch 
PainDETECT [29] and the DN4 [30,31]. The PainDETECT [32] and the DN4 [33] were both developed 
to screen for the presence of neuropathic pain. The patient self-administered PainDETECT is a simple 
screening tool with no need for physical examination. The instrument consists of one item about 
the pain course pattern, one about radiating pain, and seven questions about the gradation of pain. 
The clinician-administered DN4 consists of a total of 10 items with yes/no answers. It is divided 
into two questions (symptoms) and two physical examination tests (signs). The two sign items 
were incorporated in the sensory examination part of the standardized assessment form [28]. The 
protocol was registered in the Dutch National Trial Register: NTR 3030 and published by Timmerman 
et al. [28] Patients provided written informed consent after screening, but before participation in 
the study. 
Participants 
We recruited patients as part of the Dutch validation studies concerning the PainDETECT and the DN4. 
Inclusion criteria were male and female adult patients aged over 18 years with chronic(≥3months)
LBLP or NSAP, or patients with chronic pain due to sPND. We excluded patients suspected for or 
diagnosed with malignancy; compression fractures; patients with diffuse pains such as fibromyalgia 
or ankylosing spondylitis; severe mental illness; chronic alcoholism or substance abuse; inability to 
fill in the questionnaire adequately; or incapable of understanding the Dutch language. 
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Pain classification 
Classification of patients’ pain was based on the NeuPSIG guidelines on neuropathic pain assessment 
[6]. Pain classification was performed consecutively but blinded for the outcome on the same patient 
independently by two physicians working in different compositions, and then categorized into three 
groups: “absent NePC”, “present NePC” where both physicians were in agreement, or “undetermined 
NePC” in cases where they did not agree. A full medical history and clinical examination including 
sensory BSE was taken [6,7,21,28,34] and considered as the gold standard for NePC diagnosis. 
Bedside examination 
Multicenter recruitment took place in the Netherlands in three academic pain centers and in 
four non-academic pain centers. A standardized BSE [28] was independently performed by two 
physicians during the validation study for the two neuropathic pain screening tools. Prior to the 
study, the physicians were trained in the standardized evaluation of patients with chronic pain 
using specific modalities such as touch, pin prick, pressure, cold, heat, vibration, and temporal 
summation. The location indicated by the patient as having maximum pain was compared with 
the mirrored location on the contralateral side. When the pain had a double-sided character, a 
location without pain but as close as possible to the original mirror site was tested for comparison. 
Patients were asked the following: 1) is a sensation present? 2) is the sensation unpleasant? Or 3) is 
the sensation painful? (all scored as yes, no, or unclear) The outcome was noted by the physician on 
the standardized assessment form [28]. The following tests were performed consecutively on each 
patient independently by two physicians: 1) mechanical static allodynia via blunt pressure with a 
finger at a force that normally does not evoke pain; 2) dynamic mechanical allodynia via stroking 
the skin with a Soft Brush (SENSElabTM, Brush-05, Somedic AB, Hörby, Sweden), 2a) one movement 
of 1-2 centimeter and 2b) three movements of 1-2 centimeters (wind-up response); 3) mechanical 
pinprick allodynia via touch of the skin with 3a) a plastic safety pin and 3b) a Von Frey hair (TOUCH 
TEST®, 5.07, 10.0 g, North Coast Medical Inc., Gilroy, CA, USA); 4) heat allodynia by use of TipTherm® 
(TipTherm, Brüggen, Germany) in a baby-bottle warmer (ISI mini Baby Bottle Warmer, Assen, the 
Netherlands) set at 45 degrees Celsius; 5) cold allodynia with an ice cube placed on the skin for 2 
seconds; and 6) vibration with a tuning fork (128 Hz; Medipharchem, Wormerveer, the Netherlands) 
applied to joint, bone, or soft tissue in the region of the pain. 
Nijmegen-Aalborg screening QST 
Patients for the additional NASQ part of the study were recruited in one academic pain center and 
two non-academic pain centers. After screening in the clinical department, patients were asked to 
participate. The NASQ was performed in a random sub-sample of 20% of the patient population 
(LBLP, NSAP, and sPND) by a trained and experienced researcher (HT) [28]. The NASQ paradigm 
[15,16,24,28] was used as screening protocol. The NASQ screens for changes in pain processing 
based on a systematic mechanism-oriented approach [16]. It maps pain sensitivity at multiple 
sites by measuring the responses (ie, painful sensations) evoked by mechanical and electrical non-
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invasive stimuli, and measures the patient’s capacity to modulate pain using the CPM. Instructions 
were standardized and read to each patient from an instruction sheet. 
Pressure pain threshold (PPT) test 
A pressure algometer (Somedic AB) was used to measure PPTs bilaterally at each location, expressed 
in kilo Pascal: thenar (middle part), musculus trapezius pars median (middle part), musculus rectus 
femoris (15 cm above patella), and musculus abductor hallucis (middle part). In addition to the 
analysis with an average value over these eight measurement points, we performed additional 
analyses in the four central measurement points: musculus trapezius pars median (both sides) and 
musculus rectus femoral (both sides), and the four peripheral measurement points: thenar (both 
sides) and m. abductor hallucis (both sides). 
Electrical pain thresholds 
The QST-3 device (JNI Biomedical ApS, Klarup, Denmark) was used to measure electrical pain 
thresholds (EPTs) on the left and right body side. Measurement locations were the musculus trapezius 
pars median (middle part) and the musculus rectus femoris (20 cm above patella). Thresholds were 
assessed and expressed in milli-Ampère. EPTs were measured as electrical pain detection threshold 
(EPDT) when the current started to feel pain, and as electrical pain tolerance threshold (EPTT) when 
the current was as high as the patient could tolerate. 
CPM response 
We assessed CPM [17,27] via the PPT (CPMp) and the EPT (CPMe) on the m. rectus femoris 
contralateral to the dominant hand. The noxious stimulus (conditioning stimulation) was to immerse 
the dominant hand to the wrist in a bucket filled with water and ice cubes (ice water bucket [IWB] 
test) [25]. The patient was instructed to “keep the hand in the water for as long as possible, until the 
moment that the sensation becomes unbearable and you want to stop directly”. Pain was recorded 
every 10 seconds on the numeric rating scale. The duration of the immersion (with a maximum of 
180 seconds) was recorded and the pain intensity at the end of the immersion was also registered. 
The PPT and the EPT were then assessed again on the contralateral m. rectus femoris. The response 
was calculated by subtracting the outcome of the pre-measurement from the outcome of the post-
measurement. The CPM values were calculated using the following formulas: 
CPMp=( [PPTpost – PPTpre]/PPTpre) * 100
CPMe=( [EPTpost – EPTpre]/EPTpre) * 100
CPM was regarded as “positive” when the outcome of the calculation was equal or higher than zero 
and negative when it was below zero. 
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Data 
All data were collected on paper from the patients and the physicians and stored at Radboudumc, 
Nijmegen, the Netherlands. Data management and monitoring were performed using MACRO 
(MACRO, version 4.1.1.3720, InferMed, London, UK). Data analysis and statistics were performed 
using Statistical Package for the Social Sciences (SPSS version 20.0, SPSS Inc., Chicago, IL, USA). 
Statistical methods 
Qualitative variables are presented as frequencies and percentages. Quantitative variables are 
presented as mean and SD or as median and interquartile range. The chi-square test was used to 
test for significant differences between nominal outcome data. Cramér’s V was used as a measure of 
association between two nominal variables, giving a value between 0 and 1. Mann-Whitney U-test 
was used to test the differences between present and absent NePC. Kruskal-Wallis test was used 
to study differences between the three (absent NePC, present NePC, and undetermined) groups. 
We used Cohen’s Kappa and the percentage of pair wise agreement to determine the agreement 
between the BSE between the patient’s first and second assessment. A two-tailed p-value below 
0.05 was considered statistically significant. 
RESULTS
In total, 330 patients with chronic LBLP, NSAP, or sPND were assessed for eligibility. Two patients did 
not provide informed consent prior to inclusion in the study. Thirty-seven patients were excluded 
because of not meeting the inclusion and exclusion criteria (n=13); not returning the baseline 
questionnaires (n=16), and missing pain classification by one physician (n=5) or both physicians 
(n=3). 
BSE was performed in this study in 291 patients by 62 different physicians from seven hospitals. 
The present NePC group (n=170) consisted of 75 patients with LBLP, 23 patients with NSAP, and 72 
patients with sPND. The absent NePC group (n=58) consisted of 28 patients with LBLP,18 patients 
with NSAP, and 12 patients with sPND. For the undetermined group (n=63), the numbers were 29, 
10, and 24, respectively (see Figure 1 and Table 1). 
The NASQ was performed in a total of 69 patients. Patients were excluded after the NASQ measurements 
were made: not fulfilling the inclusion and exclusion criteria (n=9) or a missing assessment by a second 
physician (n=2). Finally, a total of 58 patients (56 Dutch natives, 1 German native, and 1 of Chinese/
Indonesian origin) were included in the analysis: 25 with LBLP, 25 with NSAP, and 8 with sPND. After 
NePC assessment by the physicians, 16 patients were classified as absent NePC, 29 with present NePC, 
and 13 patients with an undetermined outcome. The absent NePC group, present NePC group, and 
undetermined group had 4, 14, and 7 patients with LBLP; 12, 7, and 5 patients with NSAP; and 0, 7, and 
1 patient(s) with sPND, respectively (see Figure 1 and Table 1). 
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Patients with chronic pain due to LBLP, NSAP or 
sPND assessed for eligibility  
n = 330 
No informed consent 
n = 2 
Present NePC 
n = 170 
Undetermined 
n = 63 
Absent NePC 
n = 58 
Performance of BSE (Excluded with reasons n = 37) 
n = 291  
Present NePC 
n = 29 
Undetermined 
n = 13 
Absent NePC 
n = 16 
Performance of NASQ (Excluded with reasons n = 11) 
n = 58  
Classification of NePC by Physicians Assessment 
n = 328 
Figure 1:  Flow diagram for the performance of the BSE and NASQ in patients with chronic pain with 
respect to the physicians’ assessment. 
  Notes: n, number of patients in analysis; Present NePC, NePC is present; Undetermined, both 
physicians disagree with each other about the presence of a NePC; absent NePC, no NePC is present.
  Abbreviations: LBLP, low back and leg pain; NSAP, neck shoulder arm pain; sPND, suspected 
peripheral nerve damage; BSE, bedside examination; NePC, neuropathic pain component; NASQ, 
Nijmegen- Aalborg screening quantitative sensory testing.
In Tables 2 and S1, we have shown the outcome of the BSE based on the inter-physician agreement 
on the existence of an NePC. In the first assessment by the physician, the answers on the question 
“is there a sensation (yes, no, unclear) during testing for heat, cold, touch (brush 3 times), and 
pricking (both safety pin and von Frey hair)” were significantly lower (p≤0.05) for yes in the group 
with present NePC compared to the absent NePC group. In the second assessment, the scores for 
the question “is there a sensation (yes, no, unclear) of heat, cold, touch, (only brush 1 time), and 
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pricking (von Frey hair only)” were significantly lower (p=0.05) for yes in the group with present 
NePC with a lower percentage of “yes” compared to the absent NePC. The scores for the questions 
“is the touch with a finger unpleasant?” and “is touch with a brush unpleasant?” were higher for the 
second assessment for the group with present NePC (p=0.049 and p=0.006, respectively). “Painful 
for touch with a finger” was more common in patients with present NePC (p=0.026) in the second 
assessment. “Wind-up” was more common in patients with present NePC compared to the patients 
with absent NePC (first assessment p=0.056; second assessment p=0.029). In Table S1, we have 
shown the outcome of the BSE based on the inter-physician agreement for the occurrence of NePC 
for patients with LBLP, NSAP, and sPND. 
The outcomes of the NASQ measurements related to physician agreement for the existence of 
NePC are presented in Table 3. No significant difference was detected for pressure, EPDT, EPTT, 
and duration of submerging the hand in the IWB between the absent, present, and undetermined 
NePC groups. We found no congruency between the CPMp and the CPMe. When basing the CPM 
classification on pressure values, the significance disappeared for the outcome of the CPM test 
based on electricity values (response p=0.440, CPM-value p=0.374). This was also true when the 
CPM electricity test outcome was used to analyze the response and CPM value for pressure (p=0.728 
and p=0.810, respectively). Moreover, in the IWB test, we found no significant differences regarding 
the duration (latency) of submerging the hand between the positive and negative CPM test for both 
the pressure and electricity conditions (p=0.120 and p=0.711, respectively). 
DISCUSSION
The aim of this study was to assess the potential association between a clinically diagnosed absent 
or present NePC, BSE, and NASQ in patients with chronic pain. BSE revealed minor differences, with 
a low association between patients with present NePC and patients with absent NePC following 
independent clinical NePC assessment by two independent physicians, while none were found with 
NASQ. 
Bedside examination 
We used BSE based on mechanical and thermal testing procedures, performed by two physicians 
independently and blinded for the results of the other [28]. The added value of BSE is that it gives 
insights into the pathology and the localization of the nerve lesion or disease causing the pain 
[6,7,35,36]. 
The BSE results showed statistical significant differences between patients with absent NePC and 
patients with present NePC. BSE revealed that the sensation of heat, cold, wind-up response (with 
a brush, three times), pricking with a safety pin, and pricking with a von Frey hair was less common 
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in patients with a present NePC than in those with an absent NePC. In addition, wind-up response 
occurred more often in patients with present NePC than in those with absent NePC. 
Screening QST 
We used the NASQ to assess the altered pain processing, including changes in function of 
endogenous pain modulation as a secondary test battery [15,28]. The NASQ test protocol has 
standardized instructions, an important prerequisite to ensure reliability of the measurements 
[20,37]. We found no differences between patients with absent and present NePC regarding 
PPTs, electrical pain (tolerance) thresholds, and CPM outcomes (number of positive and negative 
CPM outcomes, the response, the CPM value, and the latency times when submerging the hand 
in ice water). Granovsky [38] reported that patients with chronic neuropathic pain express a less 
efficient (negative) CPM. In our study, we could not confirm this when comparing patients with 
LBLP, NSAP, or sPND with and without NePC. As suggested by Graven-Nielsen and Arendt-Nielsen 
[39], lower PPTs may be indicative for central sensitization. We also could not find any differences 
in the pain thresholds of patients with and without NePC. Moreover, a difference in CPM may also 
suggest a central dysfunction. However, based on our results, we cannot state that there are signs 
of central sensitization or altered central pain processing as might be suspected because of lower 
pain thresholds for pressure pain or an impaired CPM, because we did not include age, sex, and 
education matched controls, which would be necessary to draw these higher level conclusions. 
Limitations 
We would have preferred to use the German Research Network on Neuropathic Pain (DFNS) [11,12] 
to BSE because of the standardization of the complete test procedure (written test instructions, 
application of the test stimuli, and data analyses) [12,40]. However, due to time constraints in a 
patient care setting, it was not possible and preferable to use such a research test battery. Moreover, 
in simulating daily clinical practice, fulfilling the DFNS protocol is not applicable due to instrument 
availability and the associated costs in all participating sites. BSE as used in our study is easy to 
learn (one training session before execution of the study) and to carry out in daily clinical practice. 
Another strength of the study is that we included a range of locations and a large group of patients 
with chronic pain arising from different origins, which is comparable to patients in a daily clinical 
(pain) practice. A limitation of the BSE examination is that we only used the question “Is there a 
sensation?” This may have led to a lower estimation of the outcomes because the patients and/
or physicians may have interpreted the question was only being related to the presence of 
hypoesthesia, hypoalgesia, or analgesia (answer “no”: negative signs) rather than assessing the 
presence of hyperalgesia or allodynia positively (answer “yes”). In a following study, we will change 
this to a more open question that can be interpreted both ways. We did not use verbal standardized 
instructions, although all participating professionals were trained in a standardized way and so this 
is another possible limitation of our BSE method. This may have led to differences in the questioning 
by the physicians, thereby influencing the patients’ answers and the test outcome. The order of the 
BSE and NASQ in patients with and without NePC
177
7
BSE tests was not randomized and so there may be an order effect resulting from the previously 
performed test. Moreover, both physicians tested the same patient directly following each other. 
Although the second physician was not aware of the first results, this may have also influenced our 
results. Furthermore, there was no correction for multiple testing while several statistical analyses 
were performed. Because of this, the results must be interpreted with caution. 
Another possible limitation is the fact that we only included a small group of patients with chronic 
pain measured via NASQ; 8 patients with sPND. This may have affected our outcome because they 
have a different disease origin compared to patients with LBLP or NSAP. For future NASQ research, 
we would suggest collecting normative data preferably matched for age, sex, and education level. 
With these data, the value of NASQ for clinical monitoring disease progression and the response of 
individual patients on treatment can be evaluated. 
CONCLUSION 
Using a standardized BSE to assess sensory dysfunction indicating the presence or absence of an 
NePC appears to be preferable compared to the NASQ paradigm in patients with chronic pain. 
However, further development of both assessments is desirable. The BSE should be adapted to 
detect sensory differences between absent and present NePC; the NASQ paradigm should be able 
to measure altered pain processing and endogenous pain modulation in patients with chronic pain 
due to present or absent NePC. We postulate that this will lead to a greater contribution to the 
assessment of neuropathic components of patients’ pain. 
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GENERAL CONCLUSIONS AND RECOMMENDATIONS
In this thesis we investigated the psychometric properties and efficacy of screening tools for 
neuropathic pain for use in a consecutive population of patients with low back and leg pain, neck-
shoulder-arm pain, or with pain due to suspected peripheral nerve damage to assist the physician 
in the assessment of a neuropathic pain component as seen in daily clinical (pain-) practice. We 
selected this group of patients for our study because they are different from the other groups 
assessed in previous validation studies. The group consists of a consecutive patient population 
as seen in daily clinical outpatient practice where there is no pre-stratification on the target 
outcome, and no minimum level of pain. In our articles, we prefer to use the term ‘neuropathic 
pain component’ instead of neuropathic pain because the pain experienced by the patient in daily 
clinical practice may be caused by neuropathic, nociceptive, and/or nociplastic mechanisms (also 
known as ’mixed pain’). Neuropathic pain is distinguishable from nociceptive pain in two ways [1]: 
1) nociceptive pain requires transduction to transfer a non-electrical signal to an electrochemical 
signal, whereas neuropathic pain is based on a direct stimulation of the (injured) nerve; 2) most 
people with nociceptive pain recover in a certain time, whereas patients with neuropathic pain 
based on an injury of a nerve often retain persistent pain. As Cohen and Mao stated [1], there is 
a considerable overlap between neuropathic and nociceptive pain regarding patho-physiological 
mechanisms and response to treatment, so they can possibly be seen as ‘different points on the 
same continuum’ [1]. Currently, multiple tests are available to screen for or to assess neuropathic 
pain, but their verified accuracy is missing and there is no ‘gold standard’ questionnaire [2] . This can 
lead to errors in prevalence studies, incorrect and expensive clinical treatment, and, most relevant 
clinically, increasing disabilities for the patient. 
Our studies show that current screening methods and tools for identifying the type of patients’ pain 
are simply not accurate enough for a definite pain classification, and that this presents a number of 
challenges: (1) the risk of starting inadequate, inappropriate or non-efficacious therapies solely based 
on these classifications is high; (2) research in the field of treatment for pain is at risk because of the 
lack of distinction between classification outcomes; (3) exploring nociception or pain as a disease 
in its own right or as a symptom of a disease, trauma or disorder remains a problem; (4) identifying 
the type of pain, in particular mixed pain with components of nociceptive pain, neuropathic pain 
and/or nociplastic pain is difficult. These show that we need valid and reliable assessment tools 
more directly related to the underlying pain mechanisms. Figure 1 presents a suggested path for 
developing and validating screening tools in a way more related to daily clinical practice. 
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Nociplastic 
pain 
Development of a screening tool for various kinds of pain 
Validation* in a pre-stratified group of patients 
(Only pure nociceptic, neuropathic or nociplastic pain 
Cross-cultural adaptation of the developed screening tool 
Validation in a multidisciplinary pain practice group of patients with pain 
Initial development of a screening 
tool for the assessment of pain 
Neuropathic pain and nociplastic pain are clinical descriptions*, not diagnoses! 
 
* Gold standard for differentiation in the classification of patients’ pain does not exist, but is 
mostly based on the opinion of two physicians by proxy  
Outcome 
Figure 1:  The proposed pathway for the validation process of screening instruments for the 
classification of patients’ pain
Many advances for researching the mechanisms of pain, like molecular and genetic medicine or 
more advanced physiological research tools (like functional magnetic resonance imaging (fMRI), 
electro encephalography (EEG) and laser evoked potentials (LEPs)), are currently in their infancy; it 
will take long time before they become applicable in daily clinical practice. Therefore, as long these 
diagnostic tools are not generally available to and practical for daily clinical practice, we need more 
refined screening and/or assessment tools. These should then have greater reliability and validity 
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than currently available methods, and should be applicable to both primary care and specialist 
academic pain centers. This will remain challenging as long as there is no true gold standard to 
diagnose neuropathic pain. Until then, in current medical pain practice, diagnosis is formed on 
history-taking, and physical assessment. The latter includes bedside examination (as suggested in 
the NeuPSIG Grading System, [3]) and remains foremost as this is, however slightly, associated with 
the pain classification ‘absent or present NePC’.
The research questions we addressed were:
Question 1: Is a cross-cultural adaptation a prerequisite for achieving a valid Dutch translation of a 
screening tool for neuropathic pain? 
Question 2: What is the reliability of clinical judgment as a surrogate for the lack of an objective 
gold standard in diagnosing a neuropathic pain component in patients with chronic pain?
Question 3: What are the psychometric properties of the PainDETECT and the DN4 questionnaire 
when used as screening tools in a daily practice consecutive patient population (patients with 
low back pain, neck shoulder or arm pain, or pain from a suspected neuropathic origin), not pre-
stratified on target outcome, for NePC detection?
Question 4: What is the potential association between clinically diagnosed, via two independent 
and trained professionals, absent or present NePC, and bedside examination / screening quantitative 
sensory testing (NASQ) in patients with chronic pain?
Our research program was designed to answer these questions, as discussed in the thesis 
Introduction, and to provide recommendations for daily clinical practice and future research.
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Answer to question 1: A cross-cultural adaptation is a prerequisite for the correct 
translation and validation of measurement instruments such as screening tools for 
the assessment of NePC.
Recently, the PainDETECT was used in an American prevalence study [4]. Freynhagen et al [5] 
translated the original German version into English, however did not provide any information about 
the translation process. Tampin et al. noted that the English language version of the PainDETECT has 
not yet been validated[6]. Although the test-retest reliability turned out to be good, the validity of 
the English language version of the PainDETECT is thus still questionable [6]. The outcome of the 
American prevalence study was that, in addition to the estimation of the prevalence of neuropathic 
pain in the USA, the prevalence of probable neuropathic pain among Blacks and Hispanics was 
consistently higher than among Whites (per age and sex group). This interpretation is, of course, 
possible, however, the PainDETECT was not cross-culturally adapted and validated for use in the USA 
and thus the variance may be a result of, for example, a difference in interpretation of the questions 
in the instrument. It may also be questioned whether the cut-off points of the PainDETECT are valid 
in patients with various chronic pain conditions and different cultural backgrounds. Moreover, the 
authors only used the English language version, which may also have influenced the outcome[4]. 
In our study (Chapter 2) which included Dutch-speaking patients from both Belgium and the 
Netherlands, we found a number of differences based on culture and/or language perception. The 
Belgian participants rated the clearness of the questions and the organization of the questionnaire 
almost 10% higher than Dutch participants. This may be attributed to the slight cultural differences 
in interpretation and use of some words between the Dutch and the Belgians.
Based on these issues, we state that a well-performed, cross-culturally adapted version should be 
used instead of a ‘traditional’ forward / forward-backward translation before using an instrument in 
another culture and/or language. We therefore followed and recommend that other groups follow 
the published guidelines [7-9] to achieve the highest equivalence with the original tool in language, 
structure and meaning. 
Answer to question 2: The clinical judgment by two physicians is reliable as a 
replacement for the lack of a gold standard when diagnosing a neuropathic pain 
component in patients with chronic pain in clinical practice
Although clinical judgment is accepted as a surrogate for an objective gold standard in the 
assessment of NePC, the reliability of this surrogate outcome is unknown. We therefore conducted 
a study to find out if the agreement of two observers, based on pain classification by the physicians 
and by the Grading System as entered by the physician, is acceptable to differentiate between 
neuropathic and non-neuropathic pain in daily clinical practice. If the kappa-value is ≥ 0.4 and the 
percentage of agreement is ≥ 70%, the outcome is considered acceptable for use in daily clinical 
practice [10]. 
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We looked at interobserver reliability of the assessment of neuropathic pain (based on clinical 
diagnosis via experienced clinical judgment) in patients with pain resulting from cancer of different 
origins. We found a moderate level of agreement between the physicians for the assessment of 
the neuropathic pain component (NePC) in patients with cancer (Chapter 3). In patients with low 
back and leg pain, neck shoulder arm pain, and patients with pain due to suspected peripheral 
nerve damage, interobserver reliability was also moderate (Chapters 5 and 6). Moreover, we found 
a moderate agreement between clinical assessment and the Grading System when comparing the 
evaluation by one clinician to the result of the Grading System on an individual level. A comparison 
of the outcome of the Grading System by only one of the physicians to the clinical assessment of the 
other physician resulted in an insufficient level of agreement (table 1).
Table 1: The agreement between the physician assessment and the Grading Systems.
Assessment physician B Grading physician A Grading physician B
Assessment physician A + + -
Assessment physician B - +
Grading physician A - +
Grading physician B + +
+: Kappa value ≥ 0.4 & Percentage of Agreement ≥ 70%
-: Kappa value < 0.4 & Percentage of Agreement < 70%
In our study on the interobserver reliability of the pain classification in 34 patients with cancer, 
the agreement of the classification of patients’ pain between the physicians was 59% (Chapter 
3). In validation studies (Chapters 5 and 6) we analyzed 228 of 291 patients (78%) classified 
with congruent pain by the physicians. In the original PainDETECT [5] and the DN4 [11] validation 
studies, the agreement of the pain classification by two physicians was 95% and 96% respectively. 
This difference can be explained by the fact that both original validation studies only included 
prestratified patients with clear neuropathic or nociceptive pain syndromes, which was not the case 
in our study. In a systematic review by Mathieson et al. on measurement properties of neuropathic 
pain screening instruments [12], they reported that many validation studies exclude patients with 
mixed pain conditions, which may influence their sensitivity and specificity. However, they found 
no consistent trend resulting in a higher or lower sensitivity and specificity when patients with 
mixed pain were included when compared to the original validation studies [12]. In addition, they 
concluded that not including patients with possible mixed pain in validation studies limits the 
generalizability of the screening instruments when used in daily clinical practice [12]. 
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The gold standard for assessing a neuropathic pain component
As stated in the introduction of this thesis, neuropathic pain is defined as “Pain arising as a direct 
consequence of a lesion or disease affecting the somatosensory system” [13, 14]. In the absence of a 
‘true diagnostic gold standard’ to support a mechanism-based pain classification for nociceptive 
pain or neuropathic pain, clinical judgement may serve as an appropriate alternative reference 
standard [15, 16]. Moreover, as stated by Cleeland et al, [17] there is currently no single, adequate 
diagnostic method to reliably assess neuropathic pain. 
The robustness of the gold standard in our study on the interobserver reliability in patients with 
cancer (Chapter 3) was improved by including only those patients with a considered present 
neuropathic pain component or pure nociceptive pain. In the validation studies (Chapters 5 and 6) 
we ruled out all incongruent outcomes (no agreement of the pain classification after independent 
assessment). Based on our results regarding agreement between the participating physicians, the 
question arises whether the chosen gold standard (congruent diagnosis by two, independently 
working, physicians) is beneficial or not. Because of the different definitions of neuropathic pain 
and differences in evaluation methods for neuropathic pain, the reliability of the accepted gold 
standard is open to question. To minimize this problem, we used a standardized assessment form, 
and all physicians were trained to reach a high level of standardization of assessment execution 
(Chapters 5 and 6). 
The assessment of neuropathic pain component following the Grading System 
Further to the clinical diagnosis regarding presence or absence of a neuropathic pain component, 
we also used the NeuPSIG Grading System as proposed by Treede et al. in 2008 [14] (Chapters 3, 5 
and 6). The Grading System is recommended by the Neuropathic Pain Special Interest Group of the 
IASP [12, 18, 19]. In patients with neck/upper limb pain, the Grading System proved to be applicable, 
however it requires time and expertise to conduct this Grading System [20]. Based on this Grading 
System, we found a 68% agreement between the physicians in patients with cancer (Chapter 
3). In our validation studies, the congruent outcome based on the Grading System between two 
physicians was 80% (Chapters 5 and 6). The classification of patients with pain or without NePC 
based on the Grading System in our studies was comparable to the outcome of the physicians’ 
assessment as shown in table 1. Konopka et al. [21] showed that there was an incongruence 
between clinical diagnosis of neuropathic pain and the outcome in the Grading System in patients 
who were previously clinically diagnosed as suffering from neuropathic pain. Only 60% were 
graded with probable or definite neuropathic pain, the other patients were classified with unlikely 
or possible neuropathic pain. Furthermore, the sensory signs based on quantitative sensory testing 
(QST) [22, 23] were the same between patients classified as probable or definite neuropathic pain 
(these patients had a similar QST profile), but the signs were different between patients classified as 
probable or definite neuropathic pain compared to those patients graded as unlikely.
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The NeuPSIG Grading System was updated in 2016 by Finnerup et al. [3] (see figure 2). Several 
adjustments were made to better reflect daily clinical practice. The most important adjustment to 
the updated Grading System is the addition that even ‘definite neuropathic pain’ does not mean 
there is a causality [3]. ‘Definite neuropathic pain’ only refers to the fact that a physician via history 
taking, physical examination, and supplementary testing is able to clinically confirm that the patient 
has a neurological lesion that might explain a patient’s pain [3]. In line with this, it is always important 
to consider whether other causes of patients pain may be present. This confirms the observation 
that currently, there is no true gold standard to diagnose neuropathic pain.
Figure 2.  Flowchart of the updated Grading System as proposed in 2016. Adapted from Finnerup et al., 
Pain, 2016 [3].
  a, pain suspected to be related to a lesion or disease of the somatosensory system which is  associated 
with neuropathic pain. b, the pain distribution as described by the patient is in line with the assumed 
lesion or disease. c, the area of sensory signs is in the same neuroanatomically plausible distribution. 
d, when the location and nature of the lesion or disease are able to explain patients’ pain, probable 
neuropathic pain confirmed by  confirmatory tests is called definite neuropathic pain.
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These issues raise questions about the different causes of patients‘ neuropathic pain component 
and the manifestation of the signs and symptoms: is the clinical picture of the neuropathic pain 
component following a nerve injury due to surgery (for example pain due to amputation or (major) 
nerve lesion) the same as a radicular pain syndrome due to a herniated disc? Are the signs and 
symptoms of a patient with trigeminal neuralgia the same as in the glove and sock distribution in 
patients with chemotherapy-induced neuropathy? It seems clear that this is not the case. Moreover, 
the classification based on the Grading System, screening tools like the DN4 or the PainDETECT, 
and quantitative sensory testing via bedside examination or the Nijmegen-Aalborg Screening QST, 
should be viewed individually. For example, in the original articles on PainDETECT (2006) [5] and 
DN4 (2005) [11], patients with osteoarthritis were viewed as patients with pain of predominantly 
nociceptive origin, thus they were included in the validation studies as no NePC. Recent studies 
show that patients with pain resulting from osteoarthritis in which neuropathic pain features (based 
on neuropathic pain screening tool outcome or pathophysiologic mechanisms) are present, may 
thus require a different treatment paradigm than patients with osteoarthritis without NePC [24-
27]. However, they also confuse the use of screening tools because the validity in patients with 
a different diagnosis may be challenged. This shows that, in neuropathic pain classification, the 
patient, the disease as such, and the manifestation of the disease, must all be taken into account 
when patients are assessed as an individual, unique, patient, and that a tailor-made treatment 
regimen should be proposed.
Based on current insights, a surrogate gold standard, two independently working, well-trained, 
experienced and blinded professionals as used in our studies can be improved by narrowing the 
clinical consensus on signs and symptom. Moreover, meticulously following the guidelines leads 
to an improved use of the Grading System. Bedside examination and quantitative sensory testing, 
testing the descending pathways (pain modulation systems) and, for example, neuro-imaging may 
also be of value when looking for ways to improve the diagnostic gold standard for the assessment 
of a neuropathic pain component in patients with pain [28, 29].
Answer to question 3: The DN4, but not the PainDETECT, is of value in the screening 
for a neuropathic pain component
In their original study, Freynhagen et al. revealed a sensitivity of 85% and a specificity of 80% for 
the PainDETECT [5]. The DN4 developed by Bouhassira et al. [11] showed a sensitivity of 83% and a 
specificity of 90%. For the DN4-symptoms, interview only, sensitivity was 78% and specificity 81%. 
In our studies of comparisons with the physicians’ assessment as the “gold standard”, we conclude 
that the cross-culturally adapted PainDETECT (sensitivity of 80% and specificity of 55%, figure 
3a) is not an effective screening tool because of its moderate sensitivity and low specificity in a 
consecutive population of patients with low back and leg pain, neck-shoulder pain, or with pain 
due to a suspected peripheral nerve damage (Chapter 5). We tested the DN4 in the same group 
of patients as the PainDETECT; this appeared to be moderately helpful in identifying a neuropathic 
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pain component (NePC) (sensitivity of 75% and specificity of 76%, figure 3b). The DN4-symptoms 
had a sensitivity of 70% and a specificity of 67% (figure 3c) and is thus less valid in both daily clinical 
practice and clinical research. (Chapter 6). 
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Figure 3a: PainDETECT: 26% of patients have a false diagnosis [108]
Figure 3b: DN4: 25% of patients have a false diagnosis [61].
Figure 3c: DN4 symptoms: 31% of patients have a false diagnosis [61].
Figure 3:  The outcome of the screening tool (PainDETECT or DN4) classified as true positive, true 
negative or false outcome in respect to the clinical assessment by both the physicians in our 
studies [61, 108]
Screening tools for NePC fail in their identification and classification of patients in about 10-20% of 
all cases [12, 19]. However, in published validation studies, the reported sensitivity and specificity 
are higher or lower than in the original papers [5, 11]: For the PainDETECT [5, 20, 30-42], sensitivity 
ranges from 18% [35] – 95% [36] and specificity from 51% [40] – 100% [37] (figure 4). The sensitivity
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Figure 4:  Comparing the sensitivity and specificity of the different validation studies as performed for 
the PainDETECT
  The red dot represents the validation study presented in this thesis [108]; Blue squares represent the 
individual papers published by different research groups [5, 20, 30-38, 40, 42]
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Figure 5:  Comparing the sensitivity and specificity of the different validation studies as performed for 
the DN4 
  The red dot represents the validation study presented in this thesis [61]. Blue squares represent the 
individual papers published by different research groups [11, 30, 35, 37, 40, 43-60, 62, 64, 109]
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Figure 6:  Comparing the sensitivity and specificity of the different validation studies as performed for 
the DN4-interview
  The red dot represents the validation study presented in this thesis [61]. Blue squares represent the 
individual papers published by different research groups [11, 39, 48, 50, 59, 64-66]
of the DN4 [11, 30, 35, 37, 40, 43-63] ranges from 59% [51] -100% [44, 49, 58] and specificity from 
42% [40] – 97% [45, 54] (figure 5). For the DN4-syptoms [11, 39, 48, 50, 59, 61, 63-65], sensitivity was 
70% [61] -97% [59] and specificity 67% [61] – 86% [66] (figure 6). These wide ranges of sensitivity 
and specificity are due to several differences in the diagnosis of the patients, differences in inclusion 
criteria such as level of perceived pain, and differences in the performance of the ‘gold standard’.
In 2017, Epping et al published a paper on the validation of the DN4 and the PainDETECT in the 
Netherlands [40]. Their group and ours worked simultaneously but independently from each other 
and found comparable outcomes. Epping’s group used the consensus expert diagnosis based on 
the Grading System as the gold standard. Their DN4 had a sensitivity of 76% and a specificity of 
42%, the PainDETECT had 75% and 51% respectively. In our studies (Chapter 5 and 6), we reported 
a DN4 sensitivity of 76% and a specificity of 64%; for the PainDETECT our results were 74% and 
46% respectively when compared with the Grading System. We can conclude that the outcomes 
of these two independent studies are more or less comparable. Both studies demonstrate that the 
probability of correctly identifying neuropathic pain is quite low. The only difference between both 
studies was that the specificity of the DN4 in our study was higher. This may be due to the fact that 
we incorporated the DN4-signs in our standardized assessment form (Chapter 4 and 6) and that 
this may have influenced the pain classification. Epping’s group tested the DN4 independently from 
the initial assessment with a medical specialist and a physiotherapist working independently of 
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each other. Hasvik et al. [67] compared the PainDETECT to clinical examination based on the 2016 
Grading System; they concluded that the PainDETECT performed poorly compared to the Grading 
System in patients with low back-related leg pain, and considered it unreliable for classifying or 
grading a neuropathic pain component.
In May 2018, Attal, Bouhassira and Baron published their review [68]. They state that “screening 
questionnaires help clinicians to identify neuropathic pain easily, particularly in patients with complex 
medical conditions”. They illustrated their statement with the medical story of a patient with the 
complex medical condition of spinal cord injury. However, they reported lower discriminative values 
for patients with lower back or neck pain; this may have been caused by the absence of a gold standard 
in these conditions [20, 40, 56, 69]. Based on our results (Chapter 2, 3, 4, 5 and 6) the presented 
numbers of sensitivity and specificity (figure 4, 5 and 6) and issues raised regarding screening tools, 
we think that a screening tool is, at best, an instrument that is suggestive for the presence of a 
NePC, but that it should always be followed by an extended interview and comprehensive clinical 
neurological examination to confirm that a patient’s pain is a direct consequence of a lesion or a 
disease affecting the somatosensory system. However, we note that combining both physicians’ 
assessments, the Grading Systems performed by the physicians, the PainDETECT and the DN4, 
might not be practicable in daily clinical practice. 
Figure 7 shows the combined classifications following clinical assessments by the physicians, the 
Grading Systems, and the screening instruments of those patients where all six outcomes were 
available (n=274). The agreement of the classification based on the assessment by the physicians 
regarding present and absent-NePC was 78% (164 NePC, 49 absent-NePC, figure 7a). Based on the 
Grading System, the agreement between physicians was 82% (139 NePC, 85 Absent-NePC, figure 
7b). Combining both the physicians scores and the Grading Systems (figure 7c) resulted in an 
agreement of 50% (118 NePC, 20 absent-NePC). Combining all six assessments (both physicians’ 
assessments, both the Grading Systems, the outcome of the PainDETECT, and the DN4) of the 274 
patients included in the analysis, only 74 (27%) had a congruent outcome regarding an NePC. In 
20 patients (7%), all six outcomes confirmed the absence of NEPC. The agreement between all 
outcomes was 34%; thus in 66% of patients at least one assessment was aberrant (figure 7d). This 
indicates that it is not necessarily ‘better’ to have more assessments about patients’ pain complaints 
because false-positive and false-negative outcomes occur in all classifications (Chapter 5 and 6). 
Together, these results show that a full clinical assessment of the patient, together with modern 
technical investigations such as imaging, laboratory testing, and electrophysiological testing, is 
required [17, 18, 29, 70-76]. To conclude, there is widespread use of screening tools to detect NePC, 
but they have a low to moderate reliability. Our studies show that the use of the PainDETECT cannot 
be recommended as a screening or diagnostic instrument to improve diagnosis, management and 
treatment of NePC in patients with low back and leg pain, neck-shoulder pain, or with pain due to a 
suspected peripheral nerve damage. We show that the DN4 does help, moderately, to identify NePC 
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in a consecutive population of patients seen in daily clinical practice, but that a comprehensive 
(physical) examination by the physician is still necessary.
 
 Absent-NePC: n=49 
Figure 7a:  VENN-Diagram [110] of the outcomes of the assessments by physicians A and B 
  Assessment A: classification of a neuropathic pain component according to the assessment by 
physician A (NePC) present; Assessment B: NePC present according to the assessment by physician B. 
 
 
 
Absent-NePC: n=85 
Figure 7b: VENN-Diagram [110] of the outcomes of the Grading Systems by physician A and B 
  Grading A: NePC present according to the Grading System by physician A; Grading B: NePC present 
according to the Grading System by physician B; 
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 Absent-NePC: n=20 
Figure 7c: VENN-Diagram [110] of the assessments and of the Grading System by physicians A and B 
  Assessment A: classification of a neuropathic pain component according (NePC) to the assessment by 
physician A present; Assessment B: NePC present according to the assessment by physician B; Grading A: 
NePC present according to the Grading System by physician A; Grading B: NePC present according to the 
Grading System by physician B.
 
 
 
 
Absent-NePC: n = 20 
Figure 7d:  VENN-Diagram [110] of all six outcomes per patient (Assessment by the physicians, Grading 
System by the physicians, PainDETECT, and the DN4). 
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  Assessment A: classification of a neuropathic pain component (NePC) according to the assessment by 
physician A present; Assessment B: NePC present according to assessment by physician B; Grading A: 
NePC present according to the Grading System by physician A; Grading B: NePC present according to 
the Grading System by physician B; PainDETECT: outcome of the PainDETECT indicates the presence 
of NePC. Absent-NePC: No NePC present according to the physicians, the Grading Systems, the 
PainDETECT and the DN4. 
Answer to question 4: Bed-side examination, but not NASQ, has a limited value in 
the classification of NePC
In Chapter 7, we discuss the value of bedside examination (BSE) and screening quantitative sensory 
testing following the Nijmegen-Aalborg Screening Quantitative Sensory Testing protocol (NASQ). 
We show that BSE revealed small differences between patients with either absent or present NePC, 
whereas NASQ did not reveal any differences (chapter 7). 
Bedside examination (BSE) is recommended as a method to identify positive and negative sensory 
signs in several guidelines for assessing neuropathic pain components [16, 18, 29, 70-74, 76-79]. 
Clinical examination can never prove that pain is of a neuropathic origin, but it can indicate an 
altered function of patients’ nervous system [18]. BSE can also indicate the presence of other 
pathological processes which may cause pain. As a supplement to neurophysiological testing, BSE 
can answer the question to where in the somatosensory system the lesion or disease that generates 
neuropathic pain can be found [80]. Moreover, the classification of clinical symptoms in patients 
with NePC based on a mechanism-based approach may be useful to quantify sensory signs [81]. As 
stated by Garcia-Larrea [79], neuropathic pain is especially associated with lesions of temperature 
and pain pathways (A-delta and C-fibers, spino-thalamo-cortical tracts). We demonstrated (chapter 
7) that heat sensation, cold sensation, wind-up response, and pricking was less present in patients 
with NePC. 
Unfortunately, BSE data from other studies are scarce. Most published studies used the quantitative 
sensory testing protocol (QST) following the German Research Network on Neuropathic Pain (DFNS) 
[22, 23, 82]. Comparison of BSE results with QST following the DFNS protocol is questionable, 
because the DFNS uses a very strict protocol which is only appropriate for trained persons using a 
standardized protocol in certified clinical neurological/ neurophysiological laboratories [83]. As far 
as we are aware, this is not the case when performing BSE tests to find support for the presence of 
neuropathic pain. However, there is a great emphasis on BSE in the diagnostic work-up of patients 
with pain in daily clinical practice. Unfortunately, very little has been published on BSE data for 
groups of patients and for individual patient outcomes alongside the clinical classification of 
patients’ pain.
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Spahr et al [84] stated that the methods used in clinical examination and the paradigms used to 
detect NePC may fail in patients with low back pain (LBP). Based on tactile threshold discrimination 
and 2-point discrimination (both methods were not used in our study, Chapter 7), they found that 
patients with chronic low back pain had an increased tactile threshold and 2-point discrimination 
when compared to healthy controls. In the comparison between patients with chronic low back pain 
with and without NePC, patients with NePC had an increased tactile threshold in comparison with 
those without. This suggests that there are differences in the clinical profiles of patients with LBP with 
and without NePC (assessment of symptom profiles instead of evidence for a direct consequence of 
a lesion or a disease affecting the somatosensory system), and that the symptoms might origin from 
an underlying maladaptive plasticity of the nervous system [84]. Leffler and Hansson [85] compared 
the outcome of clinical BSE to the outcome of standardized QST in a research setting in patients 
with a painful traumatic peripheral nerve injury. They concluded that the individual outcome of 
BSE compared to standardized QST outcome frequently differed in patients. This may be due to 
differences in, for example, performance of the applied stimuli. This was most frequently observed 
in the assessment for sensibility for touch. The differences may be explained by looking at what can 
be considered as a ‘normal’ outcome and what a ‘pathological’ outcome. Moreover, the variety in 
methodology (standardization, equipment) and conduction (force, position etc.) of the given test 
stimuli may have contributed to differences between BSE and QST. In conclusion, sensory profiling 
of patients with NePC based on QST may result in a more stratified and personalized treatment 
regimen [86, 87], but QST is not directly interchangeable with BSE, as explained above [85].
NASQ is intended to assess the processing of pain in patients [88-90]. Our intention before starting 
this study was to identify whether the assessment of NASQ benefited the classification of pain 
by, for example, identifying peripheral or central sensitization. However, the Nijmegen-Aalborg 
Screening QST (NASQ) protocol showed no association with neuropathic pain. We found no signs 
of central sensitization (widespread hyperalgesia, descending inhibition [91]) in patients with and 
without NePC included in our study. This contrasts with findings by Freynhagen et al [92] and Woolf 
et al [93] who suggest that central sensitization is most manifest in patients with NePC. It is still 
unclear whether this is due to the fact that our patients had no central sensitization, because the 
test methodology was not refined enough to detect central sensitization, or otherwise. Granovsky 
[94] stated that patients with NePC expressed less efficient CPM compared those without. However, 
we found no differences in the CPM (Chapter 7). The differences between our results and the 
literature may be due to several facts such as the low number of patients included and no inclusion 
of matched, healthy controls. However, another reason may have been the forced separation of 
patients with pain into either nociceptive or neuropathic pain. With today’s knowledge, our studies 
would possibly have had the benefit of the recently proposed threefold separation [95], however 
the term nociplastic pain did not exist when we started our studies. In patients with nociplastic pain, 
altered nociceptive functions (hypersensitivity), with a regional or widespread pain distribution do 
exist [95]. According to the IASP, central sensitization is “an increased response and reduced threshold 
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of nociceptive neurons in the central nervous system to their normal or subthreshold afferent input 
“ [96]. The underlying mechanism of nociplastic pain is probably the central sensitization of the 
nociceptive pathways [95]. 
RECOMMENDATIONS FOR CLINICAL PRACTICE, EDUCATION, FUTURE 
RESEARCH AND SOCIETAL IMPACT
From the results of our research and the discussion on each of the four research questions, we have 
formulated a number of specific recommendations that we trust will lead to improvements in the 
diagnosis and treatment of pain for the patients and for the specialists involved in their care, 
RECOMMENDATIONS FOR THE CLASSIFICATION OF PAIN IN DAILY 
CLINICAL PRACTICE
We recommend that the classification of a neuropathic pain component should 
be based on history taking, physical (neurological) examination, bedside 
examination, and up-to-date diagnostic testing.
Our studies show that it is extremely important to pay attention to a clearer identification of 
patients with pain, and to correctly classify them in terms of suffering from nociceptive, neuropathic 
or nociplastic pain components or a combination of them; we have shown that their treatment 
response may be dependent on it. 
The classification of neuropathic pain in daily clinical practice should be based on accurate 
(neurological) history taking and performing a neurological examination. History taking reveals the 
characteristics and distribution of a patient’s pain. The clinical examination also reveals possible 
negative and positive sensory signs and their association with the underlying lesion or disease. This 
can be performed via a standard neurological examination combined with a bedside examination. 
Finally, a diagnostic test such as R3 reflex testing, cutaneous response reduction (skin wrinkle test) 
test, nerve ultrasound, quantitative sudomotor axon reflex testing, quantitative sensory testing, 
laser-evoked potentials, pin-prick evoked potentials, electrophysiological testing, fMRI and skin 
biopsy may all help to confirm the lesion or disease in the somatosensory system which explains the 
pain [3, 71, 79]. However, as discussed, a factual relationship based on diagnostic testing between 
nerve damage and a patient’s pain has not yet been verified but the search for this connection 
remains of great importance for improving patient treatment [71] (Chapters 3,4,5,6 and 7).
Chapter 8
204
We recommend that pain classification should be standardized in daily clinical 
practice as this will lead to new insights and improve patient outcomes. 
By examining the patient in a standardized but individual way (history taking, physical examination, 
bedside examination and, when possible, confirmatory test procedure(s)), the clinician will be better 
able to classify a patient’s pain based on the clinical criteria and thus to design a personalized pain 
treatment program. 
The Grading System is intended to be used in individual patients in daily clinical practice as well 
as in clinical research [3]. One advantage of this system [3, 14] is to help in the standardized 
classification of neuropathic pain. By using the Grading System methodology when examining a 
patient, it is possible to grade the certainty of NePC existence on an ordinal scale: no neuropathic 
pain, possible neuropathic pain, probable neuropathic pain, and definite neuropathic pain [3]. 
However, currently the Grading System cannot be seen as a ‘gold standard’ for neuropathic pain; it is 
a clinical assessment guideline which assists in classifying a patient’s pain. An outcome of probable 
neuropathic pain in a patient should be reason for the physician to consider initiating treatment 
according to the guidelines about treating patients with neuropathic pain [97]. To use and to rely 
on the Grading System, it is important for the physicians to be experienced, and that they have the 
skills and resources to assess their patient in the best possible way [3]. (Chapters 3, 4, 5 and 6). 
We recommend that screening questionnaires should be used with caution, when 
assessing a neuropathic pain component in a daily clinical consecutive population 
of patients with chronic pain.
Screening tools like the DN4 or PainDETECT only provide a slight indication of the presence of NePC; 
they may therefore lead to misclassifying a patient’s pain. 
Our studies show that false identification with respect to the presence or absence of NePC may 
be the case in a substantial number of patients. It can be concluded that a clinical examination of 
the patient is a prerequisite; a screening tool is not a diagnostic test and can thus never replace 
a physician’s examination[12]. Moreover, it is always true that “a patient” is much more than the 
outcome of the questionnaire(s), and that a patient’s pain is whatever the patient says it is (Chapters 
5 and 6). 
We recommend that a bedside examination forms a part of the diagnostic work-up 
of patients’ pain.
After history taking, bedside examination is of second-most importance when examining the 
(cause or mechanism) of the patient’s pain. It takes time to examine the patient and the sensory 
disturbances should be noted on a body map. 
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Bedside examination will provide the physician with an overview of a patient’s pain and may better 
support a pain diagnosis and thus be valuable when monitoring a patient’s pain and treatment 
effects. BSE should be performed in a standardized way, guided by clear instructions to the patient. 
Our results suggest a low association between BSE and classification of a patient’s pain, however 
it may assist the so-called ‘fingerspitzengefühl’ with which physicians classify patients’ pain in daily 
clinical (primary) care as pain with or without a neuropathic component (Chapter 5,6 and 7).
We recommend that combining pain classification strategies to become ‘more sure’ 
of a patient’s pain classification is not standard daily clinical practice.
Our studies show that there is no proof that it is ‘better’ to have more assessments about a patient’s 
pain complaints, as false-positive and false-negative outcomes occur in all classifications (Chapters 
5 and 6). 
Running more and different clinical assessments about the type of a patient’s pain may not be 
beneficial for the patient; it may even harm the patient due to, for example, delay of treatment. As 
Goscinny and Uderzo stated in their inimitable way: “…appelle plutôt des medicines!…Je fais venir 
tous les medicines de la garnison!.... Tu ne crains pas l’intervention des medicines…? En groupe ils sont 
plus meurtriers qu’une legion armée jusqu-aux dents!” [98]. 
RECOMMENDATIONS FOR IMPROVING PHYSICIAN EDUCATION AND 
TRAINING FOR CLASSIFYING PATIENTS’ PAIN
We recommend that more attention should be paid to patients with pain, and to 
pain as a disease in its own right
Based on the epidemiology of pain, the reduced health related quality of life, lower functional 
status, and lower mental health, in combination with the high direct and indirect costs associated 
with patients with chronic pain, it is of utmost importance to create awareness about this major 
personal and socioeconomic problem. 
Each patient has his or her own ‘pain’, and that makes patients experts in their own pain based 
on personal memory, emotions, cognitive factors, and pathology (Chapter 1). Currently, pain is 
undervalued in daily clinical practice [99]. It is therefore important to pay greater attention to a 
patient’s pain and to make greater financial resources available to fund scientific research in the 
field of pain to identify potential mechanisms and to examine treatment effects. The first step in 
this might be by raising the general public’s awareness of the epidemiology, burden, costs and 
consequences of pain via newspapers, radio, television, and participation in research as a (healthy) 
volunteer etc. (Chapter 1).
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We recommend that more education in the use of screening- and diagnostic 
instruments should be provided at an undergraduate, graduate and postgraduate 
level for everyone working with people with pain 
To assess pain, physicians should use a biopsychological model to address the somatic, cognitive, 
emotional, behavioral, spiritual and social dimensions. Munrinson et al. [100] studied students in the 
preclinical phase and concluded that the integration of the cognitive and the affective dimension is 
related to the basic knowledge about emotional development and is associated with a high degree 
of student satisfaction. Moreover, physicians should address pain with an integrated view of patho-
physiology and clinical care, but this is only possible if this is based on a long term vision for pain 
education, wherein the patient plays a central role [100]. Another aspect of education is improving 
learning about and using guidelines. Clinical practice guidelines are not always exactly followed by 
the physician due to a number of factors like a lack of awareness, a lack of agreement, and a lack of 
outcome expectancy [101]. 
Education in the field of pain should be, amongst others, targeted towards identifying symptoms 
and signs, improving knowledge about screening, and assessing patients with pain (via, amongst 
others, screening tools as the PainDETECT and the DN4 and the use of the Grading System). A 
proposed pain medicine model developed by Wolff and Groen (APC, UMCG; 2016) includes different 
steps in the diagnostic work-up of the patient to come to personalized pain treatment:1) The pain 
complaint (patient history, body examination, additional examination); 2) supposed (anatomical) 
substrate; 3) pathophysiology; 4) pain mechanisms / pain diagnosis; 5) bio-psycho-social-spiritual; 6) 
conclusion; 7) management; and 8) repetition. Based on the statement “pain is whatever the patient 
says it is, existing whenever he/she says it does” [102] I would suggest moving the Bio-Psycho-Social-
Spiritual part of the model forward to second position, as this element has important consequences 
for patients with pain and leads to their daily-living limitations. Improving this knowledge may have 
consequences for therapy regimes, amongst other factors. Additionally, it is important to implement 
evaluation methods to measure and optimize treatment efficacy. Moreover, better training in 
how to educate patients about their disease, master coping skills, and improving knowledge of 
available self-care options may be beneficial [103]. Under ideal conditions this should be done in 
a continuous learning environment combined with the possibility to quickly react to new insights 
and for example, changes in treatment opportunities.
We recommend improving the knowledge and expectations about the 
psychometric values of evaluation / screening tools of the person interpreting it.
Based on our results (Chapters 5, 6 and 7) and the other studies about the validity of screening 
tools for assessing neuropathic pain, it is important for those interpreting the results to have a better 
knowledge of the tool’s correct use and an understanding of its psychometric values. Each tool, 
instrument or test results in false positive and/or false negative results. If treating physicians are 
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aware of these, they can be taken into account when evaluating the outcome of the instrument in 
question. 
RECOMMENDATIONS FOR THE IMPROVEMENT OF FUTURE RESEARCH
We recommend that patients with neuropathic pain should be treated more 
optimally; we have to be able to better identify crucial pain markers.
Neuropathic pain, as far as we can identify it, is characterized by a poor response to treatment 
with medication. The conversion rate of medication needed to treat for 50% pain relief differs 
greatly: 3.6 for tricyclic antidepressants, 6.4 for serotonin-noradrenaline reuptake inhibitor, 7.7 for 
pregabalin, and 6.3 for gabapentin [97]. We should aim for a therapy that has a higher conversion 
rate by gaining a better understanding of pain mechanisms and being better able to assess these 
mechanisms. Unfortunately, a ‘one fits all’ treatment regime does not fit the needs of an individual 
patient with pain. To further develop precise and personalized treatment, we need to develop a 
more detailed assessment strategy and matching treatment regimens. To find a real ‘gold standard’ 
for the diagnosis of NePC would be extremely valuable, however this is not expected in the short 
term. We recommend that more research should be conducted on the recently updated Grading 
System and the implementation of nociplastic pain as a third mechanistic descriptor, both in the 
laboratory and, in particular in daily clinical practice.
Collecting data (signs, symptoms, outcome measures) may influence the individual physician’s 
clinical practice based on experience (pattern recognition), as well as research. ‘Big data’ may enable 
us to recognize patterns in individual patients or in groups of patients, even where there is a great 
deal of variability in individual patient outcomes (Chapters 3, 4, 5, 6 and 7).
We do not recommend NASQ when differentiating between nociceptive pain and 
the existence of a neuropathic pain component; this needs further evaluation to 
determine the mechanisms of nociplastic pain
The acknowledgement of the third mechanism-based descriptor of pain, nociplastic pain, by the 
International Association for the Study of Pain (IASP) has led to new opportunities for the use of 
NASQ. To better differentiate between pain mechanisms, a phenomenon as central sensitization 
might be accessed via the measurement of pain thresholds and/or changes in the endogenous pain 
system. NASQ should be further developed and more research should be conducted to see whether 
NASQ offers benefits for the assessment of patients with pain (Chapter 7).
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We recommend that the screening tools used when assessing a neuropathic pain 
component should have a very high sensitivity, specificity and positive likelihood 
ratio.
A screening tool to detect neuropathic pain should have a high sensitivity to identify the patients 
with NePC; they should also have a high specificity to recognize patients without NePC. Moreover, 
the predictive value must be high to ensure that a positive test indicates the presence of NePC. 
However, the likelihood ratio should also be given in the result sections of research papers as this 
indicates how much more likely a positive test will be present in a patient with NePC compared 
to a patient without NePC. Finally, when reporting on the validity of a screening tool, test-retest 
reliability should also be stated in the paper [104-106] (Chapters 5 and 6).
RECOMMENDATIONS FOR IMPROVING THE ORGANIZATION OF PAIN CARE 
AND SOCIETAL IMPACT
We recommend that patients should be better identified and stratified; this 
will lead to a better organization and the health-economic optimization of and 
inclusion of patients in specialized treatment programs.
In the future, improved identification and stratification of patients will lead to, in addition to greater 
satisfaction about treatment, a positive effect on the health economy: reducing the costs of medical 
care. Of even greater importance is the improvement in health care and a decrease in the burden of 
chronic pain disease. Moreover, improvements in daily clinical practice will facilitate a faster return 
to work, less direct costs, less indirect costs, better education in (para-) medical schools, and a better 
stepped wedge care. 
Health and healthy behavior are important issues for the near future; the World Health Organization 
emphasize the need, “to promote health and development, and prevent or reduce risk factors for health 
conditions associated with use of tobacco, alcohol, drugs and other psychoactive substances, unhealthy 
diets, physical inactivity and unsafe sex” [107]. Education, self-management, and physical activity are 
issues that should be further developed by, amongst others, pain physicians and researchers in the 
field of pain, but always together with patients with pain. 
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SUMMARY
Pain is described as (1): “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” and as (2): “whatever the experiencing 
person says it is, existing whenever he says it does”. The first is a definition of pain as a psychosocial 
phenomenon, the second is a more patient orientated description of pain as a subjective experience. 
The experience of pain by the patient is thus influenced by personal memory, emotions, pathology 
and cognitive factors. 
The introduction of this thesis, chapter 1, is divided into five sections. In the first section we describe 
the classification of patients pain based on the type of pain and on the duration of pain. The type of 
pain can be classified as: (1) nociceptive pain: “pain that arises from actual or threatened damage to 
non-neural tissue and is due to activation of nociceptors’; (2) neuropathic pain: “pain arising as a direct 
consequence of a lesion or disease affecting the somatosensory system”; (3) nociplastic pain: “pain 
that arises from altered nociception despite no clear evidence of actual or threatened tissue damage 
causing the activation of peripheral nociceptors or evidence for disease or lesion of the somatosensory 
system causing pain”; (4) mixed pain or as (5) pain of unknown origin. Based on the duration, pain 
can be classified as acute or chronic pain (pain within or beyond the expected period of healing). 
The second section gives an overview of physiological mechanisms of pain and the important 
pathways for pain between receptors and the brain. In section three we describe the epidemiology, 
burden, costs and consequences of chronic pain and of neuropathic pain in particular. Section 
four provides an overview of the assessment of neuropathic pain in daily clinical practice: history 
taking and physical assessment, bedside examination, screening tools, the NeuPSIG grading system, 
quantitative sensory testing and neurophysiologic techniques. The requirements for a screening 
tool to assess (neuropathic) pain are described in section five. 
The objectives of this thesis were to assess the psychometric properties of the PainDETECT and 
the DN4 in a consecutive daily practice population of patients with low back and leg pain, neck-
shoulder arm pain or with pain due to a suspected peripheral nerve damage. A second aim was to 
assess the possible benefits of bed side examination and the Nijmegen Aalborg Screening QST to 
distinguish between clinically diagnosed patients with and without a neuropathic pain component.
In chapter 2 we described the process of the cross-cultural adaptation of the PainDETECT into the 
Dutch language for use in the Netherlands and Belgium. According to the literature the PainDETECT 
helps to identify a neuropathic pain component in patients suffering from pain in daily practice as 
well as in clinical trials. A prerequisite for a valid screening instrument in the Dutch language was 
to go through an extensive translation and cross-cultural adaptation process. The first phase in this 
study was to translate and cross-culturally adapt the PainDETECT into Dutch via the internationally 
accepted ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Task Force 
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guideline. The second phase was to assess the face validity in the Netherlands and Belgium using 
qualitative and quantitative data collection. Patients from Belgium and the Netherlands participated 
in this study. The length, the readability and the clarity of the questionnaire were good for all patients. 
The questionnaire was judged to have a good lay-out (formatting and administration were the same 
as in the original German version to prevent variations in response) and to be clearly organized. In 
conclusion, the PainDETECT Dutch language version might be useful, based on only the face validity, 
for screening for neuropathic pain components in the Netherlands and Belgium based. 
Chapter 3 is about the reliability of the clinical judgment as an accepted surrogate for an objective 
gold standard in diagnosing neuropathic pain. However, until this moment no publications were 
available about the reliability of this diagnosis. This reliability is of importance because the diagnosis 
of neuropathic pain has important treatment implications. In this study the levels of agreement on 
the clinical examination of neuropathic pain were estimated by calculating the kappa-value and 
percentage of pair wise agreement to determine the interobserver reliability of the assessment 
of neuropathic pain in patients with cancer. Each patient was examined by two specialists via an 
independent clinical assessment as performed in daily clinical practice. After each assessment 
physicians were asked to indicate the most adequate characterization of the pain: pure neuropathic 
pain, pure nociceptive pain, mixed pain, or no pain. A substantial level of agreement was found for 
the diagnosis of pure neuropathic pain but the values of agreement for the existence of a neuropathic 
pain component were not satisfying. There was only a fair agreement between the physicians 
regarding the NeuPSIG grading system. In patients with cancer in respect to the identification of 
neuropathic pain the agreement between physicians, as an outcome of reliability in the assessment 
of neuropathic pain, based on physical examination is in need for a better standardization of the 
clinical assessment and classification of pain.
In chapter 4 we described in detail the study protocol for our studies as stated in chapter 5, 6 and 7. 
The aim of the studies in chapter 5 and chapter 6 was to assess the validity of the Dutch versions 
of the PainDETECT and the DN4 in a large population of patients with chronic pain as seen in daily 
clinical practice: patients with chronic low back and leg pain, with neck shoulder arm pain and in 
patients with chronic pain due to suspected peripheral nerve damage. Screening tools have been 
developed to assist the physician to assess patients with neuropathic pain. These tools have typically 
been validated in patients who were pre-stratified for the outcome of neuropathic pain. The validity 
of these screening tools needs to be proven in patients with pain who were not pre-stratified on basis 
of the target outcome: neuropathic pain or non- neuropathic pain. A cross-sectional multicentre 
design was used to assess the validity of both instruments. Patients with low back pain radiating 
into the leg(s), patients with neck-shoulder-arm pain and patients with pain due to a suspected 
peripheral nerve damage were included. Patients’ pain was classified as having a neuropathic pain 
component (yes/no) by two experienced physicians (“gold standard”). Physicians opinion based 
on the NeuPSIG Grading System was used a secondary comparison. Based on the results of the 
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study in chapter 5 the Dutch version of the PainDETECT was not an effective screening tool for a 
neuropathic pain component in a population of patients with chronic pain because of its moderate 
sensitivity and low specificity. Moreover, the indiscriminate use of the PainDETECT as a surrogate for 
clinical assessment should be avoided in daily clinical practice as well as in (clinical-) research. The 
study in chapter 6 showed that the DN4 seems to be helpful in the identification of a neuropathic 
pain component because of a moderate sensitivity and specificity, but a comprehensive (physical-) 
examination by the physician is still obligate. 
The objective of the study in chapter 7 was to assess the potential association between the clinically 
diagnosed presence or absence of a neuropathic pain component, bed side examination, and the 
Nijmegen-Aalborg screening QST paradigm. Bed side examination consisted of measurements of 
touch [finger, brush], heat, cold, pricking [safety pin, von Frey hair], and vibration). The Nijmegen 
Aalborg paradigm (pressure algometry, electrical pain thresholds, and conditioned pain modulation) 
was assessed to generate new insights. Bed side examination revealed statistical significant 
differences between patients with either an absent or present neuropathic pain component. The 
Nijmegen Aalborg Screening QST did not reveal any differences between patients with and without 
a neuropathic pain component. Based on our study it can be concluded that a standardized bed 
side examination is more useful than the Nijmegen Aalborg screening QST to distinguish between 
patients with and without a neuropathic pain component.
In chapter 8 we discussed our main findings as included in this thesis with respect to the recent 
literature. Recommendations were addressed for clinical practice, education, future research and 
societal impact. These recommendations will lead to improvements in the assessment and treatment 
of pain for the patients as well as for the (pain-) physicians involved in the care for patients.
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SAMENVATTING
Pijn wordt beschreven als (1): “een onplezierige, sensorische en emotionele ervaring die is geassocieerd 
met actuele of potentiële weefselschade of beschreven wordt in termen van zulke schade” en als (2): 
“dat wat de patiënt die pijn heeft zegt dat het is en deze treedt op als de patiënt zegt dat deze optreedt”. 
De eerste is een definitie van pijn als een psychosociaal fenomeen, de tweede is een meer 
patiëntgerichte beschrijving van pijn als een subjectieve ervaring. De ervaring van pijn door de 
patiënt wordt dus mede beïnvloed door persoonlijk geheugen, emoties, pathologie en cognitieve 
factoren.
De introductie van dit proefschrift, hoofdstuk 1, is verdeeld in vijf secties. In het eerste deel 
beschrijven we de classificatie van pijn van de patiënt op basis van het soort pijn en de duur van 
pijn. De soort pijn kan worden geclassificeerd als: (1) nociceptieve pijn: “pijn die voortkomt uit actuele 
of dreigende schade aan niet-neurogeen weefsel en die het gevolg is van activatie van nociceptoren”; 
(2) neuropathische pijn: “de pijn is een direct gevolg van een beschadiging of ziekte van het perifere of 
het centrale zenuwstelsel”; (3) nociplastische pijn: “pijn die voortkomt uit een veranderde nociceptie 
ondanks dat er geen duidelijk bewijs van daadwerkelijke of bedreigde weefselbeschadiging is die de 
activering veroorzaakt van perifere nociceptoren en er ook geen bewijs voor ziekte of laesie van het 
somatosensorische systeem is die pijn veroorzaakt”; (4) gemengde pijn of als (5) pijn van onbekende 
oorsprong. Gebaseerd op de duur, kan pijn worden geclassificeerd als acute of chronische pijn 
(pijn binnen of na de verwachte periode van genezing). Het tweede deel geeft een overzicht van 
fysiologische mechanismen van pijn en de belangrijke banen voor pijn tussen receptoren en de 
hersenen. In sectie drie beschrijven we de epidemiologie, de belasting, de kosten en de gevolgen 
van chronische pijn en van neuropathische pijn in het bijzonder. Deel vier geeft een overzicht 
van de beoordeling van neuropathische pijn in de dagelijkse klinische praktijk: het uitvoeren van 
anamnese en lichamelijk onderzoek, oriënterend neurologisch onderzoek, screeningsinstrumenten, 
het NeuPSIG beoordelingssysteem, kwantitatieve sensorische testen (QST) en neurofysiologische 
technieken. De eisen die gesteld worden aan een screeningsinstrument om (neuropathische) pijn 
te beoordelen, worden beschreven in deel vijf.
De doelstellingen van dit proefschrift waren het beoordelen van de psychometrische eigenschappen 
van de PainDETECT en de DN4 (screeningsinstrumenten voor neuropathische pijn) in een populatie 
van opeenvolgende patiënten uit de dagelijkse klinische praktijk met lage rug- en beenpijn, 
nek-schouder-armpijn of pijn ten gevolge van een vermoedelijke perifere zenuwbeschadiging. 
Een tweede doel was om de mogelijke voordelen van oriënterend neurologisch onderzoek en 
de Nijmegen Aalborg Screening QST te beoordelen om onderscheid te maken tussen klinisch 
gediagnosticeerde patiënten met en zonder een neuropathische pijncomponent.
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In hoofdstuk 2 hebben we het proces van de cross-culturele aanpassing van de PainDETECT 
vanuit het Duits naar de Nederlands taal voor gebruik in Nederland en België beschreven. Volgens 
de literatuur helpt de PainDETECT bij het identificeren van een neuropathische pijncomponent 
bij patiënten met pijn in de klinische praktijk en in klinisch onderzoek. Een voorwaarde om een 
valide screeningsinstrument in de Nederlandse taal te verkrijgen was om eerst een  uitgebreide 
vertaling en een cross-cultureel aanpassingsproces te doorlopen. De eerste stap in deze studie 
was om de  PainDETECT in het Nederlands te vertalen, cross-cultureel aan te passen op basis van 
de internationaal aanvaarde ISPOR-richtlijn voor het vertalen, en linguïstisch valideren van door 
de patiënt gerapporteerde uitkomsten. De tweede fase was om de indruksvaliditeit in Nederland 
en België te beoordelen met behulp van kwalitatieve en kwantitatieve gegevensverzameling. 
Hiervoor namen patiënten uit België en Nederland deel aan de studie. De lengte, de leesbaarheid 
en de duidelijkheid van de vragenlijst was goed volgens de patiënten. De vragenlijst had een 
goede lay-out (opmaak en wijze van invullen was hetzelfde als in de originele Duitse versie om 
variaties in respons te voorkomen) en er was een duidelijke organisatie binnen de vragenlijst. De 
conclusie uit deze studie was dat de Nederlandse versie van PainDETECT mogelijk nuttig kan zijn, 
gebaseerd op alleen de indruksvaliditeit, voor screening op de aanwezigheid van neuropathische 
pijncomponenten bij patiënten in Nederland en België.
Hoofdstuk 3 gaat over de betrouwbaarheid van het klinische oordeel als geaccepteerd surrogaat 
voor een objectieve goud standaard bij het diagnosticeren van neuropathische pijn. Tot op dit 
moment waren er geen publicaties beschikbaar over de betrouwbaarheid van deze diagnose. 
Deze betrouwbaarheid is belangrijk omdat de diagnose neuropathische pijn implicaties voor de 
behandeling heeft. In deze studie werden de niveaus van overeenstemming over het klinisch 
onderzoek van neuropathische pijn vastgesteld door de kappa-waarde en het percentage 
paarsgewijze overeenstemming te berekenen, om zo de interbeoordelaarsbetrouwbaarheid van 
de diagnose neuropathische pijn bij patiënten met kanker te bepalen. Elke patiënt werd door 
twee specialisten onderzocht via een onafhankelijke klinische beoordeling zoals uitgevoerd in de 
dagelijkse klinische praktijk. Na elke beoordeling werd de artsen gevraagd om de meest adequate 
karakterisering van de pijn aan te geven: pure neuropathische pijn, pure nociceptieve pijn, 
gemengde pijn of geen pijn. Er werd een substantieel niveau van overeenstemming gevonden voor 
de diagnose van pure neuropathische pijn, maar de waarden van overeenkomst voor het bestaan 
van een neuropathische pijncomponent voldeden niet. Er was wel een redelijke overeenkomst 
tussen de artsen met betrekking tot het NeuPSIG beoordelingssysteem. Bij patiënten met kanker 
is er in de overeenstemming tussen artsen voor de identificatie van neuropathische pijn, als een 
uitkomst van betrouwbaarheid, echter nog duidelijk behoefte aan een betere standaardisatie van 
de klinische beoordeling en classificatie van pijn.
In hoofdstuk 4 hebben we het studieprotocol voor onze studies in detail beschreven, zoals gebruikt 
in hoofdstuk 5, 6 en 7.
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Het doel van de studies in hoofdstuk 5 en hoofdstuk 6 was om de validiteit te beoordelen van 
de Nederlandse versies van de PainDETECT en de DN4 in een grote populatie van patiënten met 
chronische pijn zoals gezien in de dagelijkse klinische praktijk: patiënten met chronische lage rugpijn 
met ook pijn in de benen, met pijn in de nek en de schouder of arm en bij patiënten met chronische 
pijn als gevolg van vermoedelijk een perifere zenuwbeschadiging. Screeningsinstrumenten zijn 
ontwikkeld om de arts te helpen bij het beoordelen van patiënten met neuropathische pijn. Deze 
hulpmiddelen zijn doorgaans gevalideerd bij patiënten die vooraf gestratificeerd waren voor de 
uitkomst van neuropathische pijn. De validiteit van deze screeningsinstrumenten moet echter 
ook worden bewezen bij patiënten met pijn die niet vooraf zijn gestratificeerd op basis van het 
doelresultaat: neuropathische pijn of niet-neuropathische pijn. Een cross-sectioneel multicenter 
studie design werd gebruikt om de validiteit van beide instrumenten te beoordelen. Patiënten met 
lage rugpijn uitstralend in het been (of benen), patiënten met nek-schouder-arm pijn en patiënten 
met pijn als gevolg van een vermoedelijke perifere zenuwbeschadiging werden geïncludeerd. De 
pijn van de patiënt werd door twee ervaren artsen geclassificeerd op de aanwezigheid van een 
neuropathische pijncomponent (ja / nee) (“goud standaard”). De mening van artsen op basis van 
het NeuPSIG-beoordelingssysteem werd gebruikt als secundaire vergelijking. Op basis van de 
resultaten van het onderzoek in hoofdstuk 5 bleek de Nederlandse versie van de PainDETECT geen 
effectief screeningsinstrument voor de aanwezigheid van een neuropathische pijncomponent 
in een populatie van patiënten met chronische pijn vanwege de matige sensitiviteit en lage 
specificiteit. Bovendien moet het kritiekloos gebruik van de PainDETECT als surrogaat voor klinische 
beoordeling worden vermeden in de dagelijkse klinische praktijk evenals in (klinisch-) onderzoek. 
De studie in hoofdstuk 6 toonde aan dat de DN4 nuttig lijkt te zijn bij de identificatie van een 
neuropathische pijncomponent die is gebaseerd op een matige sensitiviteit en specificiteit. Echter, 
een uitgebreid (lichamelijk) onderzoek door de arts is nog steeds nodig.
Het doel van de studie in hoofdstuk 7 was om de mogelijke associatie te bepalen tussen de 
klinisch gediagnosticeerde aanwezigheid of afwezigheid van een neuropathische pijncomponent, 
oriënterend neurologisch onderzoek en het Nijmegen-Aalborg Screening QST paradigma. 
Oriënterend neurologisch onderzoek bestond uit metingen van aanraking (vinger, kwast), hitte, 
kou, prikken (Pinprick, von Frey haar) en trilling. Het Nijmegen-Aalborg Screening QST paradigma 
(drukalgometrie, elektrische pijndrempels en geconditioneerde pijnmodulatie) werd onderzocht 
om mogelijke nieuwe inzichten te genereren. Oriënterend neurologisch onderzoek toonde 
statistische significante verschillen tussen patiënten met een aan- of afwezige neuropathische 
pijncomponent. De Nijmegen-Aalborg Screening QST bracht geen verschillen aan het licht tussen 
patiënten met en zonder een neuropathische pijncomponent. Op basis van ons onderzoek kan 
worden geconcludeerd dat een gestandaardiseerd oriënterend neurologisch onderzoek zinvoller is 
dan het Nijmeegse-Aalborg screening QST paradigma om onderscheid te maken tussen patiënten 
met en zonder een neuropathische pijncomponent.
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In hoofdstuk 8 bespraken we onze belangrijkste bevindingen zoals opgenomen in dit proefschrift 
met betrekking tot de recente literatuur. Er werden aanbevelingen gedaan voor de klinische praktijk, 
het onderwijs, toekomstig onderzoek en de maatschappelijke impact. Deze aanbevelingen zullen 
leiden tot verbeteringen in de beoordeling en behandeling van pijn voor de patiënten evenals voor 
de (pijn-)artsen die betrokken zijn bij de zorg voor patiënten.
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DATA MANAGEMENT
This thesis is based on the results of human studies, which were conducted in accordance with 
the principles of the Declaration of Helsinki. The medical and ethical review board Committee on 
Research Involving Human Subjects Region Arnhem Nijmegen, Nijmegen, the Netherlands has 
given approval to conduct these studies.
The studies in this thesis (chapter 2, 4,5,6 and 7) were performed within DALI for PAIN, a national 
program that focuses on neuropathic pain care optimization. DALI for PAIN is an initiative of 
Pfizer. This project is supported by an unrestricted grant from Pfizer. This project is stored on the 
Radboudumc, department of anesthesiology, pain and palliative medicine H-Disc as DALI-08 TIM. 
The study in chapter 3 was co-funded by the Netherlands Organisation for Health Research and 
Development and stored on the Radboudumc, department of anesthesiology, pain and palliative 
medicine H-Disc under ANES ARCHIEF as Kappa/Validatie.
In our studies patients received questionnaire booklets containing the written informed consent 
during the physical examination moment, after two weeks and after three months. The participating 
physicians filled in the research form on paper. The paper data were stored in the department 
archive (Radboudumc, room M333.04.424), closet number 7. The data of chapter 3 is stored in the 
bunker (Radboudumc, room M333.02.210) under archive number 43, closet E.
All paper data were entered into the computer by use of MACRO software (MACRO, version 
4.1.1.3720, Infermed, London, United Kingdom). Data management and monitoring were also 
performed within MACRO. An audit trail was incorporated to provide evidence of the activities that 
has altered the original data. The privacy of the participants in this study is warranted by use of 
encrypted and unique individual subject codes. This code correspondents with the code on the 
patient- and physicians booklets. 
Data where converged from MACRO to Excel (Microsoft Office, Redmond, Washington, USA) and 
then to SPSS (SPSS Inc., Chicago, Illinois, USA). In November 2013 the data is monitored by dr. M. Kox, 
department of Intensive Care, Radboudumc, Nijmegen, the Netherlands. 
The patient data for the analyses of the studies as presented in chapter 2, 4, 5,6, and 7 is stored on 
the departments’ H-drive (H:\ANES\ResearchPipa\DALI-08 TIM\Investigators file\34 Database lock) 
in SPSS format: (chapter 2) FaceValidity_PDQ_B_NL_Anonymous, (chapter 4,5, 6 and 7) PaDoVa 
database 2014, (chapter 7) PaDoVa database + Cx_QST 2014. The data for chapter 3 is stored on the 
departments’ H-drive (H:\ANES\ResearchUnit\ARCHIEF\STUDIE ARCHIEF\ANES ARCHIEF). 
Chapter 9
230
The data will be saved for 15 years after termination of the study (July 1, 2013). Using these patient 
data in future research is only possible after a renewed permission by the patient as recorded in the 
informed consent. The datasets analyzed during these studies are available from the corresponding 
author on reasonable request.
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in: Handbook Pain Treatment). Uitgeverij de Tijdstroom, Utrecht, the Netherlands. 
Posters and poster presentations:
1.  Schuttert I, Timmerman H, Groen GW, Wolff AP. Effects of Tapentadol on chronic pain and 
parameters of central sensitisation. A prospective, open label, randomized cross-over study with 
pregabaline as comparator (PRINCE study). SPBR 2018, Groningen, the Netherlands.
2.  Schuttert I, Timmerman H, Groen GW, Wolff AP. Central sensitisation in patients with chronic low 
back pain radiating to the leg (CLaSSICO STUDY). SPBR 2018, Groningen, the Netherlands.
3.  Timmerman H, Wolff AP, Wilder-Smith OH, Vissers KCP. Screening for a neuropathic pain 
component: a mission impossible? e-Poster presentation. 8th World Congress of the World 
Institute of Pain 2016, New York, USA. 
4.  Timmerman H, van Dasselaar NT, Wolff AP, Wilder-Smith OH, Steegers MAH, Vissers KCP. The 
validity of the PDQ in patients after treatment for breast cancer. 5th international congress of 
neuropathic pain special interest group: NeuPSIG 2015, Nice, France.
5.  Van Vliet J, Verrips A, Timmerman H, van Dongen R, Wilder-Smith H, van Engelen E. 
Karakterisering van pijn in patiënten met myotone dystrofie type 2. Wetenschappelijke 
vergadering van de Neurologie 2015, Nunspeet, the Netherlands. 
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6.  Timmerman H, Wolff A, van Dasselaar N, Steegers M, Wilder-Smith O, Vissers K. The validity of 
the DN4 in patients after breast cancer. 7th World Congress of the World Institute of Pain 2014, 
Maastricht, the Netherlands.
7.  Van der Wal S, Steegers M, Radema S, De Graaf W, Timmerman H, Vaneker M, Vissers K. A case 
report: lowdose intravenous lidocaine for chronic chemotherapy induced peripheral neuropathy. 
7th World Congress of the World Institute of Pain 2014, Maastricht, the Netherlands.
8.  Timmerman H, Heemstra I, Schalkwijk A, Verhagen C, Engels Y, Vissers K.The interobserver 
reliability of the diagnosis of neuropathic pain in patients with cancer: a kappa study. World 
Congress International Association for the Study of Pain 2012, Milan, Italy
9.  Timmerman H, Wolff AP, Schreyer T, Outermans J, Evers AWM, Freynhagen R, Wilder-Smith 
OH, van Zundert J, van Rijswijk E, Vissers KCP. Crossculturele adaptatie van de Nederlandstalige 
PainDETECT vragenlijst. NHG-Wetenschapsdag 2011, Nijmegen, The Netherlands
10.  Timmerman H, Wolff AP, Schreyer T, Outermans J, Evers AWM, Freynhagen R, Wilder-Smith 
OH, van Zundert J, van Rijswijk E, Vissers KCP. Cross-cultural adaptation of the PainDETECT 
questionnaire to the Dutch language. World Congress on Physical Therapy 2011, Amsterdam, 
The Netherlands
(Congress) Presentations and lectures:
1.  Timmerman, H. AUWCH! PAIN is no FUN!! Lectures for children held in the framework of 
Radboud Invites (Science Weekend). 2018, Radboud University Nijmegen, the Netherlands
2.  Timmerman H. Use of evaluation scales: Measuring the pain experience. WIP Benelux-WAPMU: 
International evidence-based medicine symposium, 2017, Nijmegen, the Netherlands. 
3.  Timmerman H. How do you communicate your science? About Lowlands Science and the Media. 
Radboud Post Doc Initiative, 2017, Nijmegen, the Netherlands
4.  Timmerman H, de Groot J, Hulzebos E, de Knikker R, Kerkkamp H, van Meeteren N. Feasibility 
of preoperative therapeutic exercise in patients with cancer. Royal Dutch Congress of Physical 
Therapy, 2007, Amsterdam, The Netherlands
5.  Timmerman H, de Groot J, Hulzebos E, de Knikker R, Kerkkamp H, van Meeteren N. Feasibility 
and patient believes of preoperative therapeutic exercise in patients with cancer. Dutch Congress 
on Psychology in Patients with Oncology, 2007, Utrecht, The Netherlands.
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Grants, Awards and Prices:
1.  Steegers M, van Boekel R, Timmerman H, van der Wal S, Blaney Davidson E. Pijngevoeligheid 
bij het zien van pijn bij mannen en vrouwen. Groot Nationaal Onderzoek. NWO/NTR. 2017, 
Hilversum, the Netherlands.
2.  Timmerman H, van der Wal S, Groot M, Steegers M. 2016. More or Less Pain with Muse. The 
influence of music on pain. Winner of the Grant for Lowlands Science 2016, Biddinghuizen, 
the Netherlands. 
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PhD Portfolio
Name PhD candidate: H. Timmerman
Department: Anesthesiology, Pain and 
                         Palliative Medicine
Graduate School: Radboud Institute for Health Sciences
PhD period: 16-06-2008 – 03-05-2019
Promotor(s):  prof. dr. K.C.P. Vissers
                            prof. dr. A.P. Wolff
Co-promotor(s): prof. dr. M.A.H. Steegers
                              dr. O.H.G. Wilder-Smith
Year(s) ECTS
TRAINING ACTIVITIES
a)  Courses & Workshops
- Basiscursus Regelgeving en Organisatie van Klinische Trials 
    (NFU, Utrecht, the Netherlands)
- Training for Coaches (Radboudumc, Nijmegen, the Netherlands)
- Media Training (PAO Heyendaal, Nijmegen, the Netherlands)
- Introductie tot de Nijmeegse Curricula (PAO Heyendaal, Nijmegen, 
the Netherlands)
- Meta Analyses (LUMC, Boerhaave, leiden, the Netherlands)
- Systematic reviews of Measurement Instruments (VUMC, 
Amsterdam, the Netherlands)
- Presentation Skills (Radboud in’to languages, Nijmegen, the 
Netherlands)
- Advanced Conversation (Radboud in’to languages, Nijmegen, the 
Netherlands)
- Quantitative Sensory Testing (DFNS, Bochum, Germany)
- Academic Writing (Radboud in’to languages, Nijmegen, the 
Netherlands)
2018
2014
2010
2016
2016
2015
2013
2013
2012
2011
2010
2009
2.0
0.5
0.2
0.2
1.0
0.3
1.5
1.5
0.3
3.0
b)  Seminars & lectures
- AUWCH! PAIN is no FUN!! Lectures for children about pain 
(Radboudumc, Nijmegen, the Netherlands)
- How do you communicate your science? About Lowlands Science 
and the Media (Radboudumc, Nijmegen, the Netherlands)
2018
2017
0.2
0.1
c)  Symposia & congresses
- IASP (Boston, USA)
- EFIC (Copenhagen, Denmark)
- WIP-Benelux (Nijmegen, the Netherlands) oral presentation
- WIP (New York, USA) poster presentation
- NeuPSIG (Nice, France) poster presentation
- WIP (Maastricht, the Netherlands) poster presentation
- NeuPSIG (Toronto, Canada)
- IASP Research Symposium (Arnhem, the Netherlands)
- IASP (Milan, Italy)
- EFIC (Hamburg, Germany)
- WCPT (Amsterdam, the Netherlands) poster presentation
- NeuPSIG (Athens, Greece)
- NeuPSIG Satellite (London, UK)
2018
2017
2017
2016
2015
2014
2013
2013
2012
2011
2011
2010
2008
1.0
1.0
0.3
1.0
1.0
1.0
1.0
0.5
1.0
1.0
0.3
1.0
1.0
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d)  Other
         Reviewer Scientific Papers
- PLoS ONE
- Pain Practice
- Pain Medicine
- BMC Neurology
- Yonsei Medical Journal
- Journal of Pain Research
- Current Medical Research & Opinion
- Journal of Back and Musculoskeletal Rehabilitation
- Transactions on Neural Systems and Rehabilitation Engineering
2012-... 5.0
TEACHING ACTIVITIES
e)  Lecturing
- Measuring Pain (Psychology, Radboud University)
- Coach for Medical Students (1st, 2nd and 3rd year students)
- Minor Pain and Palliative Medicine 
- Capita Selecta Co-Assistants
- Education Pain and Pain treatment (5KNW7)
2019
2016-...
2018-...
2012-2017
2011-2017
0.2
28.0
1.0
1.0
5.0
f)  Supervision of internships / other
- Supervisor research internship, Master Medicine, Radboud University 
Medical Center. Student: Ludo van de Linde
- Project leader ‘More or Less Pain With Muse’ (Lowlands Science, 
Biddinghuizen, the Netherlands)
2016-2017
2016
1.0
10
TOTAL 72.3
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